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Component-Based Syntheses of Trioxacarcins 
 
Abstract 
 The trioxacarcins are structurally complex, highly oxygenated bacterial isolates 
that potently inhibit the growth of human cancer cells in culture as a consequence of their 
ability to alkylate guanosine residues of duplex DNA. This dissertation presents a 
component-based synthetic route to the trioxacarcin structural class, broadly defined, 
which resulted in fully synthetic routes to trioxacarcin A (1), DC-45-A1 (10), and a  
diverse collection of analogs.  
 Two efficient synthetic routes were developed to the deoxysugar trioxacarcinose 
A (2) found within most trioxacarcins. Both routes relied on diastereoselective, chelation-
controlled additions of allylmetal reagents to free or protected syn-α,β-dihydroxyketones. 
A scalable protocol provided their common syn diol starting material 32, using a p-
phenylbenzyl ester as an expedient for purification and enantioenrichment by 
recrystallization. 
 Diastereoselective glycosylation reactions were developed for the coupling of 
activated forms of trioxacarcinose A to fully functionalized trioxacarcin core substrates. 
This methodology enabled the preparation of the natural product DC-45-A1 (10) in three 
chemical steps from synthetic precursor 23. Incorporation in tandem of an activated 
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derivative of trioxacarcinose B (3) prepared by postdoctoral researcher Thomas Magauer 
resulted in an 11-step synthesis of trioxacarcin A (1) from precursor 23. 
 
 The synthetic route to trioxacarcin A (1) proceeded by the assembly of five 
components of similar structural complexity: epoxy diazo diketone 18, cyanophthalide 
19, cyclohexenone 20, a trioxacarcinose A glycosyl donor, and a trioxacarcinose B 
glycosyl donor. A diverse collection of trioxacarcin analogs was prepared by variation of 
these modular components, both individually and in combination, to introduce deep-
seated structural modifications which would have been difficult to access by other means. 
Through measurements of antiproliferative activity in cultured human cancer cells, this 
program in analog synthesis has begun to define the structural features which enable or 
disfavor potent growth inhibition. In particular, novel trioxacarcins such as 
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methoxymethyl aglycon 127 have been identified which retain antiproliferative activity at 
levels comparable to trioxacarcin A (1) despite significant structural simplification. 
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Introduction   
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The Trioxacarcin Class of Natural Products 
The trioxacarcins are structurally complex, highly oxygenated bacterial 
metabolites that broadly inhibit the growth of cultured eukaryotic and bacterial cells. In 
1981 Tomita and coworkers1 reported the isolation of trioxacarcins A (1), B (5), and C 
(6) (previously referred to as DC-45-A, DC-45-B1, and DC-45-B2, respectively2) from 
an actinomycete bacterial strain, designated as Streptomyces bottropensis, found in a soil 
sample collected in Sapporo, Japan (Figure 1.1). A subsequent patent disclosed the 
isolation of DC-45-A1 (10) and DC-45-A2 (11) from the same bacterial strain (Figure 
1.2).3 In 2004 Maskey and coworkers examined extracts from the marine Streptomyces 
sp. isolate B8652 and isolated trioxacarcins A (1), B (5), and C (6) along with the novel 
trioxacarcins D (7), E (8), and F (9) (Figure 1.1).4 The latter report also described the 
isolation of gutingimycin (4), a 1:1 covalent adduct of trioxacarcin A (1) and guanine 
(Figure 1.2).4 Scientists at American Cyanamid Company described the isolation of the 
closely related LL-D49194 natural products from Streptomyces vinaceus-drappus, 
obtained from a soil sample collected in La Encanada, Peru (Figure 1.2).5 
All known trioxacarcins share a common aglycon core containing a 
dihydroanthracenone chromophore which is hydroxylated at positions C2 and C4 (see 
                                                 
1 (a) Tomita, F.; Tamaoki, T.; Morimoto, M.; Fujimoto, K. J. Antibiot. 1981, 34, 1519–1524. (b) Tamaoki, 
2 Tomita, F.; Tamaoki, T.; Shirahata, K.; Iida, T.; Morimoto, M.; Fujimoto, K. Antibiotic Substances DC-
45, and Their Use as Medicaments. U.S. Patent 4,511,560, 1985. 
3 Shirahata, K.; Iida, T. Compounds Having Antibiotic Activity, Processes for Their Preparation, 
Pharmaceutical Compositions Containing Them and Their Use as Medicaments. U.S. Patent 4,459,291, 
1984. 
4 Maskey, R. P.; Helmke, E.; Kayser, O.; Fiebig, H. H.; Maier, A.; Busche, A.; Laatsch, H. J. Antibiot. 
2004, 57, 771–779. 
5 (a) Maiese, W.; Labeda, D.; Korshalla, J.; Kuck, N.; Fantini, A.; Wildey, M.; Thomas, J.; Greenstein, M. 
J. Antibiot. 1990, 43, 253–258. (b) Borders, D. B.; Fantini, A. A.; Labeda, D. P.; Lee, M. D.; Maiese, W. 
M.; Testa, R. T., Antitumor Agents LL-D49194α1, LL-D49194β1, LL-D49194β2, LL-D49194β3, LL-
D49194γ,  LL-D49194δ,  LL-D49194ε,  LL-D49194ξ,  LL-D49194η,  LL-D49194ω1, LL-D49194ω2, and LL-
D49194ω3. U.S. Patent 4,626,503, 1986. 
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Figure 1.1 for trioxacarcin numbering). To this chromophore is fused a complex and 
highly oxygenated motif containing either a spiro epoxide (trioxacarcins A (1), C (6), and 
D (7)) or the corresponding vicinal diol (trioxacarcins B (5), E (8), and F (9)), along with 
a C13 hemiacetal, a C16 dimethyl acetal, and either a C15 ketal or (within trioxacarcin F 
(9)) a C15 hemiketal.  
4 
 
 
Figure 1.1. Structures of Trioxacarcins A (1), B (5), C (6), D (7), E (8), and F (9), 
Trioxacarcinose A (2), Axenose (15), Trioxacarcinose B (3), and Gutingimycin (4). 
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Figure 1.2. Structures of the Trioxacarcin Natural Products DC-45-A1 (10) and DC-45-
A2 (11), and Structures of LL-D49194 Natural Products LL-D49194α1 (12), LL-
D49194β1 (13), and LL-D49194β2 (14). 
The chemical structure of trioxacarcin A (1) was determined by a series of 
spectroscopic, degradation, and crystallographic studies. Methanolysis of trioxacarcin A 
(1) in 0.1% hydrochloric acid–methanol provided the trioxacarcin aglycon, DC-45-A2 
(11, also referred   to   as   “trioxacarcinone   A”)   along   with   two   methyl   glycosides,   both  
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obtained as mixtures of α- and β-anomers (Scheme 1.1; the α-anomers are depicted).6 The 
first such glycosidic component, eponymously named methyl trioxacarcinoside A (2), 
was found to be the 4-O-acetylated version of the previously known deoxysugar axenose 
(15). Axenose (15) appears in the natural products axenomycin,7 polyketomycin,8 and 
dutomycin,9 and has been prepared by chemical synthesis.10 The second glycosidic 
component was named methyl trioxacarcinoside B (3), a sugar also found within the 
natural product quinocycline B.11 Permethylation of DC-45-A2 (11) provided 
trimethylated derivative 16, and oxidative degradation of this product by treatment with 
potassium permanganate in acetone provided the crystalline derivative 17, which retained 
the complex oxygenated core structure in its entirety. The structure and absolute 
configuration of derivative 17 were established with certainty by X-ray crystallographic 
analysis.12 Later crystallographic studies reported the structure of gutingimycin (4)13 and 
a complex of trioxacarcin A (1) covalently bound to DNA,14 providing additional 
confirmation of the structure of trioxacarcin A (1); these reports are discussed in greater 
detail later in this chapter.  
                                                 
6 Shirahata, K.; Iida, T.; Hirayama, N. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1981, 24, 199–206. 
7 Arcamone, F.; Barbieri, W.; Franceschi, G.; Penco, S.; Vigevani, A. J. Am. Chem. Soc. 1973, 95, 2008–
2009. 
8 (a) Momose, I.; Chen, W.; Kinoshita, N.; Iinuma, H.; Hamada, M.; Takeuchi, T. J. Antibiot. 1998, 51, 21–
25. (b) Momose, I.; Chen, W.; Nakamura, H.; Naganawa, H.; Iinuma, H.; Takeuchi, T. J. Antibiot. 1998, 
51, 26–32. 
9 Xuan, L.-J.; Xu, S.-H.; Zhang, H.-L.; Xu, Y.-M.; Chen, M.-Q. J. Antibiot. 1992, 45, 1974. 
10 (a) Garegg, P.; Norberg, T. Acta. Chem. Scand. 1975, 29, 507–512. (b) Giuliano, R. M.; Villani, F. J., Jr. 
J. Org. Chem. 1995, 60, 202–211. 
11 Matern, U.; Grisebach, H.; Karl, W.; Achenbach, H. Eur. J. Biochem. 1972, 29, 1–4. 
12 Hirayama, N.; Iida, T.; Shirahata, K. Acta Crystallogr. C. 1989, 45, 632–634. 
13 Maskey, R. P.; Sevvana, M.; Usón, I.; Helmke, E.; Laatsch, H. Angew. Chem. Int. Ed. 2004, 43, 1281–
1283. 
14 Pfoh, R.; Laatsch, H.; Sheldrick, G. M. Nucleic Acids Res. 2008, 36, 3508–3514. 
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Scheme 1.1. Degradation of Trioxacarcin A (1) to Provide Methyl α-Trioxacarcinoside 
A, Methyl α-Trioxacarcinoside B, and Crystalline Derivative 17.  
Like trioxacarcin A (1), most natural trioxacarcins are glycosylated, though the 
number and nature of the glycosidic residues varies. All but two natural trioxacarcins 
contain trioxacarcinose A (2) in an α-linkage with the C4 hydroxyl group, the two 
exceptions being trioxacarcin D (7), which contains α-axenose (15), and DC-45-A2 (11), 
which is not glycosylated. Trioxacarcins A (1), B (5), D (7), and F (9) contain a 
trioxacarcinose B (2) residue in an α-linkage with the C13 hemiketal function, and 
trioxacarcin C (6) exhibits a reduced form of this sugar, 7-dihydrotrioxacarcinose B.11 
DC-45-A1 (10) and DC-45-A2 (11) represent 13-deglyco- and 4,13-bis-deglyco-
trioxacarcin A (1), respectively (Figure 1.2). All known LL-D49194 natural products are 
trisglycosides, including LL-D49194α1 (12), LL-D49194β1 (13), and LL-D49194β2 (14) 
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depicted in Figure 1.2. These molecules contain either trioxacarcinose A (2) or axenose 
(15) present at the C4 hydroxyl group and an interesting α(1→4)-linked disaccharide 
formed from two axenose (15) residues linked to the C16 hemiketal (trioxacarcin 
numbering).  
The trioxacarcins were found to exhibit a number of compelling activities in 
biological systems, the most notable of which is their striking antiproliferative activity in 
cultured human cancer cell lines. Maskey and coworkers measured the IC70 values of 
trioxacarcins A (1), B (5), C (6), and D (7) and gutingimycin in a panel of cancer cell 
lines, and trioxacarcin A (1) in particular exhibited sub-nanomolar IC70 values in several 
cases (Table 1.1).4 Trioxacarcins C (6) and D (7), also potent antiproliferative agents, 
differ from trioxacarcin A (1) only in slight modifications to the glycosyl residues, 
indicating that the precise nature of the glycosyl residues within these compounds may be 
a key determinant of their biological activity. Trioxacarcins A (1), B (5), and C (6) 
demonstrated antitumor activity in mice, showing, for example, decreased tumor volume 
in murine sarcoma 180 and increased life span in murine leukemia P388.1a,15 A 5-day 
course of daily injections of 0.10 mg/kg of trioxacarcin A (1) resulted in a 35% increased 
lifespan relative to untreated mice.1a The trioxacarcins are nevertheless toxic molecules, 
and the LD50 values of trioxacarcins A (1), B (5), and C (6) in mice were found to be 1 
mg/kg, 100 mg/kg, and 2 mg/kg, respectively, as determined by the number of survivors 
14 days after a single injection of the trioxacarcin compound.1a Trioxacarcins A (1) and C 
(6) were also reported to rapidly and potently inhibit polynucleotide biosynthesis, 
                                                 
15 Fujimoto, K.; Morimoto, M. J. Antibiot. 1983, 36, 1216–1221. 
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particularly DNA biosynthesis, in Bacillus subtilis, as measured by the rate of uptake of 
3H-labeled precursors.1b,15 Protein synthesis was inhibited to a much lesser extent. 
 
Table 1.1. Antiproliferative Activities of Trioxacarcins in a Panel of Cultured Human 
Cancer Cells (Adapted from Maskey et al.)4 
cancer cell line* (IC70,  μM) 
compound HT-20 SF-268 H-460 
LXFA  
526L 
LXFL 
526L MCF-7 
MEXF 
514L PC3M 
RXF 
631L 
trioxacarcin A <0.34 <0.0003 <0.0003 <0.34 <0.0003 <0.0003 0.002 0.01 0.08 
trioxacarcin B 7.22 1.65 1.64 2.77 0.68 1.47 6.43 >3.35 2.4 
trioxacarcin C <0.34 0.01 <0.0003 <0.34 0.02 0.002 0.16 0.04 0.13 
trioxacarcin D 0.87 0.18 0.04 <0.36 0.77 0.08 1.57 1.86 0.76 
gutingimycin >2.96 >2.96 >2.96 >2.96 3.34 >2.96 >2.96 >2.96 >2.96 
 
* HT-29 (colon cancer), SF-268 (central nervous system cancer), H-460 (large-cell lung cancer), LXFA 526L (adeno 
lung cancer), LXFL 526L (large-cell lung cancer), MCF-7 (mammary cancer), MEXF 514L (melanoma), PC3M 
(prostate cancer), RXF 613 (renal cancer).  
 
 
The trioxacarcins were also reported to exhibit antibacterial activity, particularly 
against Gram-positive organisms. As an example, trioxacarcins A (1), B (5), and C (6) 
exhibited minimum inhibitory concentrations (MICs) of 0.2, 50, and 0.4 Pg/mL, 
respectively, in Staphylococcus aureus ATCC 6538P.1a Trioxacarcins A (1) and D (7) 
were found to potently inhibit the growth of Plasmodium falciparum, a causative agent of 
malaria in humans.4 
From these biological studies of trioxacarcins a trend also emerges that 
trioxacarcin B (5) and gutingimycin (4), both of which lack an epoxide ring, are broadly 
and substantially less active in biological systems than the other trioxacarcins studied, 
indicating that an intact epoxide plays a critical role in these activities.  
10 
 
The LL-D49194 natural products are also potent antiproliferative agents, with LL-
D49194α1 (12), LL-D49194β1 (13), LL-D49194β2 (14) all promoting life extension in 
murine leukemia and melanoma.5 A phase I study of the most potent of these compounds, 
LL-D49194α1 (12), was conducted in the early 1990s in 15 patients with diverse 
metastatic cancers that were refractory to existing therapies. Although one patient in this 
study with colon cancer responded with an improvement in performance that was 
sustained for six months, a fatality associated with cardiotoxicity led to suspension of the 
trial. A retrospective analysis suggested that the murine models that were used to 
determine dosing in the trial predicted human pharmacokinetics poorly; drug exposures 
more than fourfold higher than anticipated were observed in patients.16 
Many of the above findings indicated that the biological activity of the 
trioxacarcins is believed to derive from their interaction with duplex DNA, and the nature 
of this interaction was elucidated in a series of seminal studies. Maskey and coworkers in 
2004 reported the isolation and structural determination of gutingimycin (4)13 by X-ray 
crystallographic analysis and NMR studies. Within the crystal structure (Figure 1.3), a 
covalent bond was observed between N7 of the guanine subunit and C17 of the 
trioxacarcin subunit (see Scheme 1.2 for numbering), as if the spiro epoxide present 
within trioxacarcin A (1) had been subject to nucleophilic opening by the guanine base. 
The guanine subunit in this solid-state structure is stacked nearly parallel to the plane of 
the trioxacarcin chromophore, with an interplanar distance of approximately 3.2 Å. The 
C2 hydroxyl group of the trioxacarcinose B subunit is hydrogen-bonded to the N2 amino 
group of the guanine subunit (N–H···O). The authors also reported the compelling 
                                                 
16 Cassidy, J.; Graham, M. A.; Huinink, W. T. B.; McDaniel, C.; Setanoians, A.; Rankin, E. M.; Kerr, D. J.; 
Kaye, S. B. Cancer Chemoth. Pharm. 1993, 31, 395–400. 
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observation that treatment of trioxacarcin A (1) with duplex DNA results in the formation 
of a stable complex, and that heating of this complex at 100 °C results in the liberation of 
gutingimycin (4), presumably as a result of alkylation and depurination of DNA (Scheme 
1.2). 
 
 
Figure 1.3. Two Views of the Crystal Structure of Gutingimycin (4) 
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Scheme 1.2. Formation of Gutingimycin (4) from Trioxacarcin A (1) and Duplex DNA. 
Additional insight into the sequence of events involved in the interaction of 
trioxacarcin A (1) with duplex DNA came in the form of crystallographic studies by Pfoh 
and coworkers, who in 2008 characterized by X-ray crystallography the 2:1 covalent 
intercalation complex of trioxacarcin A (1) with the self-complementary duplex 
oligonucleotide d(AACCGGTT) to 1.78-Å resolution.14 Within this structure (Figure 
1.4), a covalent bond between C17 of the trioxacarcin and the N7 position of a guanine 
residue was observed, as in the structure of gutingimycin (4). Trioxacarcin A (1) has 
intercalated on the 3' side of the alkylated guanine residue, and the dihydroanthracenone 
chromophore is oriented nearly parallel to the planes of the base pairs surrounding it, 
displaying stacking interactions. The complex showed a distorted B-DNA geometry, with 
the trioxacarcinose A (2) residue positioned within the minor groove and the 
trioxacarcinose B residue (3) positioned in the major groove. Interestingly, the 
intercalation of trioxacarcin A (1) displaced the penultimate 3'-thymine residue, which 
13 
 
flipped out of the helix. The adenine with which this flipped-out thymine residue had 
been base-paired has formed a new pairing interaction with the terminal 3'-thymine. 
 
 
 
Figure 1.4. Two Depictions of the Crystal Structure of Trioxacarcin A (1) Covalently 
Bound to the DNA Duplex d(AACCGGTT). 
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In order to examine the details of the molecular interaction of trioxacarcin A (1) 
with duplex DNA, Fitzner and coworkers studied the reaction of trioxacarcin A (1) with 
several duplex DNA oligonucleotides using a variety of analytical methods.17 The authors 
observed an increase in the melting temperature (Tm) of the self-complementary duplex 
DNA oligonucleotide d(AATTACGTAATT) from Tm = 34 °C to Tm = 41 °C upon 
treatment with 2 equivalents of trioxacarcin A (1). Because a similar increase in melting 
temperature (Tm = 42 °C) was observed upon treatment of the same oligonucleotide with 
trioxacarcin B (5), which lacks an intact spiro epoxide, it was suggested that the increase 
in helical stability can be attributed to the intercalation and groove binding of the 
trioxacarcin, and not to the formation of a covalent complex. Treatment of 
d(CAATTATAATTG) with trioxacarcin A (1), on the other hand, resulted in a small 
change in melting temperature, from 31 °C to 29 °C, from which the authors concluded 
that intercalation and/or groove binding are likely not taking place. The covalent adduct 
of trioxacarcin A (1) and d(AATTACGTAATT) was observed by HPLC-MS and found 
to be stable for more than 24 hours at 23 °C, and upon heating to 80 °C, conversion to 
gutingimycin (4) was observed with first-order kinetics. 
In the same study,17 adduct formation between trioxacarcin A (1) and six 12-mer 
DNAs of varying sequence was observed by HPLC and ESI-MS. The covalent adduct 
formed to varying extents, with the self-complementary AATTACGTAATT being the 
most reactive (53% adduct formation) and AATTAGAAATT (not self-complementary) 
showing almost no conversion to a covalent adduct (1%). These results suggest that 
double helix formation and the nature of the residues flanking the guanine to be alkylated 
                                                 
17 Fitzner, A.; Frauendorf, H.; Laatsch, H.; Diederichsen, U. Anal. Bioanal. Chem. 2008, 390, 1139–1147. 
15 
 
both influence the trioxacarcin-mediated alkylation of DNA, perhaps by influencing the 
positioning of the guanine and spiro epoxide reaction partners. 
 
A Component-Based Synthetic Strategy for Trioxacarcins 
In prior work in the Myers research group at Harvard University, graduate 
students Jakub Švenda and Nicholas Hill developed a convergent synthetic route to 
synthetic precursor 23, a differentially-protected form of DC-45-A2 (11), from three 
components of similar synthetic complexity.18 The three components—epoxy diazo 
diketone 18, cyanophthalide 19, and cyclohexenone 20—were assembled in a six-step 
sequence shown in (Scheme 1.3). Cyanophthalide 19 and cyclohexenone 20 were 
coupled in an anionic cyclization reaction to provide the full dihydroanthracenone 
chromophore present within product 21. A three-step sequence of oxidative cleavage of 
the disubstituted olefin, removal of the MOM ether protective group, and protection of 
the revealed bis-phenol function as the corresponding di-tert-butyl siloxane provided 
aldehyde 22. In a key step, aldehyde 22 underwent a dipolar cycloaddition reaction with a 
carbonyl ylide intermediate formed from epoxy diazo diketone 18 in the presence of 
rhodium acetate. This cycloaddition reaction formed a mixture of four diastereomeric 
cycloadducts, which are depicted in Scheme 1.4. Only the endo diastereomer 25 is 
stereochemically congruent with the natural trioxacarcins. This mixture was desilylated 
by brief treatment with triethylamine–trihydrofluoride to provide a mixture of 
diastereomeric hemiketals, from which synthetic precursor 23 was isolated by RP-HPLC. 
 
                                                 
18 Švenda,  J.;;  Hill,  N.;;  Myers,  A.  G.  Proc. Natl. Acad. Sci. USA 2011, 108, 6709–14. 
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Scheme 1.3. Synthesis of Synthetic Precursor 23 From Three Components: Epoxy Diazo 
Diketone 18, Cyanophthalide 19, Cyclohexenone 20 (Labeled with Circled Numbers). 
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Scheme 1.4. Carbonyl Ylide–Aldehyde Cycloaddition between Aldehyde 22 and Epoxy 
Diazo Diketone 18.18 
 
Cyanophthalide 19 was made available in an efficient, scalable sequence from 4-
methylsalicylic acid. This route is reproduced in full in Scheme 1.5 to facilitate 
discussion in Chapter 4, when modifications to this component are introduced. The 
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starting material 4-methylsalicylic acid was first converted to allyl ether 28 in a three-step 
sequence. Claisen rearrangement of 28 followed by alkene isomerization to the internal 
position and protection of the phenol as the corresponding MOM ether provided arene 29. 
Directed ortho-lithiation of 29 and trapping of the resulting aryllithium species with DMF 
furnished aldehyde 30. Treatment of aldehyde 30 with cyanotrimethylsilane provided an 
intermediate cyanohydrin (not isolated), which formed cyanophthalide 19 upon stirring in 
glacial acetic acid.18 
 
 
Scheme 1.5. Synthesis of Cyanophthalide 19. 
The diazo diketone component 18 was prepared in an 8-step sequence from 2,2-
dimethoxyacetaldehyde, and the preferred route to cyclohexenone building block 20 
proceeded in 10 steps using L-malic acid as starting material (Figure 1.5).18 
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Figure 1.5. Starting Materials and Step Counts for Syntheses of Epoxy Diazo Diketone 
Component 18 and Cyclohexenone Component 20.18 
We sought to utilize the differential protection incorporated within synthetic 
precursor 23 for the selective functionalization of the trioxacarcin aglycon. In particular, 
we anticipated that this precursor would serve directly as a substrate for the introduction 
of carbohydrates such as trioxacarcinose B (2) by glycosylation of the hemiketal 
hydroxyl group at position C13. After cleavage of the p-methoxybenzyl ether protective 
group, the precursor would provide a substrate for selective introduction of carbohydrates 
such as trioxacarcinose A (3) by glycosidation of the hydroxyl group liberated at position 
C4, which we expected to be more reactive. In this manner we sought to prepare natural 
trioxacarcins such as trioxacarcin A (1) by the addition of two remaining modular 
components (i.e. glycosidic subunits derived from trioxacarcinose A (2) and 
trioxacarcinose B (3)) to our convergent route. The result would constitute a synthesis of 
1 from five components of similar complexity. 
Additionally, we recognized the unique potential for diversification inherent in a 
convergent, component-based route and envisioned the preparation of trioxacarcin 
analogs by component variation which would be difficult or impossible to access by other 
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means. Modification of more than one component would lead to multiplicative expansion 
of the pool of trioxacarcins (broadly defined) available for study.  
In Chapter 2, I describe two practical routes to trioxacarcinose A (2) in forms 
suitable for glycosylation reactions, both proceeding by apparent chelation-controlled 
additions of allylmetal reagents to α,β-dioxygenated ketones. This work enabled fully 
synthetic routes to trioxacarcin A (1) and DC-45-A1 (10) by stereoselective glycosylation 
reactions, the details of which I present in Chapter 3. In Chapter 4 I describe the results of 
efforts in trioxacarcin analog synthesis which represent a realization of the potential for 
diversification inherent in our component-based synthetic route, and in Chapter 5 I 
present the antiproliferative activities I measured for fully synthetic trioxacarcins, 
highlighting aspects of the structure-activity relationships which our platform provided a 
unique ability to study. 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Synthesis of Trioxacarcinose A in Forms Suitable  
for Glycosylation Reactions 
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Introduction 
In this chapter, I describe the development of two efficient syntheses of the rare 
deoxysugar trioxacarcinose A (2) in forms suitable for glycosidic coupling reactions. 
After an introduction to the trioxacarcinose A carbohydrate class, I present a scalable 
synthesis of syn-2,3-dihydroxybutyrate esters in enantiomerically pure form, using a p-
phenylbenzyl ester group as an expedient for purification and enantioenrichment by 
recrystallization. The syn-2,3-dihydroxybutyrate esters prepared in this manner provided 
the starting materials for two synthetic routes to trioxacarcinose A derivatives, both of 
which utilized the principle of α-chelation control in a diastereoselective addition of an 
allylmetal reagent to a syn-α,β-dioxygenated ketone substrate. The routes I present 
enabled the preparation of gram quantities of optically pure trioxacarcinose A derivatives. 
I conclude this chapter by discussing the preparation of anomerically activated 
derivatives of this sugar. These anomerically activated derivatives were successfully 
employed in the syntheses of the glycosylated natural trioxacarcins DC-45-A1 (10) and 
trioxacarcin A (1), as described in Chapter 3, as well as in the preparation of numerous 
trioxacarcin analogs, as described in Chapter 4. 
Most known trioxacarcins, including trioxacarcin A (1) and DC-45-A1 (10), 
contain the rare, eponymous deoxysugar trioxacarcinose A (2) in an α-glycosidic linkage 
with the C4 hydroxyl group (Figure 1.1, Figure 1.2). The desacetyl form of 
trioxacarcinose A, known as axenose (15), is also naturally occurring and appears within 
the natural products axenomycin,7 polyketomycin,8 and dutomycin.9 Two synthetic routes 
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to axenose have appeared previously in the literature.10,19 Garegg and Norberg prepared 
axenose in 13 steps (1.6% yield) from L-fucose as starting material,10a and Giuliano and 
Villani prepared axenose in 12 steps (~4% yield) using 2-deoxy-D-ribose as starting 
material.10b For our planned synthetic route to the trioxacarcins we required access to 
gram quantities of optically pure trioxacarcinose A (2) in a form suitable for glycosidic 
coupling reactions, and we envisioned that an enantioselective synthesis proceeding from 
non-carbohydrate starting materials was likely to succeed. A retrosynthetic analysis of 
trioxacarcinose A (2) is shown in Figure 2.1. We considered the open-chain form of this 
sugar and focused on carbonyl addition transforms which would disconnect carbon-
carbon bonds to C3. We envisioned that addition of an allylmetal reagent to an 
appropriately protected syn-2,3-dihydroxy methyl ketone—or, alternatively, addition of a 
methylmetal reagent to a syn-2,3-dihydroxy allyl ketone—could construct the C3-tertiary 
alcohol in a diastereoselective fashion. We envisioned the preparation of either ketone 
from an appropriately protected syn-2,3-dihydroxybutyrate ester. 
 
 
Figure 2.1. Retrosynthetic Analysis of Trioxacarcinose A (2) 
 
                                                 
19 For a synthetic route to 3-epi-axenose, see: Roush,W.; Hagadorn, S. Carbohydr. Res. 1985, 136, 187–
193. 
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Scalable Synthesis of Enantiomerically Pure syn-2,3-Dihydroxybutyrate 
To prepare trioxacarcinose A (2) according to our planned route, we required 
gram quantities of (2R,3S)-dihydroxybutyric acid in protected form and targeted (2R,3S)-
dihydroxybutyric acid acetonide ((+)-31) as an early intermediate. (2R,3S)-
dihydroxybutyric acid acetonide ((+)-31) and its enantiomer have served as valuable 
building blocks for the assembly of complex carbohydrates and other densely oxygenated 
molecules.20 Three prior routes to 31 or its methyl ester had been executed previously, 
and these are summarized in Scheme 2.1.21 Servi prepared the methyl ester of (–)-31 by 
diazotization–hydrolysis of threonine.21a Oppolzer and Barras, on the other hand, 
prepared the methyl ester of (+)-31 using an auxiliary-controlled, diastereoselective 
dihydroxylation reaction.21b Finally, Röper and coworkers prepared (–)-31 by kinetic 
resolution of the corresponding racemic n-butyl ester.21c Of these routes, only the 
diazotization–hydrolysis of threonine21a has been used to prepare multigram quantities of 
31, so far as we are aware, and this route is typically used to prepare (–)-31 from the 
naturally occurring L-(–)-threonine, as D-(+)-threonine is a less readily available starting 
material.  
                                                 
20 (a) Roush, W. R.; Lin, X.; Straub, J. A. J. Org. Chem. 1991, 56, 1649–1655. (b) Ruiz, M.; Ojea, V.; 
Ruanova, T. M.; Quintela, J. M. Tetrahedron: Asymmetr. 2002, 13, 795–799. (c) Gardiner, J. M.; Panchal, 
N. R.; Stimpson, W. T.; Herbert, J. M.; Ellames, G. J. Synlett 2005, 2005, 2685–2687. 
21 (a) Servi, S. J. Org. Chem. 1985, 50, 5865–5867. (b) Oppolzer, W.; Barras, J.-P. Helv. Chim. Acta 1987, 
70, 1666–1675. (c) Pottie, M.; Van der Eycken, J.; Vandewalle, M.; Dewanckele, J.; Röper, H. Tetrahedron 
Lett. 1989, 30, 5319–5322. 
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Scheme 2.1. Prior Syntheses of syn-2,3-Dihydroxybutyrate and Its Methyl Ester 
We considered alternative routes to 31 that would allow for the preparation of 
large quantities of either enantiomer with equal ease. The Sharpless asymmetric 
dihydroxylation22 of a crotonate ester appeared to be an attractive and general solution, 
potentially providing access to 31 of either enantiomeric series. We noted the precedent 
established by Ley and coworkers as part of their efforts to synthesize natural products of 
the bengazole family, in which the dihydroxylation of ethyl crotonate furnished (–)-31 
ethyl ester23 in 96% yield (>95% ee, 3-g scale). In this methodology, relatively large 
volumes of organic extractant were used to isolate the highly water-soluble product, and 
                                                 
22 Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483–2547. 
23 As recently as 2005, literature reports had indicated that 31 ethyl ester was commercially available: 
Gardiner, J.; Panchal, N.; Stimpson, W.; Herbert, J.; Ellames, G. Synlett 2005, 17, 2685–2687. However, to 
the best of our knowledge, this substance is no longer widely available. For the preparation of 31 ethyl 
ester, see: Sakai, T.; Nakamura, T.; Fukuda, K.; Amano, E.; Utaka, M.; Takeda, A. Bull. Chem. Soc. Jpn. 
1986, 59, 3185–3188. 
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chromatographic purification was required.24 In view of this precedent, we began to 
survey a larger set of crotonate esters and reaction conditions in an attempt to develop a 
procedure which was optimized toward ease of purification, scalability, and enantiomeric 
purity of the product. 
Methyl, ethyl, and n-hexyl crotonate esters are each commercially available in 
geometrically pure form (reported purity 100% trans). Dihydroxylation of trans-methyl 
crotonate with potassium osmate (0.50 mol %), (DHQ)2PHAL25 (1.0 mol %), 
methanesulfonamide (1 equiv), potassium ferricyanide (3 equiv), and potassium 
carbonate (3 equiv), conditions reported by Sharpless and coworkers,26 afforded the syn 
diol in 89% ee27 and 45% yield (Table 2.1, entry 1). We believe the low yield can be 
attributed to the poor efficiency of the extraction of the water-soluble product from the 
aqueous reaction mixture, but more importantly, the enantioselectivity of the 
transformation was too low for our purposes. Dihydroxylation of trans-n-hexyl crotonate, 
also commercially available, afforded an improved yield (88%), but the enantioselectivity 
of the transformation was still lower than we desired (80% ee, entry 2). The 
enantioselectivity was slightly higher when (DHQ)2AQN was used as ligand (entry 3) in 
place of (DHQ)2PHAL, as expected.28  
 
                                                 
24 Bull, J. A.; Balskus, E. P.; Horan, R. A.; Langner, M.; Ley, S. V. Chem.-Eur. J. 2007, 13, 5515–5538. 
25 Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; 
Morikawa, K.; Wang, Z. M. J. Org. Chem. 1992, 57, 2768–2771. 
26 Kwong, H.-L.; Sorato, C.; Ogino, Y.; Chen, H.; Sharpless, K. B. Tetrahedron Lett. 1990, 31, 2999–3002. 
Under these biphasic reaction conditions, the osmium(VI) monoglycolate intermediate cannot be oxidized 
prior to hydrolysis and release of the diol product. This prevents entry into the so-called  “second  cycle,”  
which proceeds via an osmium(VI) bisglycolate ester and is poorly enantioselective: Wai, J. S. M.; Marko, 
I.; Svendsen, J. S.; Finn, M. G.; Jacobsen, E. N.; Sharpless, K. B. J. Am. Chem. Soc. 1989, 111, 1123–1125. 
27 The enantiomeric excess was determined by 1H NMR analysis of the corresponding bis-Mosher ester. 
See: Dale, J. A.; Dull, D. L.; Mosher, H. S. J. Org. Chem. 1969, 34, 2543–2549. 
28 Becker, H.; Sharpless, K. B. Angew. Chem. Int. Ed. 1996, 35, 448–451. 
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Table 2.1. Dihydroxylation of trans-Crotonate Estersa 
 
 
In order to improve the reaction further we prepared several crotonate esters by 
reaction of a number of alcohols and commercial crotonoyl chloride, which is 
inexpensive but impure (~20:1 mixture of trans and cis isomers, respectively; 90% 
purity). The unpurified esters were dihydroxylated and the enantiomeric excess was 
determined by 1H NMR analysis of the corresponding bis-Mosher ester as before. 
Dihydroxylation of benzyl crotonate prepared in this manner afforded diol of 92% ee 
(Table 2.1, entry 4).29 Encouraged by this result, we examined the dihydroxylation of 
several substituted benzyl crotonate esters (p-methoxybenzyl, p-nitrobenzyl, benzhydryl, 
and p-phenylbenzyl), and all of these were dihydroxylated to furnish diol products of 87–
92% ee. We were especially encouraged to observe that the dihydroxylation of p-
                                                 
29 This degree of enantioselectivity is in excellent agreement with a previous report: Tagami, K.; Takagi, S.; 
Shiro, M.; Nagao, Y. Heterocycles 1997, 45, 1663–1669. 
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phenylbenzyl crotonate (used without purification) afforded a highly crystalline diol 
product of 87% ee. A single recrystallization of the diol product from dichloromethane–
hexanes provided p-phenylbenzyl (2R,3S)-dihydroxybutyrate (32) of >95% ee (entry 5). 
 
 
Scheme 2.2. Synthesis of Carboxylic Acid (+)-31 
Dihydroxylation of p-phenylbenzyl crotonate was easily conducted on a 
multigram scale. In one experiment, p-phenylbenzyl alcohol (22 g, 119 mmol) was 
esterified with commercial crotonoyl chloride (~20:1 E:Z; 90% purity) in the presence of 
potassium carbonate (2.0 equiv) and a catalytic quantity of 4-(dimethylamino)pyridine 
(DMAP, 10 mol %) (Scheme 2.2). The crude ester, a ~17:1 mixture of E and Z isomers, 
was subjected to conditions for the Sharpless asymmetric dihydroxylation. Complete 
conversion to the diol was achieved with low catalyst loading (0.25 mol % potassium 
osmate, 0.50 mol % (DHQ)2AQN), an extended reaction time (~5 days), and distributed 
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addition of potassium ferricyanide (6 equiv).30 Methanesulfonamide was removed by a 
sequence of aqueous washes.31 The unpurified diol product was found to be of 87% ee by 
1H NMR analysis of the corresponding bis-Mosher ester. One recrystallization of the 
crude product from dichloromethane–hexanes provided pure diol (+)-32 of >95% ee in 
81% yield from p-phenylbenzyl alcohol (Table 2.2,  entry  1,  “method  A”;;  27.8-g batch; 
[α]D = +22.7° (c 1.04, CH2Cl2)). 
 
Table 2.2. Protocols for Large-Scale Dihydroxylation 
 
In light of the long reaction time required for the optimized dihydroxylation 
procedure   (~5   days),   referred   to   as   “method   A,”   (Table 2.2, entry 1) we briefly 
investigated changes which would shorten the reaction time. More rapid warming of the 
                                                 
30 As the alkene was a ~17:1 mixture of E and Z isomers, we expected the dihydroxylation reaction to 
afford a mixture of syn and anti diols. Syn and anti methyl 2,3-dihydroxybutyrate exhibit a characteristic 
difference in the  chemical shift of the C4 methyl group. 1H  NMR  (300  MHz,  CDCl3):  anti  δ  1.18  (d,  3H,  J 
=  6  Hz):  Mahalingam,  S.  M.;;  Sathyamurthi,  N.;;  Aidhen,  I.  S.  Adv. Synth. Catal. 2005, 347, 715–717;;  syn  δ  
1.31 (d, 3H, J = 6.5 Hz): Umemura, E.; Tsuchiya, T.; Umezawa, S. J. Antibiot. 1988, 41, 530–537. On this 
basis we estimate that product was formed as a ~21:1 mixture of syn and anti diastereomers, respectively. 
The minor diastereomer was removed upon recrystallization.  
31 Similar washings of diol product mixtures derived from more water-soluble esters (such as methyl) led to 
significant loss of product. 
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reaction mixture (under otherwise identical conditions, 0.1 mol scale) led to poorer 
conversion, and p-phenylbenzyl alcohol was observed in the crude product mixture. The 
latter byproduct presumably formed as a result of saponification of either the diol product 
(32) or the substrate under the moderately basic aqueous reaction conditions.32 Sharpless 
and coworkers have noted that for electron-poor olefins turnover can be increased with 
little or no diminution in enantioselectivity by increasing the loading of osmium.33 Using 
increased catalyst loading (1.0 mol% potassium osmate, 1.0 mol % (DHQ)2AQN) and 
adding sodium bicarbonate (3 equiv) to buffer the aqueous phase, the large-scale 
dihydroxylation reaction was complete within 25 h. The crude product mixture contained 
≤3%   p-phenylbenzyl alcohol, as determined by integration of its 1H NMR spectrum. 
Recrystallization of this crude product from dichloromethane–hexanes provided pure diol 
32 in 60% yield and >95% ee (Table 2.2,   entry   2,   “method  B”).  We   believe   that   this  
protocol, with a shorter reaction time and a lower yield, provides a viable alternative to 
the longer reaction time but higher yield obtained using method A. 
With efficient procedures for the preparation of enantiomerically pure diol (+)-32, 
we found that a short sequence of standard transformations led to the desired 
dihydroxybutyric acid acetonide (+)-31 (Scheme 2.2). Protection of the diol function was 
accomplished in quantitative yield by stirring with 2,2-dimethoxypropane and p-
toluenesulfonic acid monohydrate (5 mol %) to provide acetonide 33. Saponification in 
                                                 
32 Saponification appears to be a background process under all conditions examined for the large-scale 
dihydroxylation of 4-phenylbenzyl  crotonate.  Thus,  using  “method  A”  (0.25  mol  %  K2OsO4·2H2O, 5-day 
reaction time), the saponification product comprised ~3% of the crude mixture, as determined by 
integration of a diagnostic signal in the 1H  NMR  spectrum  (500  MHz,  CDCl3):  δ  4.75  (s,  2H,  Ar–CH2OH). 
33 (a) Walsh, P. J.; Sharpless, K. B. Synlett 1993, 605–606. (b) AD-mix containing 5 mol % potassium 
osmate  and  1  mol  %  PHAL  ligand  is  referred  to  in  the  literature  as  “Modified-AD-mix”.  See:  Bennani,  Y.  
L.; Sharpless, K. B. Tetrahedron Lett. 1993, 34, 2079–2082.  (c)  Roberts  et  al.  have  designed  a  “Super-AD-
mix”  containing 8–10 mol % osmium tetroxide and 10 mol % PHAL ligand: Hermitage, S. A.; Murphy, A.; 
Nielsen, P.; and Roberts, S. M. Tetrahedron 1998, 54, 13185–13202. 
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aqueous lithium hydroxide furnished the desired carboxylic acid (+)-31 in 99% yield after 
extractive isolation. In the largest run, this route furnished 15 g of enantiomerically pure 
acid (+)-31 in 4 steps and 79% overall yield. Additionally, p-phenylbenzyl alcohol, which 
functioned as an expedient for purification and enantioenrichment by recrystallization, 
was recovered in 73% overall yield and could be used in subsequent runs. 
 
Synthesis of Methyl Trioxacarcinoside A  
With a practical protocol for preparing carboxylic acid (+)-31 on a multigram 
scale, we turned our attention to the conversion of this material to trioxacarcinose A (2). 
We hoped to form the C3 tertiary alcohol of trioxacarcinose A in a diastereoselective 
fashion by addition of an appropriate allylmetal reagent to a methyl ketone derived from 
carboxylic acid 31 (or diol 32), or, alternatively, by addition of an appropriate 
methylmetal reagent to an allyl ketone derived from the same material (see the 
retrosynthetic analysis in Figure 2.1). We expected that the choice of diol protective 
group(s) would influence the stereochemical outcome of organometallic additions to such 
ketones. It was initially unclear whether the acetonide protective group present within 
carboxylic acid 31 would be optimal for the diastereoselective additions we envisioned, 
as the literature did not offer clear guidance as to which protective groups might ensure 
the desired stereochemical outcome. While α-chelation-controlled34 additions of Grignard 
reagents to substrates containing 2-tetrahydrofuranyl  and  α-benzyloxymethyloxy ketones 
                                                 
34 (a) Cram, D. J.; Kopecky, K. R. J. Am. Chem. Soc. 1959, 81, 2748–2755. (b) Still, W. C.; McDonald III, 
J. H. Tetrahedron Lett. 1980, 21, 1031–1034. (c) Reetz, M. T. Acc. Chem. Res. 1993, 26, 462–468. (d) 
Mengel, A.; Reiser, O. Chem. Rev. 1999, 99, 1191–1224. (e) Reetz, M. T. Angew. Chem. Int. Ed. 1984, 23, 
556–569. 
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have been featured in landmark syntheses of natural products,35 Grignard additions to 
acyclic   ketones   bearing   both   α- and   β-oxygenated substituents are of a less certain 
stereochemical outcome.36 
To prepare ketone substrates for initial studies of organometallic addition 
reactions, we first prepared the corresponding Weinreb amide 34 in excellent yield by 
stirring (+)-31 with N,O-dimethylhydroxylamine, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), and N-methylmorpholine (17.4-g batch, Scheme 
2.3).37 Weinreb amide 34 was then converted to both the methyl ketone 3538 and the allyl 
ketone 36 by reaction with methylmagnesium chloride and allylmagnesium chloride, 
respectively, in THF as solvent. 
 
 
Scheme 2.3. Synthesis of Ketones 35 and 36 from Carboxylic Acid 31 via Weinreb 
Amide 34. 
                                                 
35 (a) Nakata, T.; Kishi, Y. Tetrahedron Lett. 1978, 19, 2745–2748. (b) Collum, D. B.; McDonald III, J. H.; 
Still, W. C. J. Am. Chem. Soc. 1980, 102, 2118–2120. 
36 (a) Mulzer, J.; Angermann, A. Tetrahedron Lett. 1983, 24, 2843–2846. (b) Mead, K.; Macdonald, T. L. J. 
Org. Chem. 1985, 50, 422–424. 
37 (a) Campbell, A. D.; Raynham, T. M.; Taylor, R. J. Synthesis 1998, 1707–1709. (b) Nahm, S.; Weinreb, 
S. M. Tetrahedron Lett. 1981, 22, 3815–3818. 
38 The methyl ketone 35 is volatile, especially at reduced pressure. For this reason the crude product, 
estimated  to  be  of  ~90%  purity,  was  used  in  subsequent  transformations  without  puriﬁcation. 
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We briefly explored additions of Grignard reagents to acetonide-protected methyl 
ketone 35 and allyl ketone 36 as summarized in Scheme 2.4; however, in neither case 
was the stereochemical outcome favorable for the purpose of synthesizing trioxacarcinose 
A (2). In one experiment, addition of allylmagnesium chloride to methyl ketone 35 
furnished predominantly the stereoisomer 37 (as the major component of a 4:1 mixture of 
epimers), which is not congruent with trioxacarcinose A at position C3, established by 
conversion of the adduct 37 to methyl 3-epi-axenoside (39) by a three-step sequence 
(Scheme 2.4). In this sequence, the terminal olefin of 37 was cleaved oxidatively to 
furnish aldehyde 38, and the acetonide within this product was cleaved by treatment with 
a catalytic quantity of triflic acid in 2,2,2-trifluoroethanol as solvent at –40 °C.39 The 
resulting 2,2,2-trifluoroethyl glycoside was converted to the methyl glycoside 39 by 
treatment with methanolic hydrochloric acid (formed in situ by addition of acetyl chloride 
to methanol), and the 1H NMR spectrum of the major product was in agreement with that 
of  methyl 3-epi-axenoside.19 The stereochemical course of allylmagnesium chloride 
addition to ketone 35 is   therefore   consistent   with   either   “polar   Felkin–Anh”40 or   β-
chelation-controlled transition   states,   but   not   with   α-chelation-controlled addition. We 
also observed that addition of methylmagnesium chloride to allyl ketone 36 also provided 
the same epimer of tertiary alcohol 37 as the major product, which in this case is 
consistent  with  an  α-chelation-controlled addition. There have been reported instances in 
which the stereochemical outcomes of allyl and methyl Grignard reagents to the same 
                                                 
39 Kobayashi, S.; Reddy, R. S.; Sugiura, Y.; Sasaki, D.; Miyagawa, N.; Hirama, M. J. Am. Chem. Soc. 
2001, 123, 2887–2888. 
40 Anh, N. T., Regio- and Stereo-Selectivities in Some Nucleophilic Reactions. In Organic Chemistry 
Syntheses and Reactivity, Springer Berlin Heidelberg: 1980; Vol. 88, pp 145–162. 
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ketone substrate have been different.41 We briefly surveyed other achiral allylmetal 
additions to 35 and methylmetal additions to 36, but none of the conditions examined 
produced the desired stereochemical outcome. 
 
 
Scheme 2.4. Additions to Acetonide-Protected syn-2,3-Dihydroxyketones 
Due to the unfavorable stereochemical outcomes of addition reactions to the 
acetonide-protected ketone substrates 35 and 36, we were led to explore the use of other 
protective groups for the diol function of diol ester 32. Accordingly, we prepared the 
corresponding di-tert-butyl siloxane derivative42 40 (95% yield, 12.7 g, Scheme 2.5). 
Fortuitously, upon attempted transformation of the di-tert-butylsiloxane ester 40 into the 
corresponding methyl ketone using the Merck single step process (via the Weinreb amide 
                                                 
41 Carda, M.; González, F.; Rodríguez, S.; Marco, J. A. Tetrahedron: Asymm. 1993, 4, 1799–1802. 
42 (a) Trost, B. M.; Caldwell, C. G. Tetrahedron Lett. 1981, 22, 4999–5002. (b) Corey, E.; Hopkins, P. B. 
Tetrahedron Lett. 1982, 23, 4871–4874. 
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derivative),37b,43 concomitant, regioselective cleavage of the cyclic siloxane group 
occurred, giving rise to the di-tert-butylmethyl silyl ether 41 (5.3 g, 65% yield). Although 
regioselective openings of di-tert-butylsiloxane derivatives with organolithium reagents 
have been described,44 we are unaware of previous examples of the corresponding 
transformations with Grignard reagents. 
 
 
Scheme 2.5. Synthesis of Methyl Ketone 41 
 
The conversion of cyclic siloxane 40 to the monosilyl ether 41 enabled our first 
route to trioxacarcinose A (Scheme 2.6).   Treatment   of   α-hydroxyketone 41 with 
allylmagnesium chloride in THF at –78 °C provided tertiary alcohol 42 with 13:1 
diastereoselectivity,  consistent  with  an  α-chelation-controlled addition mechanism (3.59 
                                                 
43 Williams, J. M.; Jobson, R. B.; Yasuda, N.; Marchesini, G.; Dolling, U.-H.; Grabowski, E. J. 
Tetrahedron Lett. 1995, 36, 5461–5464. 
44 (a) Mukaiyama, T.; Shiina, I.; Kimura, K.; Akiyama, Y.; Iwadare, H. Chem. Lett. 1995, 1995, 229–230. 
(b) Tanino, K.; Shimizu, T.; Kuwahara, M.; Kuwajima, I. J. Org. Chem. 1998, 63, 2422–2423. 
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g, 86% yield).45 The product 42 is stereochemically congruent with trioxacarcinose A (2), 
as established by its conversion to methyl axenoside (46), en route to 2.  
 
 
Scheme 2.6. Syntheses of Methyl Axenoside (46) and Methyl Trioxacarcinoside A (47) 
Oxidative cleavage of the terminal alkene of 42 occurred in the presence of 
potassium osmate and sodium metaperiodate,46 providing the furanose derivative 43 as a 
mixture   of   anomers   (1.97   g,   55%   yield,   α:β   ≈   1:5).   Deprotection of the di-tert-
                                                 
45 Chelation-controlled  Grignard   additions  of   α-hydroxyketones, while relatively uncommon, are known. 
For an example, see: Matsunaga, N.; Kaku, T.; Ojida, A.; Tasaka, A. Tetrahedron: Asymm. 2004, 15, 
2021–2028. 
46 Yu, W.; Mei, Y.; Kang, Y.; Hua, Z.; Jin, Z. Org. Lett. 2004, 6, 3217–3219. 
37 
 
butylmethyl silyl ether, a robust and hindered protective group,47 was best accomplished 
by a two-step sequence. The cyclic hemiacetal 43 was first converted to the more stable 
methyl glycoside 44 with p-toluenesulfonic acid (p-TSA) in methanol (89% yield). The 
methyl glycoside was then smoothly desilylated with TBAF at 23 °C to provide the 
mixture of methyl furanoside anomers 45 (890 mg, 91% yield). The methyl furanosides 
45 were isomerized to the more stable methyl pyranosides 46 (methyl   α- and   β-
axenoside) by a known transformation with methanolic HCl at 23 °C.10b,48 Analytical data 
for 46 were in agreement with those previously reported for methyl axenoside.10 
Selective acetylation of the secondary hydroxyl group provided methyl trioxacarcinoside 
A (47, 970 mg, 88% over two steps). Analytical data were in agreement with those 
reported for the same substance derived from natural sources.6  
Hydrolysis of methyl trioxacarcinoside A (47) in 1.0 M aqueous hydrochloric acid 
provided trioxacarcinose A itself (2), which in turn was acetylated at the anomeric 
position to provide the 1-O-acetyl glycoside 48 in  69%  yield  over  two  steps  (α:β  ≈  1:3).  
1-O-acetyl glycosides are known to be effective glycosyl donors, do not require 
activation for coupling,49 and can be converted into several other types of glycosyl 
donors.50 Our synthetic route provided this anomerically activated form of 
                                                 
47 Nicolaou, K.; Yue, E. W.; La Greca, S.; Nadin, A.; Yang, Z.; Leresche, J. E.; Tsuri, T.; Naniwa, Y.; de 
Riccardis, F. Chem.-Eur. J. 1995, 1, 467–494. 
48 The  product  is  a  (presumably,  thermodynamic)  mixture  of  methyl  pyranoside  and  furanoside  isomers:  β-
pyranoside:  62%,  α-pyranoside:  34%,  β-furanoside:  4%,  α-furanoside: <1%. 
49 Toshima, K.; Tatsuta, K. Chem. Rev. 1993, 93, 1503–1531. (a) Ogawa, T.; Kitajima, T.; Nukada, T. 
Carbohyd. Res. 1983, 123, C8–C11. (b) Hayashi, M.; Hashimoto, S.-i.; Noyori, R. Chem. Lett. 1984, 1747–
1750. (c) Kihlberg, J. O.; Leigh, D. A.; Bundle, D. R. J. Org. Chem. 1990, 55, 2860–2863. (d) Sarkar, S.; 
Lombardo, S. A.; Herner, D. N.; Talan, R. S.; Wall, K. A.; Sucheck, S. J. J. Am. Chem. Soc. 2010, 132, 
17236–17246. 
50 (a) Ogawa, T.; Kitajima, T.; Nukada, T. Carbohyd. Res. 1983, 123, C8–C11. (b) Hayashi, M.; 
Hashimoto, S.-i.; Noyori, R. Chem Lett 1984, 1747–1750. (c) Kihlberg, J. O.; Leigh, D. A.; Bundle, D. R. 
J. Org. Chem. 1990, 55, 2860–2863. (d) Sarkar, S.; Lombardo, S. A.; Herner, D. N.; Talan, R. S.; Wall, K. 
A.; Sucheck, S. J. J. Am. Chem. Soc. 2010, 132, 17236–17246. 
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trioxacarcinose A in 12 steps from p-phenylbenzyl alcohol in 12% overall yield (84% 
average yield per step). 
 
Second-Generation Synthesis of Trioxacarcinose A in Activated Form 
The route outlined above proved to be an effective means of synthesizing 
trioxacarcinose A (2) and derivatives thereof. Nevertheless, we considered an even 
shorter sequence based on remarkable work from Paquette and coworkers describing 
diastereoselective, indium-mediated allylation reactions of aldehyde and ketone 
substrates containing free hydroxyl groups, in water as solvent.51 Selected examples from 
the work of Paquette are summarized in Scheme 2.7. For example, Paquette and Mitzel 
demonstrated that indium-mediated   allylation   of   the   α-hydroxyaldehyde 49 proceeded 
with high diastereoselectivity to afford predominantly the syn product, which is 
consistent   with   an   α-chelation-controlled addition mechanism.51a Allylation   of   β-
hydroxyaldehyde 50 under the same conditions furnished the anti product, consistent with 
a  β-chelation-controlled mechanism. They also reported the very interesting case of In-
mediated allylation of the polyol D-arabinose (51), for which the directing effects of the 
α- and  β-hydroxyl groups were, in principle, nonreinforcing (and the effects of  the  γ- and 
δ-hydroxyl  groups  were  unknown).   In   this  case,   the  product  of  α-chelation control was 
formed with high diastereoselectivity. This result in particular suggested that allylation of 
the dihydroxy ketone (3R,4S)-dihydroxy-2-pentanone (52), with nonreinforcing  α- and  β-
                                                 
51 (a) Paquette, L. A.; Mitzel, T. M. Tetrahedron Lett. 1995, 36, 6863–6866. (b) Paquette, L. A.; Mitzel, T. 
M. J. Am. Chem. Soc. 1996, 118, 1931–1937. (c) Paquette, L. A.; Lobben, P. C. J. Org. Chem. 1998, 63, 
5604–5616. 
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directing  effects,  might  proceed  in  the  desired  sense  (with  α-chelation control) to provide 
an extraordinarily short and practical sequence to trioxacarcinose A. 
 
 
Scheme 2.7. Indium-Mediated Allylations of Hydroxyaldehydes as Described by 
Paquette and Mitzel.51a 
 
To investigate the proposed indium-mediated allylation reaction, the Weinreb 
amide 34 (see Scheme 2.3) was first converted to the required dihydroxyketone substrate 
52 (9.89 g, 98% yield) in a single operation (Scheme 2.8). Allylation of ketone 52 (3.43 
g) using indium powder (1.6 equiv) and allyl bromide  (1.6 equiv) in water at 23 °C, 
conditions typical of those employed by Paquette and Mitzel,51b indeed proceeded with 
predominant  α-chelation control to provide the water-soluble triol 53 as a 15:1 mixture of 
diastereomers. Direct ozonolysis of this diastereomeric mixture followed by reductive 
quenching with dimethylsulfide provided axenose (15), predominantly in its pyranose 
form. The crude product was acetylated to provide 1-O-acetyl trioxacarcinose A (48) in 
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pure form after chromatographic purification (42% yield over three steps from 52, 2.97 g, 
α:β  ≈  1:12).   
 
 
Scheme 2.8. Second-Generation Synthesis of 1-O-Acetyl Trioxacarcinose A (48) 
Methanolysis (using acetyl chloride in methanol) of 1-O-acetyl trioxacarcinose A 
(48) synthesized by this second route provided methyl trioxacarcinoside A (47, 74% 
yield, see Experimental Section), which provided analytical data indistinguishable from 
those of 47 from the first route, described above. This second route provided 1-O-acetyl 
trioxacarcinose A (48) in 9 steps from p-phenylbenzyl alcohol, in 29% overall yield 
(average 87% yield per step). By virtue of its shorter step count, higher overall yield, and 
greater convenience, this route provides a particularly useful means to access 
anomerically activated forms of trioxacarcinose A (2). 
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Synthesis of Anomerically Activated Derivatives of Trioxacarcinose A 
Fully synthetic 1-O-acetyltrioxacarcinose A (48), which was first prepared using 
the first-generation route to trioxacarcinose A (Scheme 2.6) and specifically targeted in 
the second-generation route (Scheme 2.8), provided one very useful anomerically 
activated derivative of this sugar. We also briefly explored the preparation of other 
anomerically activated derivatives of trioxacarcinose A (Scheme 2.9). Addition of 
diethylaminosulfur trifluoride (DAST) to a solution of trioxacarcinose A (2) (prepared by 
acidic hydrolysis of the methyl glycoside 47, Scheme 2.6) in tetrahydrofuran at –30 °C 
afforded the moisture- and acid-sensitive glycosyl fluoride 54 (22 mg, 84%). Analysis of 
the 1H and 19F NMR spectra of the crude reaction product revealed that the α- and β-
anomers were present in nearly equal amounts (α:β  ≈  1:1.1).  The 1-phenylthio derivatives 
55 were prepared by treatment of 1-O-acetyltrioxacarcinose A (48) with thiophenol in the 
presence  of  boron  trifluoride  etherate  (103  mg,  86%,  α:β  ≈  1:2.4). 
 
 
Scheme 2.9. Preparation of Anomerically Activated Derivatives of Trioxacarcinose A. 
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Conclusion 
In this chapter, I have described two efficient, enantioselective synthetic routes to 
the axenose–trioxacarcinose A carbohydrate class from non-carbohydrate starting 
materials. Both routes relied upon diastereoselective addition reactions of allylmetal 
reagents to α,β-dioxygenated ketones, using the principle of α-chelation to control the 
stereochemical outcomes of these additions. The synthetic routes were enabled by a 
scalable protocol that I developed for the synthesis of their common starting material, the 
crystalline substance p-phenylbenzyl (2R,3S)-dihydroxybutyrate (32). Both routes 
allowed me to prepare gram quantities of optically pure trioxacarcinose A (2) in forms 
suitable for glycosidic coupling reactions. 
In Chapter 3, I describe a component-based synthetic route to the trioxacarcin 
natural products trioxacarcin A (1) and DC-45-A1 (10), both of which contain a 
trioxacarcinose A residue in an α-linkage to the aglycon core. The anomerically activated 
derivatives 1-O-acetyl trioxacarcinose A (48) and 1-phenylthiotrioxacarcinoside A (55) 
were used for the introduction of this sugar to synthetic precursors of DC-45-A1 (10) and 
trioxacarcin A (1), respectively. Both of these anomerically activated derivatives also 
proved useful for the introduction of the trioxacarcinose A residue to several fully 
synthetic trioxacarcin analogs, the preparation of which I describe in Chapter 4. 
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Experimental Section 
General Experimental Procedures 
All reactions were performed in round-bottom flasks fitted with rubber septa 
under a positive pressure of argon, unless otherwise noted. Air- and moisture-sensitive 
liquids were transferred by syringe or stainless steel cannula. Organic solutions were 
concentrated   by   rotary   evaporation   (house   vacuum,   ca.   25−40   Torr)   at   ambient  
temperature, unless otherwise noted. Analytical thin-layer chromatography (TLC) was 
performed using glass plates pre-coated with silica gel (0.25 mm, 60 Å pore-size, 
230−400  mesh,  Merck  KGA)   impregnated  with   a   fluorescent   indicator   (254  nm).  TLC  
plates were visualized by exposure to ultraviolet light, then were stained by submersion 
in aqueous ceric ammonium molybdate (CAM) or an aqueous sodium hydroxide–
potassium carbonate solution of potassium permanganate (KMnO4) followed by brief 
heating on a hot plate. Flash-column chromatography was performed as described by Still 
et al.,52 employing silica gel (60 Å, 32-63   μm, standard grade, Dynamic Adsorbents, 
Inc.). 
 
Materials 
Commercial solvents and reagents were used as received with the following 
exceptions. Tetrahydrofuran, dichloromethane, benzene, toluene, and ether were purified 
by the method of Pangborn et al.53 4-Å molecular sieves (powder, Aldrich) were stored in 
                                                 
52 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
53 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 
15, 1518–1520. 
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a laboratory oven at 140 °C and were allowed to cool in a desiccator immediately before 
use.  
 
Instrumentation 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded using Varian 
INOVA 500 (500 MHz) or Varian INOVA 600 (600 MHz) NMR spectrometers at 23 °C. 
Proton   chemical   shifts   are   expressed   in   parts   per   million   (ppm,   δ   scale)   and   are  
referenced to residual protium in the NMR solvent (CHCl3,   δ   7.26   ppm;;  DMSO-d5,   δ  
2.50 ppm). Data are represented as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet and/or multiple resonances), integration, 
coupling constant (J) in Hertz. Carbon nuclear magnetic resonance (13C NMR) spectra 
were recorded using Varian Mercury 400 (100 MHz) or Varian INOVA 500 (125 MHz) 
NMR spectrometers at 23 °C. Carbon chemical shifts are expressed in parts per million 
(ppm,  δ  scale)  and  are  referenced  to  the  carbon  resonances  of  the  NMR  solvent  (CDCl3,  δ  
77.0, DMSO-d6,   δ   39.52 ppm). Infrared (IR) spectra were obtained using a Shimadzu 
8400S FT-IR spectrometer. Data are represented as follows: frequency of absorption 
(cm−1), intensity of absorption (vs = very strong, s = strong, m = medium, w = weak, br = 
broad). Optical rotations were measured on a Jasco DIP-0181 digital polarimeter with a 
sodium lamp and are reported as follows: [D] T[°C] λ (c = g/100 mL, solvent). High-
resolution mass spectra were obtained at the Harvard University Mass Spectrometry 
Facility. Melting points were measured using a Thomas Hoover uni-melt apparatus 
(6427F10). 
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(For clarity, intermediates that have not been assigned numbers in the text are 
numbered sequentially in the Experimental Section beginning with 56.)  
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(2R,3S)-Biphenyl-4-ylmethyl 2,3-Dihydroxybutanoate (32). 
Method A.  
4-Dimethylaminopyridine (1.46 g, 11.9 mmol, 0.1 equiv) was added to a 
suspension of crotonoyl chloride (technical grade, 14.0 mL, 146 mmol, 1.22 equiv), p-
phenylbenzyl alcohol (22.0 g, 119 mmol, 1 equiv), and potassium carbonate (33.0 g, 239 
mmol, 2.0 equiv) in dichloromethane (240 mL) at 23 qC. After 7 h, a second portion of 
crotonoyl chloride (12.7 mL, 133 mmol, 1.11 equiv) was added. After 15 h, water (200 
mL) was added. The layers were separated. The aqueous layer was extracted with 
dichloromethane (200 mL). The organic layers were combined. The combined solution 
was washed sequentially with saturated aqueous sodium bicarbonate solution (200 mL), 
1.0 M aqueous hydrochloric acid solution (200 mL), water (200 mL), then saturated 
aqueous sodium chloride solution (200 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was dissolved in a mixture of tert-butanol (240 mL) and water (240 mL). 
Potassium carbonate (49.5 g, 358 mmol, 3.0 equiv), potassium ferricyanide (118 g, 358 
mmol, 3.0 equiv), and (DHQ)2AQN (511 mg, 0.596 mmol, 0.005 equiv) were added in 
sequence, and the mixture was cooled to  4 qC. Potassium osmate dihydrate (110 mg, 
0.928 mmol, 0.0025 equiv) was added. After 10 min, methanesulfonamide (5.67 g, 59.6 
mmol, 0.5 equiv) was added. After 48 h, the cooling bath was removed and the reaction 
flask was allowed to warm to 23 qC. After 23 h, a second portion of potassium 
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ferricyanide (59.0 g, 179 mmol, 1.5 equiv) was added. After 18 h, a third portion of 
potassium ferricyanide (59.0 g, 179 mmol, 1.5 equiv) was added. After 25 h, the reaction 
flask was cooled on an ice bath. Sodium sulfite (150 g, 1.19 mol, 10 equiv) was added 
slowly. After 1 h, the product mixture was extracted with ethyl acetate (6 u 500 mL). The 
organic layers were combined. The combined solution was washed sequentially with 1.0 
M aqueous sodium hydroxide solution (1.5 L) then saturated aqueous sodium chloride 
solution (1.0 L) and the washed solution was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The residue was dissolved in a 
minimal amount of hot dichloromethane (~200 mL, 35 qC). The resulting solution was 
heated to boiling in an oil bath at 65 qC, and hexanes was added slowly such that boiling 
was maintained. Upon the first appearance of a white precipitate, an amount of 
dichloromethane sufficient to dissolve the precipitate was added (~20 mL). The oil bath 
was removed and the flask was allowed to cool to 23 qC. The flask was further cooled to 
–20 qC. After 15 h, a light-yellow crystalline solid had precipitated from the yellow 
supernatant. The mixture was filtered and the solid was washed with cold hexanes (100 
mL, –20 qC) to provide the product, (2R,3S)-biphenyl-4-ylmethyl 2,3-
dihydroxybutanoate (32), as light-yellow needles (27.8 g, 81% yield based on p-
phenylbenzyl alcohol).  
To determine the enantiomeric excess, (S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoyl chloride (6.3 PL, 34 Pmol, 2.4 equiv) was added to a solution of 
(2R,3S)-biphenyl-4-ylmethyl 2,3-dihydroxybutanoate 32 (4 mg, 14 Pmol, 1 equiv) and 4-
dimethylaminopyridine (8.2 mg, 67 Pmol, 4.8 equiv) in dichloromethane (280 PL) at 23 
qC. After 90 min, the product solution was partitioned between ethyl acetate (20 mL) and 
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water (5 mL). The layers were separated. The organic layer was washed sequentially with 
1.0 M aqueous hydrochloric acid solution (5 mL), saturated aqueous sodium bicarbonate 
solution (5 mL), water (5 mL), then saturated aqueous sodium chloride solution (5 mL) 
and the washed solution was dried over sodium sulfate. The dried solution was filtered 
and the filtrate was concentrated. Analysis of the 1H NMR spectrum of the crude product 
established that complete conversion to the bis-Mosher ester had occurred. The product 
was determined to be of 49:1 d.r. (1H NMR analysis (500 MHz, CDCl3): G 5.76 (qd, 1H, 
J = 6.8, 2.4 Hz (2S,3R, minor)), 5.70 (qd, 1H, J = 6.4, 2.0 Hz (2R,3S, major))), from 
which we concluded that the starting diol, (2R,3S)-biphenyl-4-ylmethyl 2,3-
dihydroxybutanoate (2), was of >95% ee. 
 
Method B.  
4-Dimethylaminopyridine (1.46 g, 11.9 mmol, 0.1 equiv) was added to a 
suspension of crotonoyl chloride (technical grade, 34.3 mL, 358 mmol, 3.0 equiv), p-
phenylbenzyl alcohol (22.0 g, 119 mmol, 1 equiv), and potassium carbonate (33.0 g, 239 
mmol, 2.0 equiv) in dichloromethane (240 mL) at 23 qC. After 12 h, water (200 mL) was 
added. The layers were separated. The aqueous layer was extracted with dichloromethane 
(200 mL). The organic layers were combined. The combined solution was washed 
sequentially with saturated aqueous sodium bicarbonate solution (200 mL), 1.0 M 
aqueous hydrochloric acid solution (200 mL), water (200 mL), then saturated aqueous 
sodium chloride solution (200 mL) and the washed solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
dissolved in a mixture of tert-butanol (240 mL) and water (240 mL). Potassium carbonate 
49 
 
(49.5 g, 358 mmol, 3.0 equiv), sodium bicarbonate (30.1 g, 358 mmol, 3.0 equiv), 
potassium ferricyanide (118 g, 358 mmol, 3.0 equiv), and (DHQ)2AQN (1.02 g, 1.19 
mmol, 0.01 equiv) were added in sequence, and the mixture was cooled to  4 qC. 
Potassium osmate dihydrate (440 mg, 1.19 mmol, 0.01 equiv) was added. After 20 min, 
methanesulfonamide (11.4 g, 119 mmol, 1.0 equiv) was added. After 10 min, the cooling 
bath was removed and the reaction flask was allowed to warm to 23 qC. After 25 h, the 
reaction flask was cooled in an ice bath. Sodium sulfite (150 g, 1.19 mol, 10 equiv) was 
added slowly. After 30 min, the product mixture was extracted with ethyl acetate (6 u 
500 mL). The organic layers were combined. The combined solution was washed 
sequentially with 1.0 M aqueous sodium hydroxide solution (1.5 L), 1.0 M hydrochloric 
acid (1.0 L), then saturated aqueous sodium chloride solution (1.0 L) and the washed 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was recrystallized from dichloromethane–hexanes as in 
Method A to provide the product, (2R,3S)-biphenyl-4-ylmethyl 2,3-dihydroxybutanoate 
(32), as light-yellow needles (20.6 g, 60% based on p-phenylbenzyl alcohol). The 
recrystallized product was determined to be of >95% ee by formation of the 
corresponding bis-Mosher ester as in Method A. 
 
1H NMR:  
(500 MHz, CDCl3) 
7.60 (t, 4H, J = 8.3 Hz), 7.46 (m, 4H), 7.38 (m, 1H), 
5.33–5.28 (m, 2H), 4.17 (br, 1H), 4.11 (br, 1H), 3.46 (br, 
1H), 2.57 (br, 1H), 1.33 (d, 3H, J = 6.4 Hz).  
 
13C NMR:  173.2, 141.5, 140.4, 133.9, 128.8, 128.8, 127.5, 127.3, 
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(125 MHz, CDCl3) 127, 74.5, 68.7, 67.3, 19.6. 
 
FTIR, cm–1: 
(neat) 
3335 (br), 1701 (s), 1292 (s), 1138 (m), 1067 (m), 1018 
(m), 978 (m), 827 (m). 
 
HRMS:  
(ESI) 
Calcd for (C17H18O4Na) 
Found 
 
309.1097 
309.1100 
 
TLC: 
(30% ethyl acetate–hexanes) 
Rf = 0.11 (CAM) 
 
 
[D]23D: 22.7° (c 1.04, CH2Cl2) 
 
mp: 100.0–101.0 qC 
  
51 
 
 
(4R,5S)-Biphenyl-4-ylmethyl 2,2,5-Trimethyl-1,3-dioxolane-4-carboxylate (33).  
p-Toluenesulfonic acid monohydrate (923 mg, 4.85 mmol, 0.05 equiv) was added 
to a suspension of (2R,3S)-biphenyl-4-ylmethyl 2,3-dihydroxybutanoate 32 (27.8 g, 97.1 
mmol, 1 equiv) in 2,2-dimethoxypropane (350 mL) at 23 qC. After 40 min, triethylamine 
(677 PL, 4.85 mmol, 0.05 equiv) was added. The product solution was filtered through a 
pad of silica gel (length: 8 cm; diameter: 8 cm), eluting with ethyl acetate (2 L). The 
filtrate was concentrated to provide the product, (4R,5S)-biphenyl-4-ylmethyl 2,2,5-
trimethyl-1,3-dioxolane-4-carboxylate (33), as a colorless oil (31.4 g, 99%).  
 
1H NMR:  
(500 MHz, CDCl3) 
7.59 (m, 4H), 7.44 (m, 4H), 7.36 (m, 1H), 5.26 (m, 2H), 
4.22 (dq, 1H, J = 8.2, 6.0 Hz), 4.11 (d, 1H, J = 7.8 Hz), 
1.48 (s, 3H), 1.45 (s, 3H), 1.44 (d, 3H, J = 6.0 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
170.3, 141.3, 140.4, 134.2, 128.7, 128.7, 127.4, 127.3, 
127, 110.6, 80.3, 75.1, 66.6, 27.1, 25.6, 18.5. 
 
FTIR, cm–1: 
(neat) 
2988 (w), 1757 (s), 1184 (s), 1099 (s), 850 (s), 762 (s), 
698 (s). 
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HRMS:  
(ESI) 
Calcd for (C20H22O4Na) 
Found 
 
349.1410 
349.1416 
 
TLC: 
(30% ethyl acetate–hexanes) 
Rf = 0.67 (CAM) 
 
 
  
53 
 
 
(4R,5S)-2,2,5-Trimethyl-1,3-dioxolane-4-carboxylic Acid (31).  
Lithium hydroxide (1.0 M in water, 192 mL, 192 mmol, 2.0 equiv) was added 
over 5 min to an ice-cooled solution of (4R,5S)-biphenyl-4-ylmethyl 2,2,5-trimethyl-1,3-
dioxolane-4-carboxylate 33 (31.4 g, 96.0 mmol, 1 equiv) in a mixture of tetrahydrofuran 
(380 mL) and methanol (190 mL). After 10 min, the product mixture was concentrated to 
remove organic solvents. The aqueous residue was diluted with ether (1 L). The layers 
were separated. The aqueous layer was extracted with ether (500 mL). The organic layers 
were combined. The combined solution was dried over sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated to provide p-phenylbenzyl alcohol (56) as a 
white solid (16.1 g, 91%). The aqueous layer was acidified to pH ~2 by addition of 1.0 M 
aqueous hydrochloric acid solution (~100 mL). The acidified solution was extracted with 
ethyl acetate (500 mL). The pH of the aqueous layer was observed to increase to ~4 after 
extraction of the acidic product. The aqueous layer was again acidified to pH ~2 by 
addition of 1.0 M aqueous hydrochloric acid solution (~50 mL). The acidified solution 
was extracted with ethyl acetate (3 u 500 mL).  The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated to provide the product, (4R,5S)-2,2,5-trimethyl-1,3-dioxolane-4-
carboxylic acid (31), as a colorless oil (15.2 g, 99%). 1H and 13C NMR data were in 
agreement with previously reported values.54 
                                                 
54 Klein, U.; Mohrs, K.; Wild, H.; Steglich, W. Liebigs Ann. Chem. 1987, 1987, 485–489. 
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1H NMR:  
(500 MHz, CDCl3) 
10.23 (br, 1H), 4.24 (dq, 1H, J = 8.3, 5.9 Hz), 4.09 (d, 
1H, J = 8.3 Hz), 1.49 (s, 3H), 1.48 (d, 3H, J = 5.9 Hz), 
1.46 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
175.0, 111.0, 79.8, 75.2, 27.1, 25.6, 18.5. 
 
 
FTIR, cm–1: 
(neat) 
3158 (br), 2990 (w), 1734 (s), 1383 (m), 1219 (s), 1173 
(m), 1099 (s), 853 (m). 
 
HRMS:  
(ESI) 
Calcd for (C7H12O4+H) 
Found 
 
161.0808 
161.0816 
TLC: 
(ethyl acetate) 
Rf = 0.13 (CAM) 
 
 
[D]23D: 34.2° (c 0.61, CHCl3),  
lit.54 31.2° (c 1, CHCl3). 
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(4R,5S)-N-Methoxy-N,2,2,5-tetramethyl-1,3-dioxolane-4-carboxamide (34).  
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (20.1 g, 105 
mmol, 1.1 equiv) was added over 2 min to a solution of (4R,5S)-2,2,5-trimethyl-1,3-
dioxolane-4-carboxylic acid 31 (15.2 g, 95.2 mmol, 1 equiv) and N-methylmorpholine 
(11.5 mL, 105 mmol, 1.1 equiv) in dichloromethane (475 mL) at –20 qC. After 3.5 h, 1.0 
M aqueous hydrochloric acid solution (150 mL) was added. The cooling bath was 
removed and the reaction flask was allowed to warm to 23 qC. The layers were separated. 
The aqueous layer was extracted with dichloromethane (400 mL). The organic layers 
were combined. The combined solution was washed with saturated aqueous sodium 
bicarbonate solution (150 mL) and the washed solution was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated to provide of the product, 
(4R,5S)-N-methoxy-N,2,2,5-tetramethyl-1,3-dioxolane-4-carboxamide (34), as a pale 
yellow oil (17.4 g, 90%).55 
 
1H NMR:  
(500 MHz, CDCl3) 
4.40 (m, 2H), 3.73 (s, 3H), 3.22 (s, 3H), 1.47 (s, 3H), 
1.46 (s, 3H), 1.37 (d, 3H, J = 5.9 Hz). 
 
13C NMR:  170.0, 109.9, 78.2, 74.5, 61.3, 32.0, 27.2, 25.8, 17.9. 
                                                 
55 A preparation of amide ent-34 is described, but characterization data were not reported: Ziegler, F.; Kim, 
H. Tetrahedron Lett. 1993, 34, 7669–7672. 
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(125 MHz, CDCl3) 
 
FTIR, cm–1: 
(neat) 
2986 (w), 2938 (w), 1670 (s), 1371 (m), 1171 (s), 1055 
(m), 854 (m). 
 
HRMS:  
(ESI) 
Calcd for (C9H17NO4Na) 
Found 
 
226.1050 
226.1050 
TLC: 
(40% ethyl acetatehexanes) 
Rf = 0.36 (CAM) 
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1-((4R,5S)-2,2,5-Trimethyl-1,3-dioxolan-4-yl)ethanone (35).  
Methylmagnesium chloride (3.0 M solution in tetrahydrofuran, 6.25 mL, 18.7 
mmol, 3.0 equiv) was added dropwise to an ice-cooled solution of (4R,5S)-N-methoxy-
N,2,2,5-tetramethyl-1,3-dioxolane-4-carboxamide 34 (1.27 g, 6.25 mmol, 1 equiv) in 
tetrahydrofuran (60 mL). After 35 min, saturated aqueous ammonium chloride solution 
(30 mL) was added, and the reaction flask was allowed to warm to 23 qC. The product 
mixture was extracted with ethyl acetate (3 u 70 mL). The organic layers were combined. 
The combined solution was dried over sodium sulfate. The dried solution was filtered and 
the filtrate was concentrated to provide the product, 1-((4R,5S)-2,2,5-trimethyl-1,3-
dioxolan-4-yl)ethanone (35), as a colorless oil (770 mg, 79%). 1H NMR, 13C NMR, IR, 
and MS data were in agreement with previously reported values.56 
 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.70 (CAM) 
 
 
 
  
                                                 
56 For characterization data for ent-35, see: Aoyagi, S.; Wang, T. C.; Kibayashi, C. J. Am. Chem. Soc. 1993, 
115, 11393–11409. 
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1-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)but-3-en-1-one (36).  
Allylmagnesium chloride (2.0 M solution in tetrahydrofuran, 1.48 mL, 2.95 
mmol, 3.0 equiv) was added dropwise to a solution of (4R,5S)-N-methoxy-N,2,2,5-
tetramethyl-1,3-dioxolane-4-carboxamide 34 (200 mg, 0.984 mmol, 1 equiv) in 
tetrahydrofuran (10 mL) at –78 qC. After 25 min, saturated aqueous ammonium chloride 
(5 mL) was added, and the reaction flask was allowed to warm to 23 qC. Water (2 mL) 
was added and the product mixture was extracted with ethyl acetate (2 × 20 mL). The 
organic layers were combined. The combined solution was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (4% ethyl acetate–hexanes) to provide the product, 1-
((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)but-3-en-1-one (36), as a colorless oil (113 
mg, 62%).  
 
1H NMR:  
(500 MHz, CDCl3) 
5.94 (m, 1H), 5.22–5.14 (m, 2H), 4.05 (dq, 1H, J = 8.3, 
6.4 Hz), 3.93 (dd, 1H, J = 8.3, 1.0 Hz), 3.43 (m, 2H), 
1.46 (s, 3H), 1.44 (s, 3H), 1.39 (d, 3H, J = 5.9 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
207.7, 129.7, 119.1, 110.1, 86.3, 74.3, 43.3, 27.2, 26.3, 
18.5. 
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FTIR, cm–1: 
(neat) 
 
2987 (m), 1719 (s), 1382 (s), 1242 (s), 1099 (s), 856 (s). 
HRMS:  
(ESI) 
Calcd for (C10H16O3H) 
Found 
 
185.1172 
185.1179 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.75 (CAM) 
 
 
 
  
60 
 
 
(S)-2-((4R,5S)-2,2,5-Trimethyl-1,3-dioxolan-4-yl)pent-4-en-2-ol (37). 
Allylmagnesium chloride (2.0 M solution in tetrahydrofuran, 2.92 mL, 5.84 
mmol, 2.2 equiv) was added dropwise to a solution of 1-((4R,5S)-2,2,5-trimethyl-1,3-
dioxolan-4-yl)ethanone 35 (420 mg, 2.66 mmol, 1 equiv) in tetrahydrofuran (25 mL) at –
78 °C. After 10 min, saturated aqueous ammonium chloride solution (5 mL) was added 
carefully. The cooling bath was removed and the reaction flask was allowed to warm to 
23 °C. The mixture was extracted with dichloromethane (3 × 30 mL). The organic layers 
were combined. The combined solution was dried over sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated to provide (S)-2-((4R,5S)-2,2,5-trimethyl-
1,3-dioxolan-4-yl)pent-4-en-2-ol (37) as a colorless oil (460 mg, 87%).57 
 
1H NMR:  
(500 MHz, CDCl3) 
5.94–5.86 (m, 1H), 5.19–5.13 (m, 2H), 4.15–4.10 (m, 
1H), 3.50 (d, 1H, J = 7.8 Hz), 2.35 (dd, 1H, J = 13.7, 6.8 
Hz), 2.15 (dd, 1H, J = 13.7, 7.8 Hz), 1.97 (s, 1H), 1.41 (s, 
3H), 1.40 (s, 3H), 1.35 (d, 3H, J = 5.9 Hz), 1.21 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
133.0, 118.7, 107.7, 87.4, 72.5, 71.3, 42.6, 27.3, 26.8, 
23.5, 20.0 
                                                 
57 The product obtained in this procedure is a 4:1 mixture of diastereomers (epimeric tertiary alcohols); the 
major diastereomer is depicted in the equation above.  The minor epimer was not easily separable by 
chromatography and was carried through as an impurity. 
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FTIR, cm–1: 
(neat) 
 
3481 (br), 2984 (m), 1378 (s), 122 (s), 1174 (s), 1082 (s), 
1055 (s), 916 (m). 
HRMS:  
(ESI) 
Calcd for (C11H20O3+Na) 
Found 
 
223.1305 
223.1280 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.59 (CAM) 
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(S)-3-Hydroxy-3-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)butanal (38). 
2,6-Lutidine (341 μL, 2.95 mmol, 2.0 equiv) was added to a vigorously stirring 
suspension of (S)-2-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pent-4-en-2-ol 37 (295 
mg, 1.47 mmol, 1 equiv), potassium osmate dihydrate (27 mg, 0.074 mmol, 0.05 equiv), 
and sodium periodate (1.26 g, 5.89 mmol, 4.0 equiv) in a mixture of tetrahydrofuran (20 
mL) and water (10 mL). After 4 h, saturated aqueous sodium chloride solution was added 
(50 mL). The mixture was extracted with 1:1 ethyl acetate–hexanes (3 × 60 mL). The 
organic layers were combined. The combined solution was washed sequentially with 
saturated aqueous copper(II) sulfate solution (50 mL) then saturated aqueous sodium 
chloride solution (50 mL) and the washed solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue was purified by 
flash-column chromatography (10% ethyl acetate–hexanes initially, grading to 30% ethyl 
acetate–hexanes) to provide (S)-3-hydroxy-3-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-
yl)butanal (38) as a pale brown oil (166 mg, 56%).  
 
1H NMR:  
(500 MHz, CDCl3) 
9.88 (m, 1H), 4.02 (m, 1H), 3.57 (d, 1H, J = 8.2 Hz), 
2.88 (br, 1H), 2.75 (d, 1H, J = 16.0 Hz), 2.46 (dt, 1H, J = 
16.5, 1.8 Hz), 1.38 (s, 3H), 1.37 (s, 3H), 1.32 (d, 3H, J = 
6.0 Hz), 1.31 (s, 3H). 
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13C NMR:  
(125 MHz, CDCl3) 
 
202.3, 108.4, 87.1, 72.8, 71.6, 50.8, 27.3, 26.9, 24.1, 
20.0. 
 
FTIR, cm–1: 
(neat) 
 
3475 (br) 2985 (m), 1718 (s), 1379 (s), 1217 (s), 1173 
(s), 1077 (s), 862 (m). 
HRMS:  
(ESI) 
Calcd for (C10H18O4+Na) 
Found 
 
225.1113 
225.1097 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.26 (CAM) 
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Confirmation of Stereochemistry: Methyl 2,6-Dideoxy-3-C-methyl-ʟ-lyxo-
hexopyranoside (Methyl 3-epi-Axenoside, 39). 
Triflic acid (5% solution in 2,2,2-trifluoroethanol, 56 μL, 0.05 equiv) was added 
to a solution of (S)-3-hydroxy-3-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)butanal 38 
(128 mg, 0.633 mmol, 1 equiv) in 2,2,2-trifluoroethanol (9.9 mL) at –40 °C. After 40 
min, triethylamine (10 μL) was added. The cooling bath was removed and the product 
solution was concentrated. 1H NMR analysis of the residue established that the acetonide 
protective group had been removed. The residue was dissolved in methanol (6.3 mL). 
Acetyl chloride (451 μL, 6.35 mmol, 10 equiv) was added dropwise at 23 °C. After 20 
min, silver carbonate (2.1 g, 7.62 mmol, 12 equiv) was added. After 10 min, the product 
mixture was filtered through a pad of Celite. The filtrate was concentrated. The residue 
was purified by flash-column chromatography (50% ethyl acetate–hexanes) to provide 
the product (72 mg, 64% yield over two steps) as a colorless oil. 1H NMR analysis 
revealed that the purified product was a mixture of α  and  β  methyl glycosides. The most 
abundant component of the mixture exhibited 1H NMR data in full agreement with those 
reported for methyl α-3-epi-axenoside (39).58 
 
1H NMR:  
(500 MHz, CDCl3) 
4.74 (d, 1H, J = 4.4 Hz), 3.98 (q, 1H, J = 6.4 Hz), 3.31 (s, 
3H), 3.19 (s, 1H), 2.67 (br, 1H), 2.28 (br, 1H), 1.75–1.87 
                                                 
58 Roush, W. R.; Hagadorn, S. M. Carbohyd. Res. 1985, 136, 187–193. 
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(m, 2H), 1.39 (s, 3H), 1.28 (d, 3H, J = 6.4 Hz). 
 
Methyl β-axenoside was observed as a minor impurity:10  
1H NMR:  
(500 MHz, CDCl3) 
4.61 (dd, 1H, J = 9.3, 2.4 Hz), 4.12 (q, 1H, J = 6.4 Hz). 
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(S)-2-((4R,5S)-2,2,5-Trimethyl-1,3-dioxolan-4-yl)pent-4-en-2-ol (37). 
Methylmagnesium chloride (3.0 M solution in tetrahydrofuran, 288 μL, 0.863 
mmol, 1.5 equiv) was added dropwise to a solution of 1-((4R,5S)-2,2,5-trimethyl-1,3-
dioxolan-4-yl)but-3-en-1-one 36 (106 mg, 0.575 mmol, 1 equiv) in tetrahydrofuran (6.0 
mL) at –78 °C. After 45 min, a second portion of methylmagnesium chloride (3.0 M 
solution in tetrahydrofuran, 95 μL, 0.288 mmol, 0.5 equiv) was added. After 15 min, 
saturated aqueous ammonium chloride solution (2 mL) was added carefully. The cooling 
bath was removed and the reaction flask was allowed to warm to 23 °C. The mixture was 
extracted with dichloromethane (3 × 10 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(10% ethyl acetate–hexanes) to provide (S)-2-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-
yl)pent-4-en-2-ol (37) as a colorless oil (65 mg, 57%). The product obtained in this 
procedure is a 4:1 mixture of diastereomers (epimeric tertiary alcohols); the major 
diastereomer is depicted in the equation above. See above for characterization data. 
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(4R,5S)-Biphenyl-4-ylmethyl 2,2-Di-tert-butyl-5-methyl-1,3,2-dioxasilolane-4-
carboxylate (40). 
Di-tert-butylsilyl bis(trifluoromethanesulfonate) (12.6 mL, 34.6 mmol, 1.1 equiv) 
was added to a suspension of 2,6-lutidine (11.0 mL, 94.0 mmol, 3.0 equiv) and (2R,3S)-
biphenyl-4-ylmethyl 2,3-dihydroxybutanoate 32 (9.00 g, 31.4 mmol, 1 equiv) in 
dichloromethane (80 mL) at 23 °C. After 30 h, benzene (100 mL) was added and the 
solution was filtered through a column of silica gel, eluting with 10% ethyl acetate–
hexanes. The filtrate was concentrated to provide (4R,5S)-biphenyl-4-ylmethyl 2,2-di-
tert-butyl-5-methyl-1,3,2-dioxasilolane-4-carboxylate (40) as a colorless oil (12.71 g, 
95%).  
 
1H NMR:  
(500 MHz, CDCl3) 
7.59 (d, 4H, J = 7.8 Hz), 7.46–7.42 (m, 4H), 7.36 (t, 1H, 
J = 7.3 Hz), 5.31 (d, 1H, J = 12.2 Hz), 5.19 (d, 1H, J = 
12.2 Hz), 4.18–4.10 (m, 2H), 1.44 (d, 3H, J = 5.9 Hz), 
1.08 (s, 9H), 1.05 (s, 9H). 
 
13C NMR:  
(125 MHz, CDCl3) 
170.9, 141.2, 140.4, 134.3, 128.7, 128.6, 127.4, 127.2, 
127.0, 80.2, 74.4, 66.4, 26.7, 26.7, 21.3, 21.0, 20.5. 
 
FTIR, cm–1: 2934 (m), 1759 (m), 1473 (m), 1279 (m), 1119 (s), 1090 
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(neat) (s), 928 (m), 826 (s). 
 
HRMS:  
(ESI) 
Calcd for (C25H34O4Si+Na) 
Found 
 
449.2119 
449.2122 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.82 (CAM) 
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(3R,4S)-4-(Di-tert-butyl(methyl)silyloxy)-3-hydroxypentan-2-one (41). 
Methylmagnesium chloride (3.0 M solution in tetrahydrofuran, 79.0 mL, 238 
mmol, 8.0 equiv) was added dropwise through an addition funnel over 20 min to a 
suspension of N,O-dimethylhydroxylamine hydrochloride (3.63 g, 37.2 mmol, 1.25 
equiv) and (4R,5S)-biphenyl-4-ylmethyl 2,2-di-tert-butyl-5-methyl-1,3,2-dioxasilolane-4-
carboxylate 40 (12.71 g, 29.8 mmol, 1 equiv) in tetrahydrofuran (300 mL) at –10 °C. 
After 10 min, saturated aqueous ammonium chloride solution (50 mL) was added 
carefully. The cooling bath was removed and the reaction flask was allowed to warm to 
23 °C. Water (200 mL) was added, and the mixture was extracted with ether (4 × 200 
mL). The organic layers were combined. The combined solution was washed with 
saturated aqueous sodium chloride solution (100 mL) and the washed solution was dried 
over magnesium sulfate. The dried solution was filtered and the filtrate was concentrated. 
The residue was purified by flash-column chromatography (5% ethyl acetate–hexanes 
initially, grading to 30% ethyl acetate–hexanes) to provide (3R,4S)-4-(Di-tert-
butyl(methyl)silyloxy)-3-hydroxypentan-2-one (41) as a colorless oil (5.34 g, 65%). In 
addition to the desired product, the tertiary alcohol byproduct, (3R,4S)-4-(di-tert-
butyl(methyl)silyloxy)-2-methylpentane-2,3-diol (57), was obtained as a colorless oil 
(1.36 g, 16%). Finally, a fraction containing p-phenylbenzyl alcohol (56) (~90% purity) 
was collected. Recrystallization from dichloromethane–hexanes furnished pure p-
phenylbenzyl alcohol as a white solid (≥95% purity, 4.68 g, 85%).  
70 
 
(3R,4S)-4-(Di-tert-butyl(methyl)silyloxy)-3-hydroxypentan-2-one (41): 
1H NMR:  
(500 MHz, CDCl3) 
4.19 (m, 1H), 4.14 (m, 1H), 3.62 (d, 1H, J = 5.5 Hz), 
2.31 (s, 3H), 1.05 (d, 1H, J = 6.4 Hz), 0.98 (s, 9H), 0.95 
(s, 9H), 0.09 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
209.6, 80.4, 70.5, 27.8, 27.7, 27.6, 20.9, 20.1, 18.4, –8.9. 
FTIR, cm–1: 
(neat) 
3482 (br), 2934 (m), 1715 (m), 1472 (m), 1256 (m), 1105 
(s), 1007 (m), 824 (s). 
 
HRMS:  
(ESI) 
Calcd for (C14H30O3Si+H) 
Found 
 
275.2037 
275.2034 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.60 (CAM) 
 
 
(3R,4S)-4-(Di-tert-butyl(methyl)silyloxy)-2-methylpentane-2,3-diol (57): 
1H NMR:  
(500 MHz, CDCl3) 
4.30–4.25 (m, 1H), 3.08–3.04 (m, 2H), 2.83 (s, 1H), 1.31 
(d, 3H, J = 6.4 Hz), 1.26 (s, 6H), 1.02 (s, 9H), 0.99 (s, 
9H). 
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13C NMR:  
(125 MHz, CDCl3) 
 
80.1, 72.3, 69.8, 28.0, 27.8, 26.8, 26.1, 22.7, 21.2, 20.2,  
–6.8. 
FTIR, cm–1: 
(neat) 
3470 (br), 2859 (m), 1471 (m), 1256 (m), 1128 (m), 1060 
(s), 934 (s), 823 (s). 
 
HRMS:  
(ESI) 
Calcd for (C15H34O3Si+H) 
Found 
 
291.2350 
291.2362 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.38 (CAM) 
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(2S,3R,4R)-2-(Di-tert-butyl(methyl)silyloxy)-4-methylhept-6-ene-3,4-diol (42). 
Allylmagnesium chloride (2.0 M solution in tetrahydrofuran, 19.8 mL, 39.6 
mmol, 3.0 equiv) was added dropwise to a solution of (3R,4S)-4-(di-tert-
butyl(methyl)silyloxy)-3-hydroxypentan-2-one 41 (3.62 g, 13.2 mmol, 1 equiv) in 
tetrahydrofuran (88 mL) at –78 °C. After 3 h, a second portion of allylmagnesium 
chloride (2.0 M solution in tetrahydrofuran, 6.6 mL, 13.2 mmol, 1.0 equiv) was added. 
After 1 h, the cooling bath was removed. After 10 min, aqueous ammonium chloride 
solution (50% saturated, 25 mL) was added slowly, and the reaction flask was allowed to 
warm to 23 °C.  Aqueous sodium chloride solution (25% saturated, 50 mL), and methyl 
tert-butyl ether (50 mL) were added. The layers were separated. The aqueous layer was 
extracted with methyl tert-butyl ether (2 × 100 mL). The organic layers were combined. 
The combined solution was washed with saturated aqueous sodium chloride solution (50 
mL) and the washed solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (5% ethyl acetate–hexanes) to provide (2S,3R,4R)-2-(di-tert-
butyl(methyl)silyloxy)-4-methylhept-6-ene-3,4-diol (42) as a colorless oil (3.59 g, 
86%).59 
 
                                                 
59 The product obtained in this procedure is a 13:1 mixture of diastereomers (epimeric tertiary alcohols); the 
major diastereomer is depicted in the equation above. The minor epimer was carried through as an impurity 
to the stage of the oxidative cleavage reaction (vide infra), where the diastereomeric products were easily 
separated. 
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1H NMR:  
(500 MHz, CDCl3) 
5.86 (m, 1H), 5.12 (m, 1H), 5.10 (t, 1H, J = 1.5 Hz), 4.3 
(dq, 1H, J = 5.9, 3.9 Hz), 3.11 (dd, 1H, J = 6.8, 3.4 Hz), 
3.05 (d, 1H, J = 6.8 Hz), 2.90 (s, 1H), 2.26 (m, 2H), 1.30 
(d, 3H, J = 6.4 Hz), 1.20  (s, 3H), 1.02 (s, 9H), 0.99 (s, 
9H), 0.17 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
134.0, 118.1, 77.9, 73.9, 69.6, 44.1, 28.0, 27.9, 23.2, 
22.8, 21.3, 20.3, –6.7. 
 
FTIR, cm–1: 
(neat) 
3503 (br), 2934 (m), 1472 (m), 1256 (m), 1065 (s), 928 
(m), 824 (s). 
 
HRMS:  
(ESI) 
Calcd for (C17H36O3Si+Na) 
Found 
 
339.2326 
339.2330 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.60 (CAM) 
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5-O-(Di-tert-butylmethylsilyl)-2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranose (43). 
Potassium osmate dihydrate (209 mg, 0.567 mmol, 0.05 equiv) was added to a 
solution of (2S,3R,4R)-2-(di-tert-butyl(methyl)silyloxy)-4-methylhept-6-ene-3,4-diol 42 
(3.59 g, 11.3 mmol, 1 equiv), sodium periodate (9.70 g, 45.4 mmol, 4.0 equiv), and 2,6-
lutidine (2.64 mL, 22.7 mmol, 2.0 equiv) in a mixture of tetrahydrofuran (76 mL) and 
water (38 mL) at 23 °C. After 3 h, the product mixture was partitioned between saturated 
aqueous sodium chloride solution (100 mL), ethyl acetate (50 mL), and hexanes (50 mL). 
The layers were separated. The aqueous layer was extracted with 50% ethyl acetate–
hexanes (2 × 100 mL). The organic layers were combined. The combined solution was 
washed with saturated aqueous copper(II) sulfate solution (100 mL) then saturated 
aqueous sodium chloride solution (100 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography (10% ethyl acetate–hexanes 
initially, grading to 20% ethyl acetate–hexanes) to provide 5-O-(di-tert-butylmethylsilyl)-
2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranose (43) as a 1:1.9 mixture of α- and β-
anomers, respectively (1.97 g, 55%).  
 
1H NMR:  
(500 MHz, CDCl3) 
α-anomer (minor): 5.66 (m, 1H), 4,35 (m, 1H) 4.17 (s, 
1H), 3.79 (d, 1H, J = 3.9 Hz), 2.61 (br, 1H), 2.33 (dd, 
1H, J = 13.7, 5.9 Hz), 1.92 (dd, 1H, J = 13.7, 3.4 Hz), 
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1.48 (s, 3H), 1.37 (d, 3H, J = 6.4 Hz), 1.01 (s, 9H), 0.98 
(s, 9H), 0.16 (s, 3H). 
 
β-anomer (major): 5.41 (dd, 1H, J = 8.8, 4.9 Hz), 4.46 
(s, 1H), 4.35 (m, 1H), 3.68 (d, 1H, J = 8.8 Hz), 3.48 (d, 
1H, J = 4.4 Hz), 2.52 (s, 1H), 2.10 (d, 1H, J = 13.7 Hz), 
2.02 (dd, 1H, J = 13.2, 4.9 Hz), 1.42 (s, 3H), 1.38 (d, 3H, 
J = 6.4 Hz), 1.03 (s, 9H), 1.00 (s, 9H), 0.18 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
97.8, 97.5, 89.0, 85.8, 79.2, 78.1, 70.7, 70.1, 50.1, 48.7, 
27.9, 27.9, 27.8, 27.7, 27.3, 24.6, 21.2, 21.2, 20.9, 20.5, 
20.3, 20.2, –7.1, –7.2. 
 
FTIR, cm–1: 
(neat) 
3420 (br), 2934 (m), 1472 (m), 1256 (m), 1086 (s), 934 
(m), 824 (s). 
 
HRMS:  
(ESI) 
Calcd for (C16H34O4Si+Na) 
Found 
 
341.2119 
341.2129 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.27 (CAM) 
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Methyl 5-O-(Di-tert-butylmethylsilyl)-2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside 
(44). 
p-Toluenesulfonic acid monohydrate (353 mg, 1.86 mmol, 0.3 equiv) was added 
to a solution of 5-O-(di-tert-butylmethylsilyl)-2,6-dideoxy-3-C-methyl-ʟ-xylo-
hexofuranose 43 (1.97 g, 6.18 mmol, 1 equiv) in methanol (16 mL) at 23 °C. After 50 
min, triethylamine (300 μL) was added and the product solution was concentrated. The 
residue was filtered through a short pad of silica gel (length: 2.5 cm, diameter: 3.5 cm), 
eluting with ethyl acetate (60 mL). The filtrate was concentrated to provide methyl 5-O-
(di-tert-butylmethylsilyl)-2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside (44) as a 1:4.8 
mixture of α- and  β-anomers, respectively (1.84 g, 89%).  
 
1H NMR:  
(600 MHz, CDCl3) 
α-anomer (minor): 4.93 (dd, 1H, J = 4.4, 0.9 Hz), 4.05 
(m, 1H), 3.54 (d, 1H, J = 7.0 Hz), 3.45 (s, 1H), 3.37 (s, 
3H), 2.07–2.01 (m, 2H), 1.36 (s, 3H), 1.28 (d, 3H, J = 6.2 
Hz), 1.00 (s, 9H), 0.96 (s, 9H), 0.11 (s, 3H). 
 
β-anomer (major): 5.06 (dd, 1H, J = 5.9, 2.9 Hz), 4.30 
(dq, 1H, J = 6.4, 4.4 Hz), 3.80 (s, 1H), 3.64 (d, 1H, J = 
4.1 Hz), 3.33 (s, 3H), 2.26 (dd, 1H, J = 13.7, 5.9 Hz), 
1.92 (dd, 1H, J = 13.8, 2.6 Hz), 1.43 (s, 3H), 1.34 (d, 3H, 
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J = 6.4 Hz), 1.00 (s, 9H), 0.96 (s, 9H), 0.13 (s, 3H). 
 
13C NMR:  
(100 MHz, CDCl3) 
 
103.9, 103.7, 91.8, 85.6, 78.9, 77.0, 71.8, 70.3, 55.4, 
55.1, 49.7, 48.5, 27.9, 27.9, 27.8, 27.7, 24.5, 21.5, 21.1, 
21.0, 20.5, 20.3, 20.3, 20.2, –7.5, –8.1. 
 
FTIR, cm–1: 
(neat) 
3482 (br), 2934 (m), 1472 (m), 1254 (m), 1105 (s), 1044 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C17H36O4Si+Na) 
Found 
 
355.2275 
355.2266 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.49, 0.69 (CAM) 
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Methyl 2,6-Dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside (45). 
Tetra-n-butylammonium fluoride (1.0 M solution in tetrahydrofuran, 6.07 mL, 
6.07 mmol, 1.1 equiv) was added to a solution of methyl 5-O-(di-tert-butylmethylsilyl)-
2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside 44 (1.836 g, 5.52 mmol, 1 equiv) in 
tetrahydrofuran (37 mL) at 23 °C. After 16 h, the reaction mixture was partitioned 
between saturated aqueous sodium bicarbonate solution (10 mL) and ethyl acetate (50 
mL). The layers were separated. The aqueous layer was extracted with ethyl acetate (3 × 
50 mL). The organic layers were combined. The combined solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography (10% ethyl acetate–hexanes 
initially, grading to 30% ethyl acetate–hexanes, then 80% ethyl acetate–hexanes, then 
ethyl acetate) to provide methyl 2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside (45) as a 
1:5.0 mixture of α- and  β-anomers, respectively (890 mg, 91%).  
 
1H NMR:  
(500 MHz, CDCl3) 
α-anomer (minor): 5.02 (d, 1H, J = 4.9 Hz), 4.01 (m, 
1H), 3.66 (s, 1H), 3.55 (s, 1H), 3.42 (s, 3H), 3.02 (d, 1H, 
J = 5.0 Hz), 2.17–2.08 (m, 2H), 1.38 (s, 3H), 1.28 (d, 3H, 
J = 6.4). 
 
β-anomer (major): 5.16 (dd, 1H, J = 5.9, 3.4 Hz), 4.11 
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(m, 1H), 3.73 (s, 1H), 3.56 (d, 1H, J = 1.5 Hz), 3.39 (s, 
3H), 2.44 (d, 1H, J = 7.9 Hz), 2.30 (dd, 1H, J = 13.8, 5.6 
Hz), 1.94 (dd, 1H, J = 13.8, 3.2 Hz), 1.39 (s, 3H), 1.36 
(d, 3H, J = 6.7 Hz). 
 
13C NMR:  
(100 MHz, CDCl3) 
 
104.1, 103.8, 90.2, 85.0, 79.1, 77.6, 67.2, 65.9, 55.3, 
55.0, 49.6, 48.1, 25.4, 25.2, 21.4, 19.6. 
FTIR, cm–1: 
(neat) 
3385 (br), 1375 (m), 1285 (w), 1198 (m), 1101 (s), 1028 
(s), 970 (m). 
 
HRMS:  
(ESI) 
Calcd for (C8H16O4+Na) 
Found 
 
199.0941 
199.0932 
TLC: 
(80% ethyl acetatehexanes) 
Rf = 0.38 (CAM) 
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Methyl 2,6-Dideoxy-3-C-methyl-ʟ-xylo-hexopyranoside (Methyl Axenoside, 46). 
Hydrochloric acid (1.0 M solution in methanol, 5.60 mL, 5.60 mmol, 1.1 equiv) 
was added to a solution of methyl 2,6-dideoxy-3-C-methyl-ʟ-xylo-hexofuranoside 45 
(890 mg, 5.05 mmol, 1 equiv) in methanol (45 mL) at 23 °C. After 22 h, silver carbonate 
(2.23 g, 8.08 mmol, 1.6 equiv) was added. After 30 min, the product mixture was filtered 
through a short pad of Celite, washing with methanol (50 mL). The filtrate was 
concentrated to provide the product, methyl 2,6-dideoxy-3-C-methyl-ʟ-xylo-
hexopyranoside (46), as a 1:1.8 mixture of α- and   β-anomers, respectively, which was 
used directly in the next reaction without purification.48 
 
1H NMR:  
(500 MHz, CDCl3) 
α-anomer (minor): 4.80 (d, 1H, J = 3.9 Hz), 4.30 (q, 
1H, J = 6.8 Hz), 4.02 (s, 1H), 3.38 (s, 3H), 3.14 (d, 1H, J 
= 7.8 Hz), 1.91 (dd, 1H, J = 14.7, 3.9 Hz), 1.73 (d, 1H, J 
= 8.3 Hz), 1.26 (d, 3H, J = 6.8 Hz), 1.24 (s, 3H). 
 
β-anomer (major): 4.62 (dd, 1H, J = 9.8, 2.4 Hz), 4.13 
(dq, 1H, J = 6.8, 1.0 Hz), 3.50 (s, 3H), 2.98 (d, 1H, J = 
10.3 Hz), 1.97 (d, 1H, J = 9.8 Hz), 1.69–1.57 (m, 2H), 
1.34 (s, 3H), 1.27 (d, 3H, J = 6.8 Hz). 
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13C NMR:  
(125 MHz, CDCl3) 
 
100.4, 99.0, 74.6, 74.4, 72.5, 70.2, 68.9, 62.5, 56.5, 55.2, 
39.1, 35.4, 27.8, 26.0, 16.7, 16.6. 
FTIR, cm–1: 
(neat) 
3447 (br), 2934 (m), 1375 (m), 1121 (s), 1059 (s), 995 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C8H16O4+Na) 
Found 
 
199.0941 
199.0929 
TLC: 
(5% methanol– 
dichloromethane) 
Rf = 0.26, 0.36 (CAM) 
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Methyl Trioxacarcinoside A (47). 
Acetic anhydride (500 μL, 5.30 mmol, 1.05 equiv) was added to a solution of 
methyl 2,6-dideoxy-3-C-methyl-ʟ-xylo-hexopyranoside 46 (1 equiv, see paragraph 
above) and 4-dimethylaminopyridine (1.23 g, 10.1 mmol, 2.0 equiv) in pyridine (50 mL) 
at 23 °C. After 20 h, a second portion of acetic anhydride (100 μL, 1.06 mmol, 0.2 equiv) 
was added. After 90 min, a third portion of acetic anhydride (150 μL, 1.59 mmol, 0.3 
equiv) was added. After 40 min, the product solution was partitioned between ethyl 
acetate (150 mL) and saturated aqueous sodium bicarbonate solution (20 mL). The layers 
were separated. The organic layer was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (20% ethyl acetate–hexanes initially, grading to 60% ethyl acetate–
hexanes) to provide methyl trioxacarcinoside A (47) as a 1:1.7 mixture of α- and   β-
anomers, respectively (970 mg, 88% yield over two steps). For characterization purposes, 
a sample of the product (~50 mg) was purified by flash-column chromatography (20% 
ethyl acetate–hexanes initially, grading to 60% ethyl acetate–hexanes) to provide 
separately α- and β-methyl trioxacarcinoside A (47), which were characterized by 1H 
NMR, 13C NMR, IR, and HRMS. Analytical data for the synthetic substances were in 
agreement with those reported in the literature.6  
 
α-anomer (minor): 
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1H NMR:  
(500 MHz, CDCl3) 
4.86 (d, 1H, J = 3.4 Hz), 4.70 (s, 1H), 4.32 (q, 1H, J = 
6.4 Hz), 4.28 (s, 1H), 3.39 (s, 3H), 2.14 (s 3H), 1.93 (dd, 
1H, J = 14.2, 3.9 Hz), 1.72 (dt, 1H, J = 14.7, 1.2 Hz), 
1.13 (d, 3H, J = 6.4 Hz), 1.10 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.4, 99.1, 74.6, 68.8, 61.8, 55.2, 36.2, 25.7, 20.9, 16.6. 
FTIR, cm–1: 
(neat) 
3507 (br, w), 2938 (w), 1748 (s), 1375 (m), 1233 (s), 
1140 (m), 1121 (s), 1082 (m), 1047 (s), 1020 (m), 997 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C10H18O5+Na) 
Found 
 
241.1046 
241.1050 
TLC: 
(50% ethyl acetatehexanes) 
Rf = 0.63 (CAM) 
 
 
 
β-anomer (major):  
1H NMR:  
(500 MHz, CDCl3) 
4.67 (dd, 1H, J = 9.5, 2.7 Hz), 4.57 (d, 1H, J = 1.5 Hz), 
4.15 (dq, 1H, J = 6.4, 1.5 Hz), 3.52 (s, 3H), 2.14 (s, 3H), 
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1.75–1.64 (m, 2H), 1.43 (s, 1H), 1.21 (s, 3H), 1.16 (d, 
3H, J = 6.4 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.9, 99.9, 74.1, 71.3, 67.9, 56.5, 39.6, 27.1, 20.8, 16.5. 
FTIR, cm–1: 
(neat) 
3468 (br), 2936 (w), 1745 (s), 1447 (m), 1373 (m), 1234 
(s), 1169 (m), 1153 (m), 1119 (m), 1053 (s), 1011 (s), 
922 (m). 
 
HRMS:  
(ESI) 
Calcd for (C10H18O5+Na) 
Found 
 
241.1046 
241.1051 
TLC: 
(50% ethyl acetatehexanes) 
 
Rf = 0.47 (CAM) 
 
[D]D 13.3° (c 0.40, CHCl3),  
lit.6 14.5° (c 0.5, CHCl3). 
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1-O-Acetyl Trioxacarcinose A (48). 
Methyl trioxacarcinoside A 47 (200 mg, 0.916 mmol, 1 equiv, 1:1.7 mixture of α- 
and β- anomers, respectively) was treated with 1.0 M aqueous hydrochloric acid (9.16 
mL, 9.16 mmol, 10.0 equiv) at 23 °C. After 16 h, sodium bicarbonate (924 mg, 11.0 
mmol, 12 equiv) was added, and the product solution was saturated with sodium chloride. 
The mixture was extracted with ethyl acetate (3 × 50 mL). The organic layers were 
combined. The combined solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was dissolved in pyridine (13.9 
mL). 4-Dimethylaminopyridine (170 mg, 1.39 mmol, 2.0 equiv) and acetic anhydride (69 
μL, 0.73 mmol, 1.05 equiv) were added in sequence at 23 °C. After 15 h, a second 
portion of acetic anhydride (16 μL, 0.17 mmol, 0.25 equiv) was added. After 2.5 h, the 
product solution was partitioned between ethyl acetate (50 mL) and water (10 mL). The 
layers were separated. The organic layer was washed sequentially with 1.0 M aqueous 
hydrochloric acid solution (2 × 10 mL), saturated aqueous sodium bicarbonate solution 
(10 mL), then saturated aqueous sodium chloride solution (10 mL) and the washed 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (15% ethyl 
acetate–hexanes initially, grading to 40% ethyl acetate–hexanes) to provide 1-O-acetyl 
trioxacarcinose A (48) as a 1:3.4 mixture of α- and   β-anomers, respectively (155 mg, 
69%). For characterization purposes, a sample of the product (~50 mg) was further 
purified by flash-column chromatography (10% ethyl acetate–hexanes initially, grading 
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to 30% ethyl acetate–hexanes) to provide the pure β-anomer, which was characterized by 
1H NMR, 13C NMR, IR, and HRMS.  
 
β-48: 
1H NMR:  
(500 MHz, CDCl3) 
5.99 (dd, 1H, J = 7.8, 4.9 Hz), 4.60 (s, 1H), 4.29 (q, 1H, J 
= 6.4 Hz), 2.25 (s, 1H), 2.13 (s, 3H), 2.08 (s, 3H), 1.76 
(m, 2H), 1.20 (s, 3H), 1.13 (d, 3H, J = 6.4 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.7, 169.4, 91.8, 73.6, 71.0, 69.1, 38.4, 26.9, 21.1, 
20.8, 16.4. 
FTIR, cm–1: 
(neat) 
3482 (br), 2984 (m), 1734 (s), 1374 (m), 1233 (s), 1144 
(s), 995 (s). 
 
HRMS:  
(ESI) 
Calcd for (C11H18O6+Na) 
Found 
 
269.0996 
269.0994 
TLC: 
(50% ethyl acetatehexanes) 
 
Rf = 0.42 (CAM) 
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(3R,4S)-3,4-Dihydroxypentan-2-one (52). 
Methylmagnesium chloride (3.0 M solution in tetrahydrofuran, 86.0 mL, 257 
mmol, 3.0 equiv) was added over 15 min to an ice-cooled solution of  (4R,5S)-N-
methoxy-N,2,2,5-tetramethyl-1,3-dioxolane-4-carboxamide 34 (17.4 g, 86.0 mmol, 1 
equiv) in tetrahydrofuran (570 mL). After 5 min, saturated aqueous ammonium chloride 
solution (80 mL) was added dropwise, and the reaction flask was allowed to warm to 23 
°C. Aqueous hydrochloric acid solution (1.0 M, 570 mL) was added, a reflux condenser 
was affixed, and the reaction flask was heated at 60 °C. After 90 min of vigorous stirring, 
the reaction flask was allowed to cool to 23 °C. The product mixture was concentrated. 
Ethyl acetate (1 L) was added, and the suspension was dried over sodium sulfate. The 
dried suspension was filtered and the filtrate was concentrated to provide (3R,4S)-3,4-
dihydroxypentan-2-one (52) as a colorless oil (9.89 g, 98%). Analytical data were in 
agreement with values previously reported.60  
 
1H NMR:  
(500 MHz, CDCl3) 
4.18 (m, 1H), 3.98 (dd, 1H, J = 4.6, 2.3 Hz), 3.81 (d, 1H, 
J = 4.6 Hz), 2.44 (d, 1H,  J = 9.2 Hz), 2.24 (s, 3H), 1.30 
(d, 3H, J = 6.4 Hz). 
 
13C NMR:  208.3, 80.4, 67.9, 25.5, 20.0. 
                                                 
60 Zörb, A.; Brückner, R. Eur. J. Org. Chem. 2010, 2010, 4785–4801. 
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(125 MHz, CDCl3) 
 
FTIR, cm–1: 
(neat) 
3421 (br), 2934 (w), 1713 (s), 1360 (m), 1242 (m), 1134 
(s), 1074 (s), 1009 (m). 
 
HRMS:  
(ESI) 
Calcd for (C5H10O3+Na) 
Found 
 
141.0522 
141.0524 
TLC: 
(80% ethyl acetatehexanes) 
 
Rf = 0.37 (CAM) 
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(2S,3R,4R)-4-Methylhept-6-ene-2,3,4-triol (53). 
Allyl bromide (3.77 mL, 43.5 mmol, 1.5 equiv) was added to a mixture of 
(3R,4S)-3,4-dihydroxypentan-2-one 52 (3.43 g, 29.0 mmol, 1 equiv) and indium powder 
(5.00 g, 43.5 mmol, 1.5 equiv) in water (290 mL) at 23 °C. The reaction flask was sealed 
with a rubber septum. After 1 h of vigorous stirring, the product mixture was 
concentrated. Ethyl acetate (200 mL) was added, and the suspension was dried over 
sodium sulfate. The dried suspension was filtered and the filtrate was concentrated. A 
small sample of the product (~50 mg) was purified by flash-column chromatography 
(60% ethyl acetate–hexanes initially, grading to 100% ethyl acetate) and the purified 
product was characterized by 1H NMR, 13C NMR, IR, and HRMS.61 The balance of the 
product, (2S,3R,4R)-4-methylhept-6-ene-2,3,4-triol (53), was used directly in the next 
reaction without purification.  
 
1H NMR:  
(500 MHz, DMSO-d6) 
5.88–5.79 (m, 1H), 5.01 (d, 1H, J = 4.9 Hz), 4.99 (d, 1H, 
J = 1.0 Hz), 4.45 (s, 1H), 4.40 (d, 1H, J = 4.9 Hz), 4.18 
(d, 1H, J = 7.8 Hz), 3.95 (m, 1H), 2.91 (d, 1H, J = 7.8 
Hz), 2.23 (m, 2H), 1.08 (d, 3H, J = 6.4 Hz), 1.06 (s, 3H). 
 
                                                 
61 The product obtained in this procedure is a 15:1 mixture of diastereomers (epimeric tertiary alcohols); the 
major diastereomer is depicted in the equation above.  The minor C4 epimer was carried through as an 
impurity to the stage of the acetylation reaction (vide infra), where the diastereomeric products were easily 
separated. 
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13C NMR:  
(125 MHz, DMSO-d6) 
 
135.5, 116.8, 76.8, 74.3, 65.5, 42.9, 24.1, 21.4. 
FTIR, cm–1: 
(neat) 
 
3379 (br), 2934 (m), 1377 (m), 1124 (s), 997 (s), 916 (s). 
HRMS:  
(ESI) 
Calcd for (C8H16O3+Na) 
Found 
 
183.0992 
183.0982 
TLC: 
(5% methanol 
dichloromethane) 
 
Rf = 0.25 (CAM) 
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1-O-Acetyl Trioxacarcinose A (48). 
Ozone was bubbled through a solution of (2S,3R,4R)-4-methylhept-6-ene-2,3,4-
triol 53 (1 equiv, see paragraph above) in methanol (290 mL) at –78 °C. After 30 min, 
oxygen was bubbled through the blue-green solution. After 10 min, methyl sulfide (21.3 
mL, 290 mmol, 10.0 equiv) was added, and the reaction flask was allowed to warm to 23 
°C. After 16 h, the solution was concentrated. The residue was dissolved in pyridine (290 
mL). Acetic anhydride (5.76 mL, 61.0 mmol, ~2.1 equiv) and 4-dimethylaminopyridine 
(7.45 g, 61.0 mmol, ~2.1 equiv) were added in sequence at 23 °C. After 2 h, a second 
portion of acetic anhydride (2.74 mL, 29.0 mmol, ~1.0 equiv) was added. After 45 min, 
saturated aqueous sodium bicarbonate solution (100 mL) was added, and the product 
mixture was concentrated. The residue was partitioned between ethyl acetate (800 mL) 
and saturated aqueous sodium bicarbonate solution (200 mL). The layers were separated. 
The aqueous layer was extracted with ethyl acetate (800 mL). The organic layers were 
combined. The combined solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (15% ethyl acetate–hexanes initially, grading to 40% ethyl acetate–
hexanes) to provide the product, 1-O-acetyl trioxacarcinose A (48), as a 1:12.1 mixture of 
α- and β-anomers, respectively (2.97 g, 42% yield over 3 steps). For characterization 
purposes, a sample of the product (~50 mg) was further purified by flash-column 
chromatography (10% ethyl acetate–hexanes initially, grading to 30% ethyl acetate–
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hexanes) to provide the pure β-anomer, which was characterized by 1H NMR, 13C NMR, 
IR, and HRMS. See above for characterization data. 
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Conversion of 1-O-Acetyl Trioxacarcinose A  (48) to Methyl Trioxacarcinoside A (47). 
Acetyl chloride (289 μL, 4.06 mmol, 10.0 equiv) was added to a solution of 1-O-
acetyl trioxacarcinose A 48 (100 mg, 406 μmol, 1 equiv, prepared from triol 53) in 
methanol (4 mL) at 23 °C. After 10 min, sodium bicarbonate (341 mg, 4.06 mmol, 10.0 
equiv) was added. The product mixture was filtered through a pad of Celite, washing with 
dichloromethane (40 mL). The filtrate was concentrated. The residue was purified by 
flash-column chromatography (20% ethyl acetate–hexanes initially, grading to 60% ethyl 
acetate–hexanes) to provide separately α- and β-methyl trioxacarcinoside A (47) (α-
anomer: 10 mg, 11%; β-anomer: 56 mg, 63%). Analytical data for the synthetic 
substances were in agreement with those reported in the literature.6  
 
α-anomer:  
1H NMR:  
(500 MHz, CDCl3) 
4.86 (d, 1H, J = 3.4 Hz), 4.70 (s, 1H), 4.32 (q, 1H, J = 
6.4 Hz), 4.28 (s, 1H), 3.39 (s, 3H), 2.14 (s 3H), 1.93 (dd, 
1H, J = 14.2, 3.9 Hz), 1.72 (dt, 1H, J = 14.7, 1.2 Hz), 
1.13 (d, 3H, J = 6.4 Hz), 1.10 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
170.4, 99.1, 74.6, 68.8, 61.8, 55.2, 36.2, 25.7, 20.9, 16.6. 
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FTIR, cm–1: 
(neat) 
3507 (br), 2938 (w), 1748 (s), 1375 (m), 1233 (s), 1121 
(s), 1082 (m), 1047 (s), 997 (s). 
 
HRMS:  
(ESI) 
Calcd for (C10H18O5+Na) 
Found 
 
241.1046 
241.1050 
TLC: 
(50% ethyl acetatehexanes) 
 
Rf = 0.63 (CAM) 
 
 
β-anomer:  
1H NMR:  
(500 MHz, CDCl3) 
4.67 (dd, 1H, J = 9.5, 2.7 Hz), 4.57 (d, 1H, J = 1.5 Hz), 
4.15 (dq, 1H, J = 6.4, 1.5 Hz), 3.52 (s, 3H), 2.14 (s, 3H), 
1.75-1.64 (m, 2H), 1.43 (s, 1H), 1.21 (s, 3H), 1.16 (d, 
3H, J = 6.4 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.9, 99.9, 74.1, 71.3, 67.9, 56.5, 39.6, 27.1, 20.8, 16.5. 
FTIR, cm–1: 3468 (br), 2936 (w), 1745 (s), 1447 (m), 1373 (m), 1234 
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(neat) (s), 1119 (m), 1053 (s), 1011 (s). 
 
HRMS:  
(ESI) 
Calcd for (C10H18O5+Na) 
Found 
 
241.1046 
241.1051 
TLC: 
(50% ethyl acetatehexanes) 
 
Rf = 0.47 (CAM) 
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1-Fluorotrioxacarcinose A (54). 
Diethylaminosulfur trifluoride (20 µL, 0.153 mmol, 1.2 equiv) was added to a 
solution of trioxacarcinose A (2) (26 mg, 0.127 mmol, 1 equiv) in tetrahydrofuran (2.5 
mL) at –30 °C. The reaction flask was allowed to warm gradually to 0 °C over 30 min. 
Methanol (300 µL) was added and the reaction flask was allowed to warm to 23 °C. The 
mixture was partitioned between saturated aqueous sodium bicarbonate solution (1 mL) 
and ethyl acetate (10 ml). The layers were separated. The aqueous layer was extracted 
with ethyl acetate (2 × 10 mL). The organic layers were combined and the combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (30% ethyl 
acetate–hexanes) to provide 1-fluoro glycoside 54 as a 1:1.1 mixture of α  and  β  anomers,  
respectively (22 mg, 84%). 
 
1H NMR:  
(500 MHz, CDCl3) 
5.79 (d, 1H, J = 53 Hz), 5.59 (ddd, 1H, J = 53, 9.3, 2.4 
Hz), 4.78 (s, 1H), 4.59 (m, 2H), 4.27 (q, 1H, J = 6.8 Hz), 
2.16 (s, 3H), 2.14 (s, 3H), 2.05–1.72 (m, 4H), 1.24 (s, 
3H), 1.20 (d, 3H, J = 6.8 Hz), 1.17 (s, 3H), 1.16 (d, 3H, J 
= 6.8 Hz).  
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19F NMR:  
(375 MHz, CDCl3) 
–124.25 (t, 1F, J = 52.5 Hz), –135.02 (dd, 1F, J = 52.5, 
13.4 Hz). 
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1-Phenylthiotrioxacarcinoside A (55). 
Boron  trifluoride  etherate  (72  μL,  0.57  mmol,  1.4  equiv)  was  added  to  a  solution  
of 1-O-acetyltrioxacarcinoside A (48) (100 mg, 0.41 mmol, 1 equiv, a 1:12 mixture of D- 
and E-anomers, respectively) and thiophenol (50   μL,   0.49   mmol,   1.2   equiv)   in  
dichloromethane (8.1 mL) at –40 °C. After 5 min, saturated aqueous sodium bicarbonate 
solution (2 mL) was added rapidly. The cooling bath was removed and the reaction flask 
was allowed to warm to 23 °C. The mixture was partitioned between dichloromethane 
(50 mL) and saturated aqueous sodium bicarbonate solution (5 mL). The layers were 
separated. The organic layer was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (25% ethyl acetate–hexanes) to provide 1-phenylthiotrioxacarcinoside A 
(55), as a 2.4:1 mixture of E- and D-anomers, respectively (103 mg, 86%).  
 
1H NMR:  
(500 MHz, CDCl3) 
α-anomer (minor): 7.49 (d, J = 7.8 Hz, 2H), 7.31–7.22 
(m, 3H), 5.64 (d,  J = 6.4 Hz, 1H), 4.81 (q, J = 6.4 Hz, 
1H), 4.74 (s, 1H), 2.58 (br, 1H), 2.35 (dd, J = 14.7, 6.4 
Hz, 1H), 2.15 (s, 3H), 1.95 (m, 1H), 1.21 (s, 3H), 1.12 (d, 
J = 6.4 Hz, 3H). 
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β-anomer (major): 7.51 (d, J = 7.8 Hz, 2H), 7.31–7.22 
(m, 3H), 5.19 (d, J = 11.7 Hz, 1H), 4.62 (s, 1H), 4.21 (q, 
J = 6.4 Hz, 1H), 2.15 (s, 3H), 1.93 (m, 1H), 1.82 (d, J = 
13.7 Hz, 1H), 1.20 (s, 3H), 1.17 (d, J = 6.4 Hz, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.8, 170.5, 136.4, 134.7, 130.7, 130.6, 128.8, 128.7, 
126.9, 126.8, 83.4, 80.7, 74.4, 73.7, 70.6, 70.4, 69.1, 
62.8, 39.5, 38.3, 27.0, 26.8, 20.8, 20.8, 17.0, 16.6. 
 
FTIR, cm–1: 
(neat) 
3493 (br), 2980 (m), 1743 (s), 1373 (m), 1233 (s), 1067 
(s), 1007 (s). 
 
HRMS:  
(ESI) 
Calcd for (C15H20O4S+Na) 
Found 
 
319.0975 
319.0987 
TLC: 
(50% ethyl acetatehexanes) 
 
Rf = 0.71 (CAM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
Component-Based Syntheses of Trioxacarcin A and DC-45-A1 
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Introduction 
In this chapter, I present details of the research that led to the development of a 
component-based synthetic route to trioxacarcin A (1) and DC-45-A1 (10), both 
glycosylated natural products of the trioxacarcin class. In the first section, I describe the 
gram-scale execution of the route to differentially protected synthetic precursor 23 
originally developed by graduate students Jakub Švenda and Nicholas Hill.18 This route 
proceeds by the assembly of three components of similar synthetic complexity: epoxy 
diazo diketone 18, cyanophthalide 19, cyclohexenone 20. I then discuss the development 
of α-selective glycosylation methodology for the coupling of a trioxacarcinose A residue 
to the C4 hydroxyl group of fully functionalized trioxacarcin core substrates. These 
studies enabled a three-step synthesis of the natural glycosylated trioxacarcin DC-45-A1 
(10) from synthetic precursor 23. Simultaneously, postdoctoral researcher Thomas 
Magauer developed a method for the α-selective introduction of trioxacarcinose B (3) to 
the C13 hemiketal group of the trioxacarcins.62 In the final section, I describe the use of 
these two glycosylation methodologies in tandem to prepare bisglycosylated trioxacarcins 
containing both trioxacarcinose A (2) and trioxacarcinose B (3). The result of these 
efforts was a highly convergent synthesis of trioxacarcin A (1), proceeding in 11 steps 
from five components of similar complexity: epoxy diazo diketone 18, cyanophthalide 
19, cyclohexenone 20, trioxacarcinose A glycosyl donor 48, and a trioxacarcinose B 
glycosyl donor 65. 
 
 
                                                 
62 Magauer, T.; Smaltz, D. J.; Myers, A. G. Nat. Chem. 2013, 5, 886–893. 
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Large-Scale Synthesis of Differentially Protected DC-45-A2 
Before beginning glycosylation studies, it was necessary to prepare large 
quantities of synthetic precursor 23, which represents a differentially protected form of 
the natural product DC-45-A2, the aglycon common to glycosylated trioxacarcins (see 
Scheme 3.1). We had anticipated that this precursor would serve directly as a substrate 
for the introduction of carbohydrates such as trioxacarcinose B (3) by glycosylation of 
the hemiketal hydroxyl group at position C13. Furthermore, after cleavage of the p-
methoxybenzyl ether protective group, this precursor would provide a substrate for 
selective introduction of carbohydrates such as trioxacarcinose A (2) by glycosylation of 
the hydroxyl group liberated at position C4, which we expected to be more reactive than 
the C13 hemiketal. In earlier  work,   graduate   students   Jakub   Švenda   and  Nicholas  Hill  
prepared 48 mg of differentially protected DC-45-A2 (23) in a single batch.18 We 
anticipated a need for larger quantities of this material for glycosylation studies directed 
toward the synthesis of DC-45-A1 (10) and trioxacarcin A (1), as well as for the synthesis 
of unnatural trioxacarcin analogs. 
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Scheme 3.1. Large-Scale Synthesis of Synthetic Precursor 23, a Differentially-Protected 
Form of DC-45-A2. 
We were therefore led to scale the synthetic route to the differentially protected 
synthetic precursor 23, and we observed increased yields for many steps upon scaling (cf. 
Scheme 1.3). These improvements combined with procedural refinements allowed us to 
prepare 690 mg of synthetic precursor 23 in diastereomerically pure form in a single 
batch, a more than tenfold scaling of the previous route (Scheme 3.1). Thus, coupling of 
cyanophthalide 19 and enone 20 in an anionic cyclization reaction furnished the 
dihydroanthracenone adduct 21 in 70% yield. Dihydroanthracenone 21 was transformed 
into aldehyde 22 (2.50 g) in a three-step sequence involving oxidative cleavage of the 
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disubstituted olefin (67% yield), removal of the methoxymethyl ether protective group, 
and silylation of the bisphenol function (55% yield over two steps). To conduct the key 
carbonyl ylide–aldehyde cycloaddition on a large scale, a solution of the epoxy diazo 
diketone component 18 (2.27 g, 3.0 equiv, 2.72 M in dichloromethane) was added by a 
motor-driven syringe pump over 6 h to a suspension of differentially protected aldehyde 
22 (2.50 g, 1 equiv, 0.91 M in dichloromethane), rhodium(II) acetate (0.02 equiv), and 
powdered 4-Å molecular sieves at 23 °C. After filtration to remove molecular sieves and 
the rhodium catalyst, purification by flash-column chromatography on silica gel provided 
a mixture of the four possible diastereomeric cycloadducts (see Scheme 1.4) in 82% yield 
(2.59 g), and, separately, the aldehyde starting material in 15% yield. Separation of the 
individual diastereomeric cycloadducts at this stage was challenging; instead, it proved 
more convenient to remove the cyclic di-tert-butylsiloxane protective group first, after 
which only the endo diastereomers underwent spontaneous hemiketalization. Critically, 
we found that the two major endo diastereomers, which in previous smaller-scale runs 
had been separated by preparatory RP-HPLC,18 could be separated by flash-column 
chromatography on silica gel deactivated with triethylamine (as the exo diastereomers do 
not undergo hemiketalization, they differ greatly in polarity from the endo diastereomers 
at this stage). In this manner we isolated 690 mg (32% yield) of synthetic precursor 23 in 
a single batch.  
 
Synthesis of DC-45-A1 
With a scalable route to large quantities of synthetic precursor 23, we began to 
study the glycosidic coupling of an appropriately activated trioxacarcinose A derivative 
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to the benzylic hydroxyl group at C4 of the trioxacarcin skeleton. The substrate for 
glycosylation, benzylic alcohol 58, was prepared in 83% yield by treatment of synthetic 
precursor 23 with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in a mixture of 
dichloromethane and pH 7 aqueous phosphate buffer at 23 °C (Scheme 3.2).18 We 
expected the benzylic C4 hydroxyl group revealed by this transformation to be more 
reactive in glycosylation reactions than either the C13 hemiketal group or the hydrogen-
bonded phenol, neither of which were protected. 
 
 
Scheme 3.2. Synthesis of DC-45-A1 (10) from Synthetic Precursor 23. 
 
In addition to the monoglycoside DC-45-A1 (10), the trioxacarcinose A residue is 
common to many of the naturally occurring trioxacarcins, including the bisglycoside 
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trioxacarcin A (1) and the trisglycoside LL-D49194α1 (12) (Figure 1.2). Trioxacarcinose 
A (2) contains a free hydroxyl group which lies in a 1,3-diaxial  relationship  with  the  α-
glycosidic linkage present within each of these natural products. One early point of 
concern for glycosylation studies was the issue of whether to protect this alcohol, and if 
so   how.   It   was   easy   to   envision   many   protection   schemes   that   would   disfavor   α-
glycosylation through steric interactions, and less obvious how to functionalize this 
alcohol to promote the desired stereochemical outcome. Furthermore, trioxacarcinose A 
(2) is a 2-deoxy sugar and, lacking 2-substituents to direct the stereochemistry of 
anomeric bond formation, these frequently prove to be problematic substrates.63 
I explored initial glycosidic couplings using 1-O-acetyl trioxacarcinose A (48). I 
found that when a mixture of aglycon 58 (1 equiv), glycosyl donor 48 (2 equiv, a 1:12 
mixture of α- and β-anomers, respectively) and powdered 4-Å molecular sieves in 
dichloromethane at –40 °C was treated with boron trifluoride etherate (1.0 equiv) as 
promoter, the α-monoglycoside 59 was formed in 79% yield (23 mg, Scheme 3.2). The β-
configured glycosylation product was not observed. Trimethylsilyl 
trifluoromethanesulfonate was also effective for the stereoselective coupling of 1-O-
acetyltrioxacarcinose A (48) to substrate 58, although the yield was lower. Thus, when a 
suspension of substrate 58 (1 equiv), 1-O-acetyltrioxacarcinose A (48, 2 equiv, a 1:12 
mixture of α- and   β-anomers, respectively), and powdered 4-Å molecular sieves in 
dichloromethane at –78 °C was treated with a catalytic quantity of trimethylsilyl 
trifluoromethanesulfonate (0.3 equiv), the  α-monoglycoside 59 was formed in 52% yield, 
and the  β-glycoside product was not observed. In neither of the above coupling reactions 
                                                 
63 (a) Veyrières, A.; Ernst, B.; Hart, G. W.; Sinaý, P., Special Problems in Glycosylation Reactions: 2-
Deoxy Sugars. In Carbohydrates in Chemistry and Biology, Wiley-VCH Verlag GmbH: 2008; pp 367–405. 
(b) Gholap, S. L.; Woo, C. M.; Ravikumar, P.; Herzon, S. B. Org. Lett. 2009, 11, 4322–4325. 
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did I observe glycosylation of either the C13 hemiketal or the phenol. Furthermore, the 
success of these glycosidic couplings indicated that protection of the free 3-hydroxyl 
group present within the 1-O-acetyl glycoside 48 was unnecessary. In contrast to these 
successful couplings, attempts to introduce the trioxacarcinose A residue using the 
corresponding moisture- and acid-sensitive 1-fluoro glycoside derivative 54 (Scheme 2.9) 
did not afford any quantifiable amount of coupling products.  
Removal of the tert-butyldimethylsilyl   (TBS)   ether   of   α-glycoside 59 was 
accomplished by treatment with a large excess of triethylamine trihydrofluoride (30 
equiv) in acetonitrile at 23 °C for 16 h to provide DC-45-A1 (10) in 76% yield after 
purification by RP-HPLC (4.6 mg, Scheme 3.2). Analytical data obtained from the 
synthetic material were in agreement with values reported for the natural product.3 The 
synthetic sample was also indistinguishable spectroscopically and chromatographically 
from an authentic sample (see Experimental Section). 
Both conformational and stereoelectronic arguments can be advanced to explain 
the  high  α-selectivity observed in the glycosylation reaction of trioxacarcinose A. Lewis 
acid-promoted ionization of the trioxacarcinose A donor 48 forms an oxocarbenium ion 
intermediate that can in principle exist in two different half-chair conformations, depicted 
as 60 and 61 (Scheme 3.3). Two axial methyl groups would greatly impede axial addition 
of a glycosyl acceptor to the half-chair 61, which is also disfavored stereoelectronically 
(as a consequence of the equatorial orientation of the 3-hydroxyl group), whereas axial 
addition to half-chair 60 is both sterically and stereoelectronically favored.64  
                                                 
64 Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. J. Am. Chem. Soc. 2000, 122, 168–169. (b) Ayala, L.; 
Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. J. Am. Chem. Soc. 2003, 125, 15521–
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Scheme 3.3. Rationalization of the Stereochemical Outcome of Glycosylation Reactions 
with Trioxacarcinose A Donor 48. 
A remarkable—and essential—feature of the glycosylation reaction of the 
trioxacarcinose A donor 48 is that it is compatible with the spiro epoxide function of the 
core substrate. Evidence suggests that the epoxy group efficiently alkylates only 
nucleophiles that benefit from π-stacking interactions with the aromatic core, such as a 
guanosine base of duplex DNA.17 
                                                                                                                                                 
15528. (c) Chamberland, S.; Ziller, J. W.; Woerpel, K. A. J. Am. Chem. Soc. 2005, 127, 5322–5323. (d) 
Yang, M. T.; Woerpel, K. A. J. Org. Chem. 2009, 74, 545–553. 
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Synthesis of Trioxacarcin A 
Having developed a method for the coupling of trioxacarcinose A to the C4 
hydroxyl group of trioxacarcin aglycon substrates such as 58, we turned our attention to 
the introduction of trioxacarcinose B (3) to the sterically hindered C13 hemiketal. A 
variety of anomerically activated derivatives of trioxacarcinose B are available from a 
short and practical sequence developed by postdoctoral researcher Thomas Magauer.65 
Attempts to glycosylate differentially protected aglycon substrate 23 with trioxacarcinose 
B derivatives bearing a free 3-hydroxyl group were not successful, so we elected to 
protect that hydroxyl group. In evaluating potential protective groups, we prioritized 
those which might minimize a potential 1,3-diaxial steric interaction with an incoming 
nucleophile, for we anticipated that such an interaction would serve to disfavor the 
required   α-glycosidic bond formation. For this reason we prioritized ester protective 
groups. Because the trioxacarcinose A residue present in many natural trioxacarcins bears 
an acetate ester, initially we sought to use an ester group other than acetate to protect 
position C3 of the trioxacarcinose B donor, to avoid a problem of redundant 
functionality. In a model study, Thomas Magauer evaluated the use of a 4-azidobutyryl 
ester as a differentiated ester protective group. Accordingly, hydrogenolysis of model 
substrate 62 (Pd/C, 1 atm H2, ethanol, 23 °C), followed by brief heating at 80 °C to 
promote cleavage of the intermediate 4-aminobutyryl ester, produced a complex mixture 
of products including the desired C3-alcohol (63) and its epimer (3-epi-63). We reasoned 
that 3-epi-63 likely arose from a retroaldol fragmentation–aldol cyclization sequence. 
                                                 
65 Magauer, T.; Myers, A. G. Org. Lett. 2011, 13, 5584–5587. 
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This not only indicated that a 4-azidobutyryl ester was unsuitable in this context, but also 
suggested that earlier attempts at glycosidic coupling of trioxacarcinose B derivatives 
bearing a free 3-hydroxyl group failed due to decomposition of the sugar by pathways 
initiated by retroaldol fragmentation.  
 
 
Scheme 3.4. Attempted Deprotection of 4-Azidobutyryl Ester 62. 
At this stage we considered carefully whether it was necessary to differentiate the 
3-hydroxyl protective group of the trioxacarcinose B residue from the acetate ester within 
the trioxacarcinose A residue. We conducted a competition experiment suggesting that 
such   differentiation   was   unnecessary.   Thus,   a   mixture   of   methyl   α-3-O-acetyl 
trioxacarcinoside B (64)   (1   equiv)   and  methyl   α-trioxacarcinoside A (47) (1 equiv) in 
CD3OD was treated with potassium carbonate (1 equiv) at 0 °C, and the mixture was 
monitored by 1H NMR analysis (500 MHz). Within 2 h, complete deprotection of the 3-
O-acetyl protective group of the trioxacarcinose B residue occurred to give methyl α-
trioxacarcinoside B (63), and the acetate ester within the methyl α-trioxacarcinoside A 
residue was unaffected (Scheme 3.5). (Complete deprotection of both esters occurred on 
prolonged stirring at 0 °C.) We rationalized the difference in stability between these two 
acetate  esters  based  on  their  different  steric  environments:  Whereas  the  α-trioxacarcinose 
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A ester is flanked on both sides by equatorial methyl groups, the 3-O-acetyl ester group 
of the trioxacarcinose B residue has only one flanking equatorial group.  
 
 
Scheme 3.5. Simultaneous  Methanolysis  of  Methyl  α-3-O-Acetyl Trioxacarcinoside B 
(64)  and  Methyl  α-Trioxacarcinoside A (47). 
With the above evidence that 1,3-di-O-acetyl trioxacarcinose B (65) could be a 
viable glycosyl donor for the preparation of fully synthetic bisglycoside trioxacarcins 
such as trioxacarcin A, postdoctoral researcher Thomas Magauer developed conditions 
for the coupling of this activated sugar to differentially protected synthetic precursor 23. 
In an early successful coupling, a suspension of crushed, activated 4-Å molecular sieves, 
aglycon substrate 23 (1 equiv., 0.18 mM) and a large excess of donor 65 (30 equiv) in 
dichloromethane–ether at –78 °C was treated with excess TMSOTf (20 equiv)66 to 
furnish the α-glycoside 66 as the sole product in 78% yield (30 mg).62 By increasing the 
concentration of substrate 23, the number of equivalents of donor 65 and Lewis acid that 
                                                 
66 (a) Kimura, Y.; Suzuki, M.; Matsumoto, T.; Abe, R.; Terashima, S. Chem. Lett. 1984, 501–504. (b) 
Kimura, Y.; Suzuki, M.; Matsumoto, T.; Abe, R.; Terashima, S. Chem. Soc. Jpn 1986, 59, 423–431. 
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were necessary to achieve full conversion was reduced (e.g., 8.5 equiv. 65, 58% yield, 
120 mg, employing TMSNTf2 as Lewis acid).62 
 
 
Scheme 3.6. Synthesis of Trioxacarcinose B Glycoside (66)62 
With methods to independently couple both trioxacarcinose A (2) and 
trioxacarcinose B (3) to fully functionalized aglycon substrates, it remained to coordinate 
the two couplings to prepare trioxacarcin A (1). In principle, the two glycosidic couplings 
could be conducted in either possible sequence, but in practice it was necessary to 
conduct the coupling with trioxacarcinose B first, for when we attempted to glycosylate 
the trioxacarcinose-A containing monoglycoside 59 (see Scheme 3.2) with 1,3-di-O-
acetyl trioxacarcinose B (65) using TMSOTf as promoter, conditions that were successful 
for the glycosylation of aglycon 23,  only  products  arising  from  cleavage  of  the  existing  α-
glycosidic linkage were observed.  
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Scheme 3.7. Cleavage of the PMB Ether within Glycoside 66. 
To evaluate the alternative sequence, the PMB ether within monoglycoside 66 
was cleaved (DDQ, 1.1 equiv., 95% yield) to provide benzylic alcohol 67 (Scheme 3.7). 
Attempted glycosylations of 67 with 1-O-acetyl trioxacarcinose A (48) using either 
TMSOTf or boron trifluoride etherate as Lewis-acidic promoter provided the desired 
bisglycoside product 68 alongside a byproduct arising from cleavage of the 
trioxacarcinose B residue, namely monoglycoside 59 (Scheme 3.8).  
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Scheme 3.8. Attempted Lewis Acid-Promoted Glycosylation of Monoglycoside 67 with 
1-O-Acetyltrioxacarcinose A (48). 
We were therefore led to explore orthogonal conditions for glycosylation and 
considered the use of 1-phenylthiotrioxacarcinoside A (55, see Scheme 2.9) as an 
alternative coupling partner. Addition of silver hexafluorophosphate (6.0 equiv) to a 
mixture of substrate 67 (65 mg, 1 equiv), 1-phenylthiotrioxacarcinoside A (55, 3.0 equiv, 
a 1:2.4 mixture of α- and β-anomers, respectively), 2,6-di-tert-butyl-4-methylpyridine 
(8.0 equiv) and powdered 4-Å molecular sieves in dichloromethane at 0 °C led to 
complete glycosylation within 1 hour (Scheme 3.9).67 The α,α-bisglycoside 68 was 
obtained as a greenish-yellow foam after purification by RP-HPLC (58 mg, 74%). The  β-
glycoside was not observed, and, critically, no products resulting from cleavage of the 
trioxacarcinose B residue were detected. 
                                                 
67 (a) Lear, M. J.; Yoshimura, F.; Hirama, M. Ang. Chem. Int. Ed. 2001, 40, 946–949. (b) Ren, F.; Hogan, 
P. C.; Anderson, A. J.; Myers, A. G. J. Am. Chem. Soc. 2007, 129, 5381–5383. 
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Scheme 3.9. Coupling of Benzylic Alcohol Monoglycoside 67 with 1-
Phenylthiotrioxacarcinoside A (55) 
From bisglycoside 68, the cleavage of two protective groups, namely the C2 tert-
butyldimethylsilyl ether and the trioxacarcinose B acetate ester, was required to prepare 
trioxacarcin A (1). Selective cleavage of the trioxacarcinose B acetate ester protective 
group occurred on exposure of the α,α-bisglycoside 68 to potassium carbonate for one 
hour in ice-cold methanol (Scheme 3.10); higher temperatures led to decomposition. 1H 
NMR analysis of the yellow-orange residue established that methanolysis of the 
trioxacarcinose B acetate ester had occurred cleanly, and showed no evidence of any 
competing cleavage of the trioxacarcinose A acetate ester, as anticipated from model 
studies (see Scheme 3.5). The product was not purified, but was subjected to immediate 
deprotection with triethylamine–trihydrofluoride in acetonitrile at 23 °C (16 hours). After 
isolation by RP-HPLC, pure trioxacarcin A (1) was obtained as an orange-red powder (23 
mg, 55% yield over two steps). Analytical data obtained from the synthetic material were 
in agreement with values reported for the natural product.2,6 The synthetic sample was 
also indistinguishable spectroscopically and chromatographically from an authentic 
sample. We observed that trioxacarcin A, like its precursor 68, is unstable towards a base 
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in alcoholic solvents; decomposition is evidenced by the formation of a deep burgundy-
red solution (solutions of pure trioxacarcin A in ethanol and chloroform are typically 
orange). 
 
 
Scheme 3.10. Synthesis of Trioxacarcin A (1) 
 
Conclusion 
In this chapter, I have described the development of component-based synthetic 
routes to trioxacarcin A (1) and DC-45-A1 (10). These routes represent the first syntheses 
of natural, glycosylated trioxacarcins. Both rely on the late-stage glycosidic coupling of 
an activated form of trioxacarcinose A (48 or 55) to a fully functionalized trioxacarcin 
core substrate. 
The synthetic route to trioxacarcin A (1) assembles five components of similar 
synthetic complexity: epoxy diazo diketone 18, cyanophthalide 19, cyclohexenone 20, 
trioxacarcinose A donor 55, and trioxacarcinose B donor 65. Each of these components in 
turn was prepared in multigram quantities by a short, practical sequence. Starting from 
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the five components, trioxacarcin A (1) is prepared in 11 linear steps, four of which are 
convergent coupling reactions. The route is summarized in Scheme 3.11, with convergent 
couplings denoted by branched vertical arrows and other linear steps by horizontal 
arrows. A graphical schematic of the route is shown in Figure 3.1 and emphasizes the 
convergent, component-based nature of the sequence. Within the schematic, synthetic 
intermediates involved in convergent coupling reactions are represented with circles, and 
each chemical step is represented by an arrow.  
One key advantage of the component-based assembly strategy pursued for 
trioxacarcin A (1) and DC-45-A1 (10) is that deep-seated structural modifications can be 
introduced relatively rapidly by modification of the components. Modification of more 
than one component simultaneously leads to multiplicative expansion of the set of 
structures available for study. In Chapter 4 I describe the synthesis of a variety of novel 
trioxacarcin analogs by variation of the components, both individually and in 
combination, as well as by late-stage modification. Many of these analogs would be 
inaccessible by other means, demonstrating the advantages of a convergent, component-
based synthetic sequence for the assembly of a target of interest. 
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Scheme 3.11. Component-Based Synthetic Route to Trioxacarcin A (1) 
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Figure 3.1. Graphical Schematic Representing the Synthetic Route to Trioxacarcin A (1). 
 
  
120 
 
Experimental Section 
General Experimental Procedures 
All reactions were performed in round-bottom flasks fitted with rubber septa 
under a positive pressure of argon, unless otherwise noted. Air- and moisture-sensitive 
liquids were transferred by syringe or stainless steel cannula. Organic solutions were 
concentrated   by   rotary   evaporation   (house   vacuum,   ca.   25−40   Torr)   at   ambient  
temperature, unless otherwise noted. Analytical thin-layer chromatography (TLC) was 
performed using glass plates pre-coated with silica gel (0.25 mm, 60 Å pore-size, 
230−400  mesh,  Merck  KGA)   impregnated  with   a   fluorescent   indicator   (254  nm).  TLC 
plates were visualized by exposure to ultraviolet light, then were stained with either an 
aqueous sulfuric acid solution of ceric ammonium molybdate (CAM), an acidic solution 
of p-anisaldehyde in ethanol (Anis), or an aqueous sodium hydroxide–potassium 
carbonate solution of potassium permanganate (KMnO4) followed by brief heating on a 
hot plate. Flash-column chromatography was performed as described by Still et al.,52 
employing silica gel (60 Å, 32-63  μm, standard grade, Dynamic Adsorbents, Inc.). 
 
Materials 
Commercial solvents and reagents were used as received with the following 
exceptions. Tetrahydrofuran, dichloromethane, benzene, toluene, and ether were purified 
by the method of Pangborn et al.53 4-Å molecular sieves (powder, Aldrich) were stored in 
a laboratory oven at 140 °C and were allowed to cool in a desiccator immediately before 
use.  
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Instrumentation 
Proton magnetic resonance (1H NMR) spectra were recorded on Varian INOVA 
500 (500 MHz) or 600 (600 MHz) NMR spectrometers at 23 °C. Proton chemical shifts 
are expressed in parts per million (ppm, G scale) and are referenced to residual protium in 
the NMR solvent (CHCl3, G 7.26). Data are represented as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and/or multiple 
resonances, br = broad, app = apparent), integration, and coupling constant (J) in Hertz. 
Carbon nuclear magnetic resonance spectra (13C NMR) were recorded on Varian INOVA 
500 (125 MHz) NMR spectrometers at 23 °C. Carbon chemical shifts are expressed in 
parts per million (ppm, G scale) and are referenced to the carbon resonances of the NMR 
solvent (CDCl3, G 77.0). Infrared (IR) spectra were obtained using a Shimadzu 8400S FT-
IR spectrometer. Data are represented as follows: frequency of absorption (cm–1), 
intensity of absorption (s = strong, m = medium, w = weak, br = broad). Optical rotations 
were measured on a Jasco DIP-0181 digital polarimeter with a sodium lamp and are 
reported as follows: [D] T[°C] λ (c = g/100 mL, solvent). Circular dichroism spectra were 
obtained using a Jasco J-710 spectropolarimeter. High-resolution mass spectra were 
obtained at the Harvard University Mass Spectrometry Facility. High performance liquid 
chromatography purifications were performed using an Agilent Technologies 1200 Series 
preparative HPLC system. 
(For clarity, intermediates that have not been assigned numbers in the text are 
numbered sequentially in the Experimental Section beginning with 69.) 
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(E)-7-Propenyl-3,4-dihydroanthracen-1-one (21).18 
Lithium tert-butoxide (1.0 M solution in tetrahydrofuran, 47.5 mL, 47.5 mmol, 
3.0 equiv) was added to a solution of (E)-4-(methoxymethoxy)-6-methyl-3-oxo-5-(prop-
1-enyl)-1,3-dihydroisobenzofuran-1-carbonitrile 19 (4.33 g, 15.8 mmol, 1 equiv) in 
tetrahydrofuran (86 mL) at –78 qC. After 5 min, a solution of (4S,6S)-6-(tert-
butyldimethylsilyloxy)-4-(4-methoxybenzyloxy)cyclohex-2-enone 20 (5.74 g, 15.83 
mmol, 1.0 equiv) in tetrahydrofuran (86 mL) was added by cannula. The reaction flask 
was allowed to warm to –20 qC over 3 h, then dimethylsulfate (13.6 mL, 142 mmol, 9.0 
equiv) was added. The reaction flask was allowed to warm to 23 qC over 2 h. After an 
additional 2 h, the reaction mixture was partitioned between saturated aqueous 
ammonium chloride solution (500 mL) and ethyl acetate (1 L). The layers were 
separated. The organic layer was washed sequentially with water (500 mL) then saturated 
aqueous sodium chloride solution (500 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography (hexanes initially, grading to 5% 
ethyl acetate–hexanes) to provide the product, (E)-7-propenyl-3,4-dihydroanthracen-1-
one (21), as an orange foam (6.87 g, 70%).18  
 
1H NMR:  14.89 (s, 1H), 7.63 (s, 1H), 7.28 (d, 2H, J = 8.5 Hz), 6.87 
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(500 MHz, CDCl3) (d, 2H, J = 8.2 Hz), 6.53 (d, 1H, J = 16.3 Hz), 6.11 (dq, 
1H, J = 16.2, 6.4 Hz), 5.2 (m, 1H), 5.09 (d, 1H, J = 6.2 
Hz), 5.04 (d, 1H, J = 6.2 Hz), 4.99 (dd, 1H, J = 12.6, 5.3 
Hz), 5.78 (d, 1H, J = 11.0 Hz), 4.58 (d, 1H, J = 11.0 Hz), 
3.85 (s, 3H), 3.79 (s, 3H), 3.59 (s, 3H), 2.72 (ddd, 1H, J 
= 13.3, 4.8, 3.2 Hz), 2.50 (s, 3H), 2.18 (m, 1H), 1.97 (d, 
3H, J = 6.4 Hz), 0.98 (s, 9H), 0.25 (s, 3H), 0.18 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
203.7, 161.4, 159.2, 153.8, 144.8, 141.2, 133.1, 132.4, 
131.7, 130.2, 129.5, 125.4, 125.1, 119.1, 188.8, 113.8, 
108.4, 101.3, 70.8, 69.4, 68.8, 62.8, 57.9, 55.3, 36.6, 
25.9, 22.2, 19.3, 18.6, –4.4, –5.3. 
 
FTIR, cm–1: 
(neat) 
2951 (w), 2930 (w), 1611 (m), 1514 (w), 1443 (w), 1381 
(w), 1362 (m), 1248 (m), 1155 (m), 1124 (m), 1040 (s), 
1003 (m), 928 (m), 872 (m), 835 (m), 779 (m). 
 
HRMS:  
(ESI) 
Calcd for (C35H46O8Si+Na) 
Found 
 
645.2854 
645.2854 
TLC: 
(17% ethyl acetatehexanes) 
 
Rf = 0.36 (CAM) 
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7-Formyl-3,4-dihydroanthracen-1-one (69)18 
2,6-Lutidine (2.57 mL, 22.1 mmol, 2.0 equiv) was added to an ice-cooled solution 
of (E)-7-propenyl-3,4-dihydroanthracen-1-one 21 (6.87 g, 11.0 mmol, 1 equiv), 
potassium osmate dihydrate (203 mg, 0.552 mmol, 0.05 equiv), and sodium periodate 
(9.44 g, 44.1 mmol, 4.0 equiv) in a mixture of tetrahydrofuran (160 mL) and water (80 
mL). After 5 min, the cooling bath was removed and the reaction flask was allowed to 
warm to 23 qC. After 2.5 h, the reaction mixture was partitioned between water (600 
mL), ethyl acetate (1.2 L), and hexanes (600 mL). The layers were separated. The organic 
layer was washed with water (600 mL) then saturated aqueous sodium chloride solution 
(600 mL) and the washed solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (10% ethyl acetate–hexanes initially, grading to 15% ethyl acetate–
hexanes) to provide the product, 7-formyl-3,4-dihydroanthracen-1-one (69), as an orange 
foam (4.52 g, 67%).18 
 
1H NMR:  
(500 MHz, CDCl3) 
14.96 (s, 1H), 9.64 (s, 1H), 7.64 (s, 3H), 7.28 (d, 2H, J = 
8.5 Hz), 6.87 (d, 2H, J = 8.5 Hz), 5.29–5.20 (m, 3H), 
5.00 (dd, 1H, J = 12.2, 5.1 Hz), 4.70 (d, 1H, J = 11.0 
Hz), 4.60 (d, 1H, J = 11.0 Hz), 3.86 (s, 3H), 3.80 (s, 3H), 
3.61 (s, 3H), 2.74 (s, 3H), 2.73 (m, 1H), 2.19 (m, 1H), 
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0.98 (s, 9H), 0.26 (s, 3H), 0.18 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.2, 193.3, 163.2, 161.6, 159.4, 144.7, 141.8, 137.0, 
129.9, 129.5, 127.6, 120.7, 118.1, 113.9, 109.2, 102.8, 
71.1, 69.3, 68.6, 62.9, 58.4, 55.3, 36.3, 25.8, 22.3, 18.5, –
4.5, –5.3. 
 
FTIR, cm–1: 
(neat) 
2953 (w), 2930 (w), 2857 (w), 1686 (m), 1611 (s), 1514 
(m), 1385 (m), 1364 (m), 1246 (s), 1153 (s), 1042 (s), 
1011 (m), 930 (m), 872 (m), 837 (m), 779 (m). 
 
HRMS:  
(ESI) 
Calcd for (C33H42O9Si+Na) 
Found 
 
633.2490 
633.2464 
TLC: 
(10% ethyl acetatehexanes) 
 
Rf = 0.18 (CAM) 
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8,9-Dihydroxy-7-formyl-3,4-dihydroanthracen-1-one (70).18 
A solution of B-bromocatecholborane (2.54 g, 12.8 mmol, 2.0 equiv) in 
dichloromethane (94 mL) was added to a solution of 7-formyl-3,4-dihydroanthracen-1-
one 69 (3.90 g, 6.39 mmol, 1 equiv) in dichloromethane (94 mL) at –78 qC. After 50 min, 
the reaction mixture was diluted with saturated aqueous sodium bicarbonate solution (300 
mL) and dichloromethane (500 mL). The cooling bath was removed, and the partially 
frozen mixture was allowed to warm to 23 qC. The biphasic mixture was diluted with 0.2 
M aqueous sodium hydroxide solution (1.25 L). The layers were separated. The dark-
purple aqueous layer was extracted with dichloromethane (2 u 1 L). The organic layers 
were combined. The combined solution was washed sequentially with 0.1 M aqueous 
hydrochloric acid solution (500 mL), water (3 u 500 mL), then saturated aqueous sodium 
chloride solution (500 mL) and the washed solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated to provide the product, 8,9-
dihydroxy-7-formyl-3,4-dihydroanthracen-1-one (70), as a yellow foam.18 Attempts to 
purify 70 by flash-column chromatography led to decomposition.  
 
1H NMR:  
(500 MHz, CDCl3) 
15.58 (br s, 1H), 10.51 (s, 1H), 7.28 (d, 2H, J = 8.7 Hz), 
7.25 (s, 1H), 6.87 (d, 2H, J = 8.7 Hz), 5.16 (m, 1H), 4.99 
(dd, 1H, J = 12.3, 5.2 Hz), 4.68 (d, 1H, J = 11.1 Hz), 
4.59 (d, 1H, J = 10.7 Hz), 3.84 (s, 3H), 3.80 (s, 3H), 2.73 
127 
 
(s, 3H), 2.71 (m, 1H), 2.18 (m, 1H), 0.97 (s, 9H), 0.25 (s, 
3H), 0.18 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
203.9, 192.7, 166.5, 163.6, 159.4, 144.8, 142.7, 137.7, 
130.7, 129.9, 129.5, 114.8, 114.2, 113.9, 108.5, 71.1, 
69.0, 68.6, 62.8, 55.3, 36.5, 25.8, 21.0, 18.5, –4.5, –5.3. 
 
FTIR, cm–1: 
(neat) 
3329 (w, br), 2953 (m), 2930 (m), 2857 (m), 1682 (m), 
1614 (s), 1514 (m) 1391 (m) 1246 (s), 1153 (s), 1049 
(m), 1034 (m) 870 (m), 837 (s). 
 
HRMS:  
(ESI) 
Calcd for (C31H38O8Si+H) 
Found 
 
567.2409 
567.2398 
TLC: 
(30% ethyl acetatehexanes) 
 
Rf = 0.22  (CAM) 
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Differentially Protected Aldehyde 22.18 
Di-tert-butyldichlorosilane (2.43 mL, 11.5 mmol, 1.8 equiv) was added to a 
solution of 8,9-dihydroxy-7-formyl-3,4-dihydroanthracen-1-one 70 (1 equiv, see 
paragraph above), N,N-diisopropylethylamine (5.58 mL, 31.9 mmol, 5.0 equiv), and 
anhydrous 1-hydroxybenzotriazole (432 mg, 3.19 mmol, 0.5 equiv) in 
dimethylformamide (128 mL) at 23 qC. The reaction flask was heated in an oil bath at 55 
qC.  After 80 min, the heating bath was removed and the reaction flask was allowed to 
cool to 23 qC. The reaction mixture was partitioned between saturated aqueous sodium 
bicarbonate solution (300 mL) and ether (1.5 L). The layers were separated. The organic 
layer was washed with water (2 × 500 mL) then saturated aqueous sodium chloride 
solution (300 mL) and the washed solution was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The residue was purified by flash-
column chromatography (10% ethyl acetate–hexanes) to provide of the product 22 as a 
yellow foam (2.50 g, 55% over steps).18 
 
1H NMR:  
(500 MHz, CDCl3) 
10.8 (s, 1H), 7.34 (s, 1H), 7.31 (d, 2H, J = 6.5 Hz), 6.88 
(d, 2H, J = 7.0 Hz), 5.20 (dd, 1H, J = 3.0, 3.0 Hz), 4.88 
(dd, 1H, J = 12.5, 5.0 Hz), 4.73 (d, 1H, J = 11.0 Hz), 
4.63 (d, 1H, J = 10.5 Hz), 3.90 (s, 3H), 3.79 (s, 3H), 
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2.772.72 (m, 1H), 2.72 (s, 3H), 2.192.13 (m, 1H), 1.15 
(s, 9H), 1.12 (s, 9H), 0.96 (s, 9H), 0.24 (s, 3H), 0.14 (s, 
3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
194.2, 190.9, 160.4, 159.4, 150.2, 146.3, 140.3, 134.0, 
133.2, 130.0, 129.8, 199.4, 116.5, 115.6, 115.3, 114.0, 
71.4, 71.2, 69.8, 62.7, 55.3, 36.3, 26.1, 26.0, 26.0, 22.5, 
21.4, 21.0, 18.7, 4.3,5.4. 
 
FTIR, cm–1: 
(neat) 
2936 (s), 1786 (s), 1684 (s), 1607 (s), 1373 (s), 1247 (s), 
1157 (s), 1034 (s). 
 
HRMS:  
(ESI) 
Calcd for (C39H54O8Si2+H) 
Found 
 
707.3430 
707.3422 
TLC: 
(40% ethyl acetatehexanes) 
 
Rf = 0.87  (CAM) 
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Gram-Scale Endo-Selective Carbonyl YlideAldehyde Cycloaddition: 
A solution of (S)-1-diazo-3-epoxy-5,5-dimethoxypenta-2,4-dione 1818 (2.27 g, 
10.6 mmol, 3.0 equiv) in dichloromethane (3.9 mL) was added by a motor-driven syringe 
pump over 6 h to a suspension of differentially protected aldehyde 22 (2.50 g, 3.54 mmol, 
1 equiv), rhodium(II) acetate (31 mg, 71 Pmol, 0.02 equiv), and powdered 4-Å molecular 
sieves (500 mg) in dichloromethane (3.9 mL) at 23 qC. After 30 min, the reaction mixture 
was filtered through a short pad of silica gel (length: 10 cm; diameter: 1.5 cm), eluting 
with 40% ethyl acetate–hexanes to remove the rhodium(II) acetate and powdered 4-Å 
molecular sieves. The filtrate was concentrated. The residue was purified by flash-
column chromatography (10% ethyl acetate–hexanes initially, grading to 40% ethyl 
acetate–hexanes) to provide, together, 2.59 g of a mixture of cycloadducts 24 (44%), 25 
(37%), 26 (16%), and 27 (3%), as depicted above (82% yield).18 In addition, 380 mg 
(15%) of the starting material, the differentially protected aldehyde 22, was recovered. 
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Synthetic Precursor 23. 
Triethylamine–trihydrofluoride (1.42 mL, 8.70 mmol, 3.0 equiv) was added to a 
solution of a mixture of cycloadducts 24, 25, 26, and 27 (2.59 g, 2.90 mmol, 1 equiv, as 
described above) in acetonitrile (58 mL) at 23 qC. After 15 min, the bright yellow 
solution was diluted with dichloromethane (500 mL). The diluted solution was washed 
sequentially with pH 7 aqueous phosphate buffer solution (100 mL) then saturated 
aqueous sodium chloride solution (100 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography on silica gel deactivated with 
triethylamine (30% ethyl acetate–hexanes initially, grading to 40% ethyl acetate–
hexanes; two purifications) to provide synthetic precursor 23 as a yellow-green foam 
(690 mg, 32%).18  
 
1H NMR:  
(500 MHz, CDCl3) 
7.37 (s, 1H), 7.30 (d, J = 9.0 Hz, 2H), 6.86 (d,  J = 8.5 
Hz, 2H), 5.74 (d, J = 3.0 Hz, 1H), 5.48 (d, J = 3.5 Hz, 
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1H), 5.15 (dd, J = 2.5, 3.0 Hz, 1 H), 4.85 (dd,  J = 12.0, 
4.5 Hz, 1H), 4.77 (s, 1H), 4.70 (d, J = 11.0 Hz, 1H), 4.60 
(d,  J = 11.0 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.63 (d, 
J = 6.0 Hz, 1H), 3.61 (s, 3H), 3.61 (s, 3H), 3.07 (d, J = 
7.0 Hz, 1H), 2.75 (s, 3H), 2.732.69 (m, 1H), 2.172.11 
(m, 1H), 1.19 (s, 9H), 1.07 (s, 9H), 0.95 (s, 9H), 0.23 (s, 
3H), 0.13 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
201.0, 194.4, 159.3, 150.1, 149.1, 146.2, 139.6, 131.2, 
130.3, 129.7, 129.4, 118.2, 116.8, 115.8, 114.5, 113.8, 
107.0, 101.6, 83.4, 79.6, 71.3, 71.2, 69.6, 64.3, 62.6, 
56.6, 55.9, 55.3, 50.9, 36.7, 26.4, 26.1, 26.0, 23.6, 21.2, 
21.2, 18.7, 4.3, 5.3. 
 
FTIR, cm–1: 
(neat) 
2928 (s), 2857 (s), 1784 (s), 1699 (s), 1611 (s), 1371 (s), 
1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C47H64O13Si2+H) 
Found 
 
893.3958 
893.3932 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.46  (CAM) 
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Benzylic Alcohol 58. 
2,3-Dichloro-5,6-dicyanobenzoquinone (16 mg, 70 mmol, 1.1 equiv) was added to 
a vigorously stirring, biphasic solution of synthetic precursor 23 (48 mg, 64 mmol, 1 
equiv) in dichloromethane (1.0 mL) and pH 7 aqueous phosphate buffer solution (100 
μL)  at  23  °C.  The  reaction  flask  was  covered  with  aluminum  foil  to  exclude  light.  Over  
the course of 2 h, the reaction mixture was observed to change from myrtle green to 
lemon yellow. The product solution was partitioned between water (5 mL) and 
dichloromethane (40 mL). The layers were separated. The organic layer was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by preparatory HPLC (Agilent Prep-C18 column, 10 μm, 30 × 150 
mm, UV detection at 270 nm, gradient elution with 40o90% acetonitrile in water, flow 
rate: 15 mL/min) to provide after concentration the pure benzylic alcohol 58 as a yellow-
green powder (33.6 mg, 83%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.62 (s, 1H), 7.40 (s, 1H), 5.41 (t, J = 3.4 Hz, 1H), 5.25 
(d, J = 4.1 Hz, 1H), 4.88 (dd, J = 11.7, 4.8 Hz, 1H), 4.85 
(d, J = 4.1 Hz, 1H), 4.70 (s, 1H), 4.55 (br, 1H), 3.90 (s, 
3H), 3.61 (s, 3H), 3.46 (s, 3H), 3.10 (d, J = 5.5 Hz, 1H), 
3.02 (d, J = 5.5 Hz, 1H), 2.58 (s, 3H), 2.52–2.46 (m, 1H), 
2.36–2.30 (m, 1H), 0.94 (s, 9H), 0.21 (s, 3H), 0.15 (s, 
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3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
202.9, 162.4, 151.5, 143.8, 142.0, 135.1, 129.5, 116.1, 
114.7, 114.7, 107.9, 103.9, 100.1, 98.5, 73.2, 69.6, 69.4, 
69.2, 62.6, 62.5, 57.0, 56.6, 50.4, 38.7, 25.8, 20.4, 18.5, –
4.5, –5.3. 
 
FTIR, cm–1: 
(neat) 
3466 (br), 2953 (w), 1622 (m), 1389 (m), 1123 (s), 1069 
(s), 945 (s), 729 (s). 
 
HRMS:  
(ESI) 
Calcd for (C31H41O12Si+H) 
Found 
 
633.2362 
633.2364 
TLC: 
(60% ethyl acetatehexanes) 
Rf = 0.39  (UV, CAM) 
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D-Glycoside 59. 
Boron  trifluoride  etherate  (4.6  μL,  36  μmol,  1.0  equiv)  was  added  to  a  suspension  
of benzylic alcohol 58 (23  mg,  36  μmol,  1  equiv),  1-O-acetyltrioxacarcinose A (48) (18 
mg,  73  μmol,  2.0  equiv,  a  1:12  mixture  of  D- and E-anomers, respectively), and powdered 
4-Å molecular sieves (~50  mg)   in   dichloromethane   (720   μL)   at   –40 qC. After 5 min, 
saturated aqueous sodium bicarbonate solution (1 mL) was added rapidly, and the 
reaction flask was allowed to warm to 23 °C. The mixture was partitioned between 
dichloromethane (40 mL) and saturated aqueous sodium chloride solution (5 mL). The 
layers were separated. The organic layer was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The residue was purified by 
preparatory HPLC (Agilent Prep-C18 column, 10 μm, 30 × 150 mm, UV detection at 270 
nm, gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to 
provide the pure D-glycoside 59 as a yellow-green powder (23.5 mg, 79%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.84 (s, 1H), 7.47 (s, 1H), 5.38 (d, J = 3.6 Hz, 1H), 5.35 
(app s, 1H), 5.26 (d, J = 4.0 Hz, 1H), 4.84 (d, J = 4.0 Hz, 
1H), 4.78 (dd, J = 12.3, 5.2 Hz, 1H), 4.75 (s, 1H), 4.71 
(s, 1H), 4.52 (q, J = 6.6 Hz, 1H), 4.35 (s, 1H), 3.83 (s, 
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3H), 3.81 (s, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 3.15 (d, J = 
5.3 Hz, 1H), 3.05 (d, J = 5.3 Hz, 1H), 2.60 (s, 3H), 2.58 
(m, 1H), 2.35 (dt, J = 12.5, 2.6 Hz, 1H), 2.14 (s, 3H), 
1.96 (dd, J = 14.6, 4.1 Hz, 1H), 1.62 (d, J = 14.6 Hz, 
1H), 1.23 (d, J = 6.6 Hz, 3H), 1.08 (s, 3H), 0.95 (s, 9H), 
0.24 (s, 3H), 0.16 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
202.8, 170.5, 163.2, 151.8, 144.4, 142.4, 135.2, 126.6, 
116.8, 115.2, 115.1, 108.3, 104.0, 100.3, 98.6, 98.3, 74.6, 
73.4, 69.8, 69.5, 69.5, 68.9, 68.4, 62.9, 62.7, 57.2, 56.8, 
50.7, 38.8, 36.8, 26.0, 25.9, 21.1, 20.6, 18.6, 17.0, –4.2, –
5.3. 
 
FTIR, cm–1: 
(neat) 
3516 (br), 2934 (w), 1749 (m), 1622 (m), 1391 (m), 1229 
(s), 1121 (s), 995 (s), 943 (s), 868 (m), 837 (m). 
 
HRMS:  
(ESI) 
Calcd for (C40H54O16Si+Na) 
Found 
 
841.3073 
841.3064 
TLC: 
(5% methanol 
dichloromethane) 
Rf = 0.40  (UV, CAM) 
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DC-45-A1 (10). 
Triethylamine–trihydrofluoride   (42   μL,   0.26   mmol,   30   equiv)   was   added   to   a  
solution of D-glycoside 59 (7.0  mg,  8.6  μmol,  1  equiv)  in  acetonitrile  (290 μL)  at  23  °C.  
The reaction flask was covered with aluminum foil to exclude light. After 15 h, the 
product solution was partitioned between dichloromethane (50 mL) and saturated 
aqueous sodium chloride solution (10 mL). The organic layer was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by preparatory HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150  mm,  UV  
detection at 270 nm, gradient elution with 20o90% acetonitrile in water, flow rate: 15 
mL/min) to provide after concentration pure DC-45-A1 (10) as a yellow-orange powder 
(4.6 mg, 76%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.23 (s, 1H), 7.49 (s, 1H), 5.40–5.37 (m, 2H), 5.26 (d, J 
= 4.0 Hz, 1H), 4.84 (d, J = 3.7 Hz, 1H), 4.78–4.73 (m, 
2H), 4.71 (s, 1H), 4.54 (q, J = 6.2 Hz, 1H), 4.43 (br, 1H), 
3.84 (s, 3H), 3.62 (s, 3H), 3.58 (br, 1H), 3.47 (s, 3H), 
3.16 (d, J = 5.1 Hz, 1H), 3.04 (d, J = 5.5 Hz, 1H), 2.83–
2.77 (m, 1H), 2.62 (s, 3H), 2.22 (dt, J = 13.2, 2.6 Hz, 
1H), 2.14 (s, 3H), 1.96 (dd, J = 14.3, 4.0 Hz, 1H), 1.61 
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(d, J = 14.3 Hz, 1H), 1.24 (d, J = 6.2 Hz, 1H), 1.07 (s, 
3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
202.8, 170.3, 163.1, 151.7, 144.8, 143, 135.5, 126.5, 
116.8, 115.3, 114.8, 107.3, 103.9, 100.1, 98.6, 98.1, 74.4, 
73.2, 69.5, 69.3, 68.8, 67.9, 67.7, 62.9, 62.7, 57.1, 56.6, 
50.5, 36.7, 36.6, 25.7, 20.9, 20.5, 16.9. 
 
FTIR, cm–1: 
(neat) 
3476 (br), 2934 (m), 1736 (s), 1622 (m), 1389 (s), 1229 
(s), 1144 (s), 1082 (s), 997 (s). 
 
HRMS:  
(ESI) 
Calcd for (C34H40O16+Na) 
Found 
 
727.2209 
727.2200 
TLC: 
(5% methanol 
dichloromethane) 
Rf = 0.30 (UV, CAM) 
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Benzylic Alcohol 67. 
To a vigorously stirring, biphasic solution of D-glycoside 66 (120 mg, 0.124 
mmol, 1 equiv) in dichloromethane (1.9 mL) and pH 7 phosphate buffer (380 μL)  at  23  
°C was added 2,3-dichloro-5,6-dicyanobenzoquinone (33.8 mg, 0.149 mmol, 1.1 equiv). 
The reaction flask was covered with aluminum foil to exclude light. Over the course of 2 
h, the color of the reaction mixture changed from myrtle green to yellow. The product 
solution was partitioned between water (10 mL) and dichloromethane (60 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 20 
mL). The combined organic layers were dried over sodium sulfate.  The dried solution 
was filtered and the filtrate was concentrated. The residue was purified by preparatory 
HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,  
gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide 
after concentration the pure benzylic alcohol 67 (100 mg, 95%, in fractions eluting at 
32.6–36.5 min) as a bright yellow solid.  
 
1H NMR:  
(500 MHz, CDCl3) 
14.40 (s, OH). 7.43 (s, 1 H), 5.82 (t, J = 2.4 Hz, 1H), 
5.43 (app d, J = 1.8 Hz, 1H), 5.30 (d, J = 4.2 Hz, 1H), 
5.30 (s, 1H), 5.19 (d, J = 3.6 Hz, 1H), 5.01 (q, J = 6.6 Hz, 
1H), 4.90 (dd, J = 12.0, 4.8 Hz, 1H), 4.75 (app t, J = 3.6 
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Hz, 1H), 4.74 (s, 1H), 3.90 (s, 3H), 3.89 (s, OH), 3.63 (s, 
3H), 3.47 (s, 3H), 2.83 (d, J = 6.0 Hz, 1H), 2.74 (d, J = 
5.4 Hz, 1H), 2.60 (s, 3H), 2.51–2.48 (m, 1H), 2.42 (br s, 
1H), 2.36 (s, 3H), 2.35–2.30 (m, 2H), 2.23 (s, 3H), 1.08 
(d, J = 6.6 Hz, 3H), 0.95 (s, 9H), 0.23 (s, 3H), 0.16 (s, 
3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.7, 202.9, 170.3, 162.6, 151.8, 143.7, 142.1, 135.2, 
129.6, 116.0, 114.8, 114.3, 107.9, 104.5, 101.6, 99.4, 
92.4, 78.1, 72.10, 70.6, 69.3, 69.1, 68.2, 64.4, 62.7, 62.6, 
56.6, 55.8, 47.4, 38.8, 28.9, 27.0, 25.8, 21.3, 20.4, 18.5, 
14.5, –4.5, –5.4. 
 
FTIR, cm–1: 
(neat) 
3475 (m), 2934 (s), 2857 (m), 1738 (s), 1721 (s), 1620 
(s), 1570 (m), 1445 (m), 1389 (s), 1240 (s), 1082 (s). 
 
HRMS:  
(ESI) 
Calcd for (C41H54O17Si+Na) 
Found 
 
869.3023 
869.2793 
TLC: 
(60% ethyl acetatehexanes) 
 
Rf = 0.31 (UV, CAM) 
 
[D]23D: 2.9° (c 0.614, CHCl3) 
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3''-O-Acetyl-2-O-(tert-butyldimethylsilyl)-trioxacarcin A (68). 
Silver hexafluorophosphate (116 mg, 0.460 mmol, 6.0 equiv) was added to a 
suspension of benzylic alcohol 67 (65.0 mg, 0.077 mmol, 1 equiv), 1-
phenylthiotrioxacarcinoside A 55 (68 mg, 0.23 mmol, 3.0 equiv, a ~1:2.4 mixture of D 
and E anomers, respectively), 2,6-di-tert-butyl-4-methylpyridine (126 mg, 0.614 mmol, 
8.0 equiv), and powdered 4-Å molecular sieves (~100 mg) in dichloromethane (3.8 mL) 
at 0 qC.  After  1  h,  pyridine  (310  μL,  3.84  mmol,  50  equiv)  was  added,  and  the  reaction  
flask was allowed to warm to 23 °C. After 30 min, the product mixture was filtered 
through a short pad of Celite, washing with dichloromethane (100 mL). The filtrate was 
concentrated. The residue was purified by preparatory HPLC (Agilent Prep-C18 column, 
10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient elution with 40o100% 
acetonitrile in water, flow rate: 15 mL/min) to provide after concentration pure 3''-O-
acetyl-2-O-(tert-butyldimethylsilyl)-trioxacarcin A (68) as a yellow-green foam (58.3 
mg, 74%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.59 (s, 1H), 7.46 (s, 1H), 5.81 (t, J = 2.7 Hz, 1H), 
5.37–5.35 (m, 2H), 5.31 (d, J = 4.4 Hz, 1H), 5.19 (d, J = 
4.0 Hz, 1H), 5.01 (q, J = 6.2 Hz, 1H), 4.78 (dd, J = 12.5, 
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5.1 Hz, 1H), 4.76–4.74 (m, 3H), 4.52 (q, 6.6 Hz, 1H), 
3.89 (br, 1H), 3.82 (s, 3H), 3.63 (s, 3H), 3.47 (s, 3H), 
2.84 (d, J = 5.9 Hz, 1H), 2.76 (d, J = 5.9 Hz, 1H), 2.59 (s, 
3H), 2.58–2.54 (m, 1H), 2.36 (s, 3H), 2.35–2.32 (m, 3H), 
2.23 (s, 3H), 2.14 (s, 3H), 1.95 (dd, J = 14.7, 4.0 Hz, 
1H), 1.63 (d, J = 14.7 Hz, 1H), 1.23 (d, J = 6.6 Hz, 3H), 
1.09–1.07 (m, 3H), 1.08 (s, 3H), 0.96 (s, 9H), 0.25 (s, 
3H), 0.16 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.6, 202.6, 170.3, 170.2, 163.1, 151.8, 144.1, 142.2, 
134.8, 126.4, 116.4, 114.9, 114.6, 108.1, 104.4, 101.5, 
99.3, 98.0, 92.3, 78.0, 74.3, 71.9, 70.5, 69.2, 68.9, 68.7, 
68.1, 68.0, 64.4, 62.6, 62.5, 56.4, 55.8, 47.3, 38.7, 36.5, 
29.6, 28.8, 26.8, 25.7, 21.2, 20.8, 20.2, 18.3, 16.8, 14.4, –
4.4, –5.6. 
 
FTIR, cm–1: 
(neat) 
3482 (br), 2934 (w), 1740 (m), 1620 (m), 1389 (m), 1227 
(s), 1117 (s), 1082 (s), 995 (s), 943 (s). 
 
HRMS:  
(ESI) 
Calcd for (C50H68O21Si+H) 
Found 
 
1033.4095 
1033.4008 
TLC: Rf = 0.39 (UV, CAM) 
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(60% ethyl acetatehexanes) 
 
 
[D]23D: –33.5° (c 0.71, CH2Cl2) 
 
 
  
144 
 
 
Trioxacarcin A (1). 
Potassium carbonate (13 mg, 95 μmol,  2.0  equiv)  was  added  to  a  solution of 3''-O-
acetyl-2-O-(tert-butyldimethylsilyl)-trioxacarcin A (68) (49   mg,   47   μmol,   1   equiv)   in  
methanol (9.5 mL) at 0 °C. After 60 min, ammonium chloride (10 mg, 0.19 mmol, 4.0 
equiv) was added. After 1 min, the mixture was filtered through a short pad of Celite, 
washing with methanol (50 mL). The filtrate was concentrated. Analysis of the residue by 
1H NMR spectroscopy (500 MHz, CDCl3) established that the 3''-O-acetyl protecting 
group (G 2.22, (s, 3H)) had been cleaved and that the 4'-O-acetyl group was retained (G 
2.13 (s, 3H)). The residue (1 equiv, see above) was dissolved in acetonitrile (1.6 mL), and 
triethylamine–trihydrofluoride   (232   μL,   1.4  mmol,   30   equiv)  was   added   at   23   °C.  The  
reaction flask was covered with aluminum foil to exclude light. After 14 h, saturated 
aqueous sodium bicarbonate solution (10 mL) was added. The mixture was extracted 
with dichloromethane (2 × 50 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and filtrate was 
concentrated. The residue was purified by preparatory HPLC (Agilent Prep-C18 column, 
10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution   with   20o80% 
acetonitrile in water, flow rate: 15 mL/min) to provide after concentration pure 
trioxacarcin A (1) as an orange-red powder (23 mg, 55% yield over two steps).  
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1H NMR:  
(500 MHz, CDCl3) 
14.05 (s, 1H), 7.51 (s, 1H), 5.85 (d, J = 2.6 Hz, 1H), 5.39 
(m, 1H), 5.37 (d, J = 4.0 Hz, 1H), 5.24 (d, J = 4.0 Hz, 
1H), 5.02 (q, J = 6.6 Hz, 1H), 4.78 (m, 1H), 4.77 (s, 1H), 
4.75 (app s), 4.54 (q, J = 6.6 Hz, 1H), 4.24 (d, J = 9.2 Hz, 
1H), 4.16 (br, 1H), 3.84 (s, 3H), 3.72 (br d, J = 8.8 Hz, 
1H), 3.63 (s, 3H), 3.56 (s, 1H), 3.49 (s, 3H), 2.99 (d, J = 
5.9 Hz, 1H), 2.91 (d, J = 5.5 Hz, 1H), 2.81 (m, 1H), 2.62 
(s, 3H), 2.50 (s, 3H), 2.45 (dt, J = 14.3, 3.3 Hz, 1H), 2.21 
(dt, J = 13.2, 2.2 Hz, 1H), 2.14 (s, 3H), 2.11 (m, 1H), 
1.97 (dd, J = 14.7, 4.0 Hz, 1H), 1.62 (d, J = 14.7 Hz, 
1H), 1.24 (d, J = 6.6 Hz, 3H), 1.10 (d, J = 6.2 Hz, 3H), 
1.07 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
14.5, 16.8, 20.3, 20.9, 25.7, 27.8, 31.5, 36.6, 48.1, 56.2, 
56.8, 62.7, 62.9, 63.8, 67.4, 67.9, 68.3, 68.8, 69.1, 70.2, 
71.4, 74.4, 79.5, 94.8, 97.9, 99.7, 101.5, 104.6, 107.4, 
114.8, 116.9, 126.6, 135.4, 142.8, 144.8, 151.7, 163.1, 
170.3, 202.9, 210.3. 
 
FTIR, cm–1: 
(neat) 
3514 (br), 2976 (w), 2940 (w), 1748 (m), 1620 (m), 1387 
(m), 1225 (s), 1086 (s), 997 (s). 
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HRMS:  
(ESI) 
Calcd for (C42H52O20–H)– 
Found 
 
875.2979 
875.2961 
TLC: 
(80% ethyl acetatehexanes) 
 
Rf = 0.25 (UV, CAM) 
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Competition Experiment: Diols 63 and 46. 
Potassium carbonate (5.7 mg, 0.040 mol, 1.0 equiv) was added to a solution of 
methyl D-3-O-acetyltrioxacarcinoside B (64)65 (9.0 mg, 0.040 mmol, 1 equiv) and methyl 
D-trioxacarcinoside A (47) (10.2 mg, 0.040 mmol, 1 equiv) in methanol-d4 (3 mL) at 0 
°C. After 2 h, analysis of the solution by 1H NMR spectroscopy (500 MHz, CD3OD) 
established that the 3-O-acetyl protecting group of 64 had been cleaved to afford methyl 
D-trioxacarcinoside B (diol 63-d2) and that the 4-O-acetyl group of 47 was retained. After 
16 h, 1H NMR analysis showed that the 4-O-acetyl group of 47 had been cleaved to give 
diol 46-d2 as the major product; additionally, complete proton-deuterium exchange of the 
methyl ketone of 63-d2 had occurred to give 63-d5. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Preparation of Fully Synthetic Trioxacarcin Analogs 
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Introduction 
In the previous chapter, I presented a synthetic route to trioxacarcin A (1) that 
proceeded by the efficient assembly of five components of similar synthetic complexity: 
the epoxy diazo diketone 18, the cyanophthalide 19, the cyclohexenone 20, the 
trioxacarcinose A donor 55, and the trioxacarcinose B donor 65. We had envisioned that 
this component-based assembly process would allow the relatively rapid introduction of 
deep-seated structural modifications by modification of the components. In this chapter I 
discuss the results of efforts related to the synthesis of novel trioxacarcin analogs, using 
component modification as our primary strategy. The compounds detailed herein 
represent a substantial expansion of the pool of known trioxacarcins and the realization of 
a key aspect of our synthetic approach to the trioxacarcin class. 
In the first section I briefly describe the synthesis of a novel trioxacarcin 
monoglycoside analog 71, formally 4-deglyco-trioxacarcin A (1). Three subsequent 
sections present efforts in analog synthesis through modification, in turn, of enone 
component 20, cyanophthalide 19, and glycosidic components 55 and 65. The final 
section discusses early efforts in trioxacarcin analog synthesis not by component 
modification but by end-stage transformations of fully functionalized trioxacarcins. 
 
Synthesis of a Novel Trioxacarcin Monoglycoside 
While a wide variety of glycosylated trioxacarcins are known (see Figure 1.1 and 
Figure 1.2), the monoglycoside 71, which contains only a trioxacarcinose B residue, has 
not been identified as a natural product. From our glycosylation studies, the 
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monoglycoside intermediate 66 was available in one step from differentially protected 
aglycon 23 (see Scheme 3.6). This intermediate 66 represents a protected form of the 
monoglycoside 71 and was converted to this analog by a sequence of three deprotection 
steps. First, cleavage of the acetate ester within the trioxacarcinose B residue by 
treatment with potassium carbonate in methanol at 0 °C proceeded efficiently to afford 
alcohol 72 in 90% yield (Scheme 4.1). Removal of the PMB ether protective group 
(DDQ, 91% yield) afforded benzylic alcohol 73, and subsequent cleavage of the TBS 
ether group within this product (Et3N·3HF, 66% yield) provided the novel 
trioxacarcinose B monoglycoside 71 as a yellow-green foam after careful purification by 
RP-HPLC.  
 
 
Scheme 4.1. Synthesis of Trioxacarcinose B Monoglycoside 71. 
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Interestingly, when we performed the deprotection steps in a different order, the 
yield of the deacetylation reaction suffered. Removal of the PMB ether group within 
intermediate 66, an operation used in the synthesis of trioxacarcin A (1) (see Scheme 3.7, 
DDQ, 95% yield) provided benzylic alcohol 67, and deacetylation of this product 
(K2CO3, CH3OH, –5 °C) proceeded in only 35% yield (Scheme 4.2). This observation 
suggested that the sensitivity of trioxacarcins to basic conditions may depend strongly on 
the nature of the substitution of the cyclohexenone ring. 
 
 
Scheme 4.2. Deacetylation of Benzylic Alcohol 67. 
 
Synthesis of Deoxygenated Trioxacarcins 
Having established a modular sequence for the assembly of trioxacarcin A (1) 
from five components of similar synthetic complexity (see Chapter 3), we next sought to 
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demonstrate the versatility of the sequence for the synthesis of analogs by component 
variation. As an important first step toward this end, graduate students Jakub Švenda and 
Nicholas Hill reported the preparation of dideoxy-DC-45-A2 (74), so named because it 
lacks the hydroxyl groups present at positions C2 and C4 within DC-45-A2 (11). This 
novel trioxacarcin was prepared without variation of the synthetic route, save for the use 
of 2-cyclohexen-1-one as starting material in place of enone component 20. The use of 2-
cyclohexen-1-one, a commercially available and achiral material, simplified the synthetic 
sequence greatly relative to the use of the chiral enone component 20, which required 10 
steps for its preparation from L-malic acid.18 
Having developed methodology for the selective coupling of trioxacarcinose A 
(2) and trioxacarcinose B (3) donors to trioxacarcin aglycon substrates, we sought to 
develop further the idea of analog synthesis by component variation through the 
preparation of glycosylated, deoxygenated trioxacarcins. First, we prepared glycosylated 
analog 76 by a simple two-step sequence of glycosylation followed by deprotection 
(Scheme 4.3). Using the glycosylation protocol developed by postdoctoral researcher 
Thomas Magauer, with N-trimethylsilyl-bis(trifluoromethanesulfonyl)imide as the Lewis-
acidic promoter, 1,3-di-O-acetyl trioxacarcinose B (65) was coupled to dideoxy-DC-45-
A2 (74) to provide the  α-glycoside 75 in 68% yield; the β-glycoside was not observed. 
Methanolysis of the acetate ester protective group within this product, using potassium 
carbonate as base, provided novel deoxygenated trioxacarcin analog 76, which in 
comparison to monoglycoside analog 71 above lacks hydroxyl groups at positions C2 and 
C4. It is noteworthy that methanolysis of glycoside 75 with potassium carbonate 
proceeded in a far higher yield than the corresponding methanolysis of bisglycoside 68 
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(see Scheme 3.10). This observation served as an indication that dideoxy trioxacarcins 
such as 76 may be more stable to basic conditions than the analogous structures 
containing hydroxyl groups or glycosides at positions C2 and C4. 
 
 
Scheme 4.3. Synthesis of Glycosylated 2,4-Dideoxy Trioxacarcin Analog 76. 
Having prepared a glycosylated 2,4-dideoxy trioxacarcin analog (76), we sought 
to prepare so-called 2-deoxy trioxacarcins, differing from natural trioxacarcins only by 
the absence of the C2 hydroxyl group. These studies provided an opportunity to study the 
effect of the absence of the C2 hydroxyl group on the antiproliferative activity of the 
resulting analogs. Furthermore, since the C4 hydroxyl group present within naturally 
occurring trioxacarcins would be retained within this series, we retained the opportunity 
to couple glycosyl residues such as trioxacarcinose A (2) to the 4-hydroxyl position. 
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For the preparation of 2-deoxy trioxacarcins we initially made use of protected 
aglycon 78, which lacks the tert-butyldimethylsilyloxy group present in differentially 
protected synthetic precursor 23 but is otherwise identical. The preparation of aglycon 78 
in turn required multigram quantities of the modified enone component (S)-4-((4-
methoxybenzyl)oxy)cyclohex-2-en-1-one (77) (Figure 4.1). Danishefsky and coworkers 
have reported a route to this compound proceeding in 7 steps from D-quinic acid; in their 
report, the authors describe the preparation of 3.80 g of enone 77.68 Graduate student 
Nicholas Hill executed this 7-step route on a multigram scale using 20 g of D-quinic acid 
as starting material and obtained 1.9 g of enone 77 in 8% overall yield, providing 
material to supply initial synthetic studies of 2-deoxy trioxacarcins. 
 
 
Figure 4.1. Preparation of Synthetic Precursor 78 for the Synthesis of 2-Deoxy 
Trioxacarcins Required Enone 77 as Starting Material. 
We considered other routes to enone 77 that would be suitable for delivering 
multigram quantities of this material and took note of a report by Matsuzawa and 
coworkers of the enantioselective preparation of (R)-4-hydroxy-2-cyclohexen-1-one (R)-
80 in the context of a synthetic route to (+)-panepophenanthrin.69 The synthesis of (R)-80 
                                                 
68 Audia, J. E.; Boisvert, L.; Patten, A. D.; Villalobos, A.; Danishefsky, S. J. J. Org. Chem. 1989, 54, 3738–
3740. 
69 Matsuzawa, M.; Kakeya, H.; Yamaguchi, J.; Shoji, M.; Onose, R.; Osada, H.; Hayashi, Y. Chem.–Asian 
J. 2006, 1, 845–851. 
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proceeded in four steps from cyclohexanedione monoethylene ketal (79) and used a 
catalytic, asymmetric, D-proline-mediated aminoxylation reaction as the key step(Scheme 
4.4). The authors reported the preparation of 64.6 mg of (R)-4-hydroxy-2-cyclohexen-1-
one (80) in 57% overall yield using this four-step sequence. 
 
 
Scheme 4.4. Synthesis of (R)-4-Hydroxy-2-Cyclohexen-1-One (R)-80 as Reported by 
Matsuzawa et al.69 
I carried out the route reported by Matsuzawa and coworkers on a multigram 
scale with 26.35 g of cyclohexanedione monoethylene ketal (79) as starting material, 
using L-proline as catalyst in the enantioselective aminoxylation reaction in order to 
prepare 4-hydroxy-2-cyclohexen-1-one of the opposite enantiomeric series (Scheme 4.5). 
After protection of the hydroxyl function of (S)-4-hydroxy-2-cyclohexen-1-one ((S)-80) 
156 
 
prepared in this manner70 as the p-methoxybenzyl ether, I obtained 6.08 g of enone 
building block 77 in 16% overall yield over the 5-step sequence. 
 
 
Scheme 4.5. Synthesis of Enone Component 77 Using the Route Reported by Matsuzawa 
et al.69 
The above route to enone building block 77 provided sufficient material for the 
preparation of various 2-deoxy trioxacarcin analogs. As an entry point to this analog 
series, aglycon 78 (Scheme 4.6) was assembled from the epoxy diazo diketone 18, 
cyanophthalide 19, and enone 77 by an analogous sequence to that used for the synthesis 
of synthetic precursor 23 (see Scheme 1.3). Glycosylation with trioxacarcinose B donor 
65 using our established protocol, with N-trimethylsilyl-
bis(trifluoromethanesulfonyl)imide as the Lewis-acidic   promoter,   provided   the   α-
glycoside 81 in 59% yield (Scheme 4.6). However, attempted cleavage of the p-
methoxybenzyl ether within either aglycon 78 or monoglycoside 81 with DDQ in a 
mixture of dichloromethane and pH 7 aqueous phosphate buffer furnished 1,4-diketone 
products 82 and 83, respectively, rather than the desired benzylic alcohols. This stands in 
contrast to the deprotection reaction of monoglycoside 66—which differs from 81 only in 
the presence of a 2-tert-butyldimethylsilyloxy substituent—in which the diketone product 
                                                 
70 (S)-80 prepared in this manner was found to be of >95% ee by analysis of the 1H and 19F NMR spectra of 
the corresponding Mosher ester. 
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was not observed and the benzylic alcohol 67 was isolated in 95% yield (see Scheme 
3.7).  
 
 
Scheme 4.6. Synthesis of Glycoside 81 from Synthetic Precursor 78, and Formation of 
1,4-Diketone Products 82 and 83. 
Evidence suggests that the corresponding benzylic alcohol is an intermediate in 
the oxidation process which forms the diketone functionality; indeed, a separate 
experiment run in dichloromethane–water at 0 °C under more dilute conditions (0.007 M 
in substrate) provided benzylic alcohol 84 from substrate 81 in 48% yield and, separately, 
unreacted p-methoxybenzyl ether starting material 81 in 18% yield (Scheme 4.7). 
Likewise, in an experiment conducted by postdoctoral researcher Thomas Magauer, 
methanolysis of 81 with potassium carbonate as base followed by treatment of the 
product with DDQ in dichloromethane–water at 23 °C (0.025 M in substrate) provided a 
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separable mixture of benzylic alcohol 85 (28% yield) and diketone 86 (22% yield). We 
were unable to suppress completely the formation of these diketones while also achieving 
high conversion of the p-methoxybenzyl ether substrates. While DDQ-promoted 
deprotection of aglycon 78 and the corresponding monoglycoside derivatives failed to 
provide an efficient approach to 2-deoxy trioxacarcin analogs bearing a C4 benzylic 
alcohol, the C4-oxo compounds 82, 83, and 86 represent a novel structural motif within 
the trioxacarcin class.  
 
 
Scheme 4.7. Formation of Benzylic Alcohols 84 and 85 from PMB-Protected Glycoside 
81. 
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Having observed a benzylic oxidation side reaction during attempted cleavage of 
p-methoxybenzyl ether substrates such as 78 and 81, we considered alternative 
deprotection conditions or protective groups which would allow the benzylic alcohol at 
position C4 to be revealed late in our routes to 2-deoxy trioxacarcins. Given that these 
substrates appeared to be particularly vulnerable to oxidative reaction conditions such as 
treatment with DDQ, a benzyl ether seemed a promising candidate for protection of the 
4-hydroxyl function, as we expected deprotection under orthogonal conditions of 
reductive hydrogenolysis to be facile. 
Benzylation of (S)-4-hydroxy-2-cyclohexen-1-one ((S)-80) (silver(I) oxide, 
benzyl bromide, dichloromethane, 23 °C, 52% yield) provided the new enone component 
87. We prepared benzyl-protected aglycon 88 from epoxy diazo diketone 18, 
cyanophthalide 19, and enone 87 by an analogous sequence to that employed for the 
synthesis of synthetic precursor 23 (see Scheme 1.3). Deprotection of aglycon 88 was 
facile and high-yielding. Stirring a suspension of aglycon 88 and palladium hydroxide on 
carbon in tetrahydrofuran under a hydrogen atmosphere provided 2-deoxy-DC-45-A2 
(89) in 90% yield (Scheme 4.8). 
 
 
Scheme 4.8. Synthesis of 2-Deoxy-DC-45-A2 (89) by Hydrogenolysis of Benzyl Ether 
88. 
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We next sought to prepare the 2-deoxy analogs of many of the fully synthetic 
trioxacarcins we had prepared thus far. Glycosylation of 2-deoxy-DC-45-A2 (89) with 1-
O-acetyl trioxacarcinose A (48) using boron trifluoride etherate as Lewis-acidic promoter 
afforded 2-deoxy-DC-45-A1 (90) in a single step (47%, Scheme 4.9). Interestingly, use 
of the glycosylation protocol that was successfully employed to prepare bisglycoside 68 
during our synthesis of trioxacarcin A, for which excess pyridine was added after the 
reaction is complete (see Scheme 3.9), resulted in formation of alkylated pyridinium 
adduct 91 (Scheme 4.9). This adduct was identified based on analysis of its 1H NMR 
spectrum and by observation of the molecular ion by ESI-MS. While it is curious that this 
alkylated pyridinium compound was not observed during the analogous glycosylative 
transformation en route to trioxacarcin A (see Scheme 3.9), its formation in the present 
application is nevertheless in keeping with the documented ability of the trioxacarcins to 
alkylate aromatic N-heterocycles such as guanosine residues within duplex DNA (see 
Scheme 1.2). 
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Scheme 4.9. Synthesis of 2-Deoxy-DC-45-A1 (90), and Observation of Pyridinium 
Adduct 91. 
 
The glycosylation methodology developed for the coupling of trioxacarcinose B 
was   used   to   prepare   α-glycoside 92 (50% yield, Scheme 4.10). An efficient two-step 
deprotection sequence proceeded by hydrogenolysis of the benzyl ether to afford benzylic 
alcohol 84 (89% yield), followed by methanolysis of the acetate ester within that product 
(90% yield) to provide triol 85, a deoxygenated analog of previously synthesized 
monoglycoside 71 (see Scheme 4.1).  
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Scheme 4.10. Synthesis of 2-Deoxy Analogs Containing Trioxacarcinose B 
Glycoside product 92 was also deacetylated directly to afford diol benzyl ether 
analog 93 (Scheme 4.11) 
 
 
Scheme 4.11. Synthesis of Diol Benzyl Ether 93. 
We were particularly interested in the preparation of 2-deoxytrioxacarcin A (95) 
and identified benzylic alcohol 84 as a suitable intermediate for this purpose. To couple a 
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trioxacarcinose A residue to benzylic alcohol 84, silver hexafluorophosphate (6.0 equiv) 
was added to a suspension of benzylic alcohol 84, 1-phenylthiotrioxacarcinoside A (55) 
(3.0 equiv), 2,6-di-tert-butyl-4-methylpyridine (8.0 equiv), and powdered 4-Å molecular 
sieves in dichloromethane at 0 °C (Scheme 4.12). After 1 h, a solution of triethylamine 
(50 equiv) in dichloromethane was added, the diluted solution was filtered, and the 
filtrate was concentrated. Purification of the crude residue by RP-HPLC provided acetyl 
2-deoxytrioxacarcin A (94) in 55% yield. Deacetylation was accomplished by treatment 
with potassium carbonate in methanol at 0 °C to afford 2-deoxytrioxacarcin A (95) (37% 
yield).  
 
 
Scheme 4.12. Synthesis of 2-Deoxytrioxacarcin A (95) 
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Modification of the Cyanophthalide Component 
Having created a series of novel trioxacarcin analogs by modification of the enone 
component 20, we turned our attention to the modification of other components used in 
our route to trioxacarcins. I considered analogs which could be prepared by modification 
of cyanophthalide component 19 and focused on alteration of the methyl substituent 
present within cyanophthalide 19 (which becomes the C6 methyl group of fully synthetic 
trioxacarcins). One straightforward modification was introduced in the form of benzyloxy 
cyanophthalide 100, which was prepared from methyl 2,4-dihydroxybenzoate (96) in an 
8-step sequence (Scheme 4.13). Thus, regioselective benzylation of methyl 2,4-
dihydroxybenzoate (96) was accomplished by treatment with benzyl bromide and 
potassium carbonate in refluxing acetone to provide benzyl ether 97 in 69% yield.71 
Benzyl ether 97 was transformed to amide 98 by a five-step sequence identical to that 
used to prepare the analogous amide 29 from 4-methylsalicylic acid in the original 
synthesis of cyanophthalide component 19 (see Scheme 1.5). In the present application 
this sequence afforded pure amide 98 in 70% yield over 5 steps, with only a single 
chromatographic purification at the conclusion of the sequence. Treatment of a solution 
of amide 98 and tetramethylethylenediamine (TMEDA) in tetrahydrofuran at –90 °C with 
tert-butyllithium accomplished directed ortho-lithiation, and trapping of the resulting 
aryllithium species with N,N-dimethylformamide provided aldehyde 99 in quantitative 
yield. Much lower conversion to the aldehyde was observed when the reaction was 
conducted at –78 °C, and this stands in contrast to the corresponding transformation of 
methyl-substituted substrate 29 (Scheme 1.5), which proceeds efficiently at –78 °C. 
                                                 
71 Tangdenpaisal, K.; Sualek, S.; Ruchirawat, S.; Ploypradith, P. Tetrahedron 2009, 65, 4316–4325. 
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Aldehyde 99 was treated with cyanotrimethylsilane to produce an intermediate 
cyanohydrin (not isolated), which upon stirring in glacial acetic acid at 23 °C for 41 h 
afforded the cyanophthalide 100 (62% yield). 
 
 
Scheme 4.13. Synthesis of Benzyloxy Cyanophthalide 100. 
Benzyloxy cyanophthalide 100, epoxy diazo diketone 18, and 2-cyclohexen-1-one 
were used to assemble benzyl ether 101 (Scheme 4.14) by an analogous sequence to that 
used for the synthesis of synthetic precursor 23 (see Scheme 1.3). The benzyl ether group 
was cleaved efficiently by hydrogenolysis to provide unstable phenol analog 102, which 
underwent decomposition during attempts at purification by RP-HPLC and upon standing 
in chloroform, forming a mixture of products (Scheme 4.14). 
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Scheme 4.14. Synthesis of Benzyl Ether Analog 101 and Phenol Analog 102. 
It is interesting to note that the carbonyl ylide–aldehyde cycloaddition used to 
prepare benzyl ether analog 101 differed in the distribution of diastereomeric cycloadduct 
products relative to the cycloaddition used to prepare differentially protected DC-45-A2 
(see Scheme 1.4), favoring the desired endo cycloadduct 2 (105) to a greater extent 
(Scheme 4.15). The distribution of diastereomers was determined by analysis of the 1H 
NMR spectrum of the crude product, assigning the structures of the diastereomers by 
analogy to those produced in the cycloaddition of aldehyde and epoxy diazo diketone 
(see Scheme 1.4).18 
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Scheme 4.15. Carbonyl Ylide–Aldehyde Cycloaddition between Aldehyde 103 and 
Diazo Diketone 18. 
I also prepared a second modified cyanophthalide component, cyclopropyl 
cyanophthalide 111, by incorporation of a bromide substituent at the outset followed by 
Suzuki coupling at a later stage (Scheme 4.16). Thus, 4-bromo-2-hydroxybenzoic acid 
(108) was converted to the allyl arene 109 by a four-step sequence identical to that used 
to prepare the analogous intermediate in the synthesis of cyanophthalide component 19 
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(see Scheme 1.5). This sequence provided 109 in 69% yield over four steps, with a single 
chromatographic purification step at the conclusion of the sequence. At this stage 
isomerization of the alkene within intermediate 109 to the internal position was required, 
but treatment with potassium tert-butoxide at elevated temperature—conditions used for 
the analogous step in the preparation of cyanophthalides 19 and 100—was not suitable 
due to the presence of the aryl bromide. Alkene isomerization was accomplished by 
treatment with bis(dibenzylideneacetone)palladium(0), tri-tert-butylphosphine, and 
isobutyryl chloride, conditions originally reported by Gauthier and coworkers.72 After 
protection of the phenol as the corresponding methoxymethyl ether, alkene 110 was 
obtained in 92% yield over two steps as a ~3.7:1 mixture of E and Z isomers, respectively 
(the alkene stereochemistry is inconsequential). The bromide group within intermediate 
110 could in principle be converted to a wide variety of novel cyanophthalides. I 
conducted a Suzuki coupling with cyclopropylboronic acid pinacol ester using 
tetrakis(triphenylphosphine)palladium(0) as catalyst and potassium phosphate as base in 
tetrahydrofuran–water at 120 °C. The cyclopropyl arene product of this reaction was 
subjected to the final two steps originally used to prepare cyanophthalide 19 (without 
modification) to provide cyclopropyl cyanophthalide 111 in 62% yield over 3 steps. The 
cyanophthalide product prepared in this manner was a 2.8:1 mixture of E and Z olefin 
isomers, respectively. 
 
                                                 
72 Gauthier, D.; Lindhardt, A. T.; Olsen, E. P.; Overgaard, J.; Skrydstrup, T. J. Am. Chem. Soc. 2010, 132, 
7998–8009. 
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Scheme 4.16. Synthesis of Cyclopropyl Cyanophthalide 111. 
Cyclopropyl cyanophthalide 111, epoxy diazo diketone 18, and 2-cyclohexen-1-
one were used to assemble cyclopropyl analog 112 (Scheme 4.17) by an analogous 
sequence to that used for the synthesis of synthetic precursor 23 (see Scheme 1.3). 
 
Scheme 4.17. Synthesis of Cyclopropyl Analog 112. 
The carbonyl ylide–aldehyde cycloaddition used to prepare cyclopropyl analog 
112 produced the desired endo diastereomer 2 (115, 45% of the crude mixture, Scheme 
4.18) to only a slightly greater extent than the corresponding cycloaddition used to 
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prepare differentially protected DC-45-A2 (40% of the crude mixture, see Scheme 1.4). 
The distribution of diastereomers was determined by analysis of the 1H NMR spectrum of 
the crude product, assigning the structures of the diastereomers by analogy to those 
produced in the cycloaddition of aldehyde and epoxy diazo diketone (see Scheme 1.4).18 
 
 
Scheme 4.18. Carbonyl Ylide–Aldehyde Cycloaddition between Cyclopropyl Aldehyde 
113 and Diazo Diketone 18. 
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Modification of the Glycosyl Components 
We also explored modification of the two glycosidic components used to prepare 
trioxacarcin A, glycosyl donors derived from trioxacarcinose A (2) and trioxacarcinose B 
(3). We successfully incorporated an azido glycoside subunit derived from the 
deoxysugar daunosamine to prepare a collection of azido glycoside trioxacarcins. In one 
case, glycosylation of differentially protected synthetic precursor 23 was conducted using 
1-O-acetyl glycoside 118 as glycosyl donor73 and N-trimethylsilyl-
bis(trifluoromethanesulfonyl)imide as the Lewis-acidic   promoter.   The   α-glycoside 
product 119 was obtained in 64% yield after purification by RP-HPLC (Scheme 4.19). 
Using the usual two-step deprotection sequence, the PMB ether was cleaved by treatment 
with DDQ, and the tert-butyldimethylsilyl ether within this product was removed by 
subsequent treatment with triethylamine trihydrofluoride to provide the diol glycoside 
120 (47% yield, 2 steps). Glycosylation of dideoxy-DC-45-A2 (74) in a similar manner 
provided glycoside 121, a 2,4-dideoxy analog of 120. 
 
                                                 
73 Zhang, G.; Fang, L.; Zhu, L.; Aimiuwu, J. E.; Shen, J.; Cheng, H.; Muller, M. T.; Lee, G. E.; Sun, D.; 
Wang, P. G. J. Med. Chem. 2005, 48, 5269–5278. 
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Scheme 4.19. Syntheses of Analogs 120 and 121 Containing an Azido Sugar in Place of 
Trioxacarcinose B. 
We were also successful in coupling the same azido sugar unit to the benzylic 
alcohol at position C4 of the trioxacarcin scaffold, the position occupied by 
trioxacarcinose A in the natural products trioxacarcin A (1) and DC-45-A1 (10). 
Thioglycoside donor 12473 was an appropriate glycosyl donor for this purpose. The 
glycosylation substrate was prepared from trimethylsilyl hemiketal 12262 by cleavage of 
the PMB ether with DDQ, to afford benzylic alcohol 123 (Scheme 4.20). Coupling of 
alcohol 123 and thioglycoside 124 was accomplished by treatment with silver 
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hexafluorophosphate and 2,6-di-tert-butyl-4-methylpyridine, conditions which were also 
employed for the coupling of monoglycoside 67 and 1-phenylthiotrioxacarcinoside A 
(55) in our synthesis of trioxacarcin A (see Scheme 3.9). In the present application we 
obtained   α-glycoside 125 in 30% yield after purification by RP-HPLC. Treatment of 
glycoside 125 with triethylamine trihydrofluoride effected the desilylation of the 
hemiketal function as well as cleavage of the tert-butyldimethylsilyl ether to afford 
alcohol 126 (30% yield), an analog of DC-45-A1 (10) in which the trioxacarcinose A 
residue has been replaced with an azido sugar. 
 
 
Scheme 4.20. Synthesis of Analog 126 Containing an Azido Sugar in Place of 
Trioxacarcinose A. 
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Transformations of Fully Functionalized Trioxacarcins 
In the previous sections I described the variation of four of the five key building 
blocks used to prepare trioxacarcin A (the cyanophthalide 19, the cyclohexenone 20, the 
trioxacarcinose B donor 65 and the trioxacarcinose A donor 55) in order to prepare novel 
trioxacarcins with deep-seated structural modifications. We also considered whether 
additional structural variability could be introduced rapidly by late-stage structural 
modification of fully functionalized trioxacarcins. In this section I describe our 
identification of various novel forms of reactivity of fully functionalized trioxacarcins 
which further expands the pool of structures available for study.  
We found that the hemiketal function of dideoxy-DC-45-A2 (74) undergoes 
smooth O-alkylation reactions with activated carbon nucleophiles. For example, 
treatment of a solution of dideoxy-DC-45-A2 and N,N-diisopropylethylamine with 
chloromethyl methyl ether (MOMCl) in dichloromethane at 23 °C afforded 
methoxymethylated ketal 127 in quantitative yield after purification by chromatography 
on silica gel. The alkylation of dideoxy-DC-45-A2 (74) with benzyl chloromethyl ether 
was equally efficient (128, 99% yield). Postdoctoral researcher Andreas Schumacher 
prepared methylated analog 129 by stirring a suspension of dideoxy-DC-45-A2, 
iodomethane, silver(I) oxide, and calcium sulfate at 23 °C, and use of allyl bromide as the 
electrophile under similar conditions afforded allylated analog 130, both in moderate 
yield. In none of the above alkylation reactions did we observe functionalization of the 
phenol. 
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Scheme 4.21. O-Alkylation Reactions of Dideoxy-DC-45-A2 (74) 
Furthermore, I found that the hemiketal function of dideoxy-DC-45-A2 (74) 
undergoes clean O-alkylation reactions with primary alkyl triflates (Scheme 4.22). For 
example, dideoxy-DC-45-A2 (74) was smoothly O-alkylated with 5-hexenyl triflate using 
1,8-bis(dimethylamino)naphthalene (Proton–Sponge) as base to afford the terminal 
alkene-containing product 131 in 95% yield. 
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Scheme 4.22. O-Alkylation of Dideoxy-DC-45-A2 (74) with a Primary Alkyl Triflate. 
Conclusion 
In this chapter I presented the results of efforts related to the synthesis of novel 
trioxacarcin analogs. Taken together, these represent a thorough examination of the 
chemistry of the trioxacarcins and an exploration of the capabilities of our component-
based synthetic route. Using component modification as the primary (albeit not 
exclusive) strategy, these studies have resulted in a substantial expansion of the pool of 
known trioxacarcins, preparing many analogs that would be inaccessible by other means 
and demonstrating the advantages of a convergent, component-based synthetic strategy 
for the assembly of a target of interest. 
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Experimental Section 
General Experimental Procedures 
All reactions were performed in round-bottom flasks fitted with rubber septa 
under a positive pressure of argon, unless otherwise noted. Air- and moisture-sensitive 
liquids were transferred by syringe or stainless steel cannula. Organic solutions were 
concentrated   by   rotary   evaporation   (house   vacuum,   ca.   25−40   Torr)   at   ambient  
temperature, unless otherwise noted. Analytical thin-layer chromatography (TLC) was 
performed using glass plates pre-coated with silica gel (0.25 mm, 60 Å pore-size, 
230−400  mesh,  Merck  KGA)   impregnated  with   a   fluorescent   indicator   (254  nm).  TLC 
plates were visualized by exposure to ultraviolet light, then were stained with either an 
aqueous sulfuric acid solution of ceric ammonium molybdate (CAM), an acidic solution 
of p-anisaldehyde in ethanol (Anis), or an aqueous sodium hydroxide–potassium 
carbonate solution of potassium permanganate (KMnO4) followed by brief heating on a 
hot plate. Flash-column chromatography was performed as described by Still et al.,52 
employing silica gel (60 Å, 32-63  μm, standard grade, Dynamic Adsorbents, Inc.). 
 
Materials 
Commercial solvents and reagents were used as received with the following 
exceptions. Tetrahydrofuran, dichloromethane, benzene, toluene, and ether were purified 
by the method of Pangborn et al.53 4-Å molecular sieves (powder, Aldrich) were stored in 
a laboratory oven at 140 °C and were allowed to cool in a desiccator immediately before 
use.  
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Instrumentation 
Proton magnetic resonance (1H NMR) spectra were recorded on Varian INOVA 
500 (500 MHz) or 600 (600 MHz) NMR spectrometers at 23 °C. Proton chemical shifts 
are expressed in parts per million (ppm, G scale) and are referenced to residual protium in 
the NMR solvent (CHCl3, G 7.26). Data are represented as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and/or multiple 
resonances, br = broad, app = apparent), integration, and coupling constant (J) in Hertz. 
Carbon nuclear magnetic resonance spectra (13C NMR) were recorded on Varian INOVA 
500 (125 MHz) NMR spectrometers at 23 °C. Carbon chemical shifts are expressed in 
parts per million (ppm, G scale) and are referenced to the carbon resonances of the NMR 
solvent (CDCl3, G 77.0). Infrared (IR) spectra were obtained using a Shimadzu 8400S FT-
IR spectrometer. Data are represented as follows: frequency of absorption (cm–1), 
intensity of absorption (s = strong, m = medium, w = weak, br = broad). Optical rotations 
were measured on a Jasco DIP-0181 digital polarimeter with a sodium lamp and are 
reported as follows: [D] T[°C] λ (c = g/100 mL, solvent). Circular dichroism spectra were 
obtained using a Jasco J-710 spectropolarimeter. High-resolution mass spectra were 
obtained at the Harvard University Mass Spectrometry Facility. High performance liquid 
chromatography purifications were performed using an Agilent Technologies 1200 Series 
preparative HPLC system. 
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Trioxacarcinose B Monoglycoside 71. 
Potassium carbonate (2.6 mg, 0.5 equiv) was added to a solution of D-glycoside 
66 (37 mg, 38 Pmol, 1 equiv) in methanol (7.7 mL) at 0 °C. After 3 h, the mixture was 
partitioned between chloroform (100 mL) and saturated aqueous sodium chloride solution 
(20 mL). The layers were separated. The aqueous layer was extracted with chloroform (2 
× 20 mL). The organic layers were combined and the combined solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated to 
provide the alcohol 72 (32 mg, 90%).  
2,3-dichloro-5,6-dicyanobenzoquinone (4.7 mg, 21 Pmol, 1.2 equiv) was added to 
a vigorously stirring, biphasic solution of alcohol 72 (16 mg, 17 Pmol, 1 equiv) in 
dichloromethane (2.2 mL) and water (440 μL)  at  23  °C.  The  reaction  flask  was  covered  
with aluminum foil to exclude light. Over the course of 2.5 h, the color of the reaction 
mixture changed from myrtle green to yellow. The product solution was partitioned 
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between water (10 mL) and dichloromethane (40 mL). The layers were separated. The 
aqueous layer was extracted with dichloromethane (20 mL). The organic layers were 
combined and the combined solution was dried over sodium sulfate.  The dried solution 
was filtered and the filtrate was concentrated. The residue was purified by preparatory 
HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,  
gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide 
after concentration the pure benzylic alcohol 73 (12.7 mg, 91%) as a yellow-green oil. 
Triethylamine–trihydrofluoride (18 PL, 110 Pmol, 30 equiv) was added to a 
solution of benzylic alcohol 73 (3.0 mg, 3.7 Pmol, 1 equiv) in acetonitrile (0.5 mL) at 23 
°C. The reaction flask was covered with aluminum foil to exclude light. After 21 h, the 
product solution was partitioned between dichloromethane (50 mL) and saturated 
aqueous sodium chloride solution (20 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (3 × 10 mL). The organic layers were combined and 
the combined solution was dried over sodium sulfate. The dried solution was filtered and 
the filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent 
Prep-C18  column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  nm,  gradient  elution  with  
20o50% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure trioxacarcinose B monoglycoside 71 (1.7 mg, 66%).  
 
1H NMR:  
(500 MHz, CDCl3) 
13.84 (br, 1H), 7.48 (s, 1H), 5.85 (d, 1H, J = 2.6 Hz), 
5.46 (t, 1H, J = 2.9 Hz), 5.37 (d, 1H, J = 4.0 Hz), 5.24 (d, 
1H, J = 4.0 Hz), 5.02 (q, 1H, J = 6.6 Hz), 4.93 (dd, 1H, J 
= 12.8, 5.5 Hz), 4.77 (s, 1H), 4.25 (d, 1H, J = 9.5 Hz), 
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4.16 (br, 1H), 3.92 (s, 3H), 3.71 (brd, 1H, J = 8.8 Hz), 
3.63 (s, 3H), 3.49 (s, 3H), 3.00 (br, 1H), 2.98 (d, 1H, J = 
5.9 Hz), 2.89 (d, 1H, J = 5.9 Hz), 2.74 (ddd, 1H, J = 
13.2, 5.5, 2.9 Hz), 2.62 (s, 3H), 2.49 (s, 3H), 2.44 (dt, 
1H, J = 14.7, 3.7 Hz), (dt, 1H, J = 13.2, 3.3 Hz), 2.11 
(ddd, 1H, J = 14.7, 2.6, 1.5 Hz), 1.09 (d, 3H, J = 6.6 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
210.4, 203.3, 162.4, 151.8, 144.4, 142.6, 135.7, 129.6, 
116.6, 114.6, 107.3, 104.7, 101.5, 99.7, 94.9, 79.6, 71.4, 
70.2, 69.2, 68.3, 67.7, 63.8, 62.9, 61.9, 56.9, 56.1, 48.2, 
45.7, 37.0, 31.6, 27.8, 20.4, 14.5. 
 
FTIR, cm–1: 
(neat) 
3431 (br w), 2926 (m), 1713 (m), 1622 (s), 1256 (s), 
1103 (s). 
 
HRMS:  
(ESI) 
Calcd for (C33H38O16+Na) 
Found 
 
713.2052 
713.2029 
TLC: 
(ethyl acetate) 
Rf = 0.18 (UV, CAM) 
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D-Glycoside 75.  
To a solution of dideoxy-DC-45-A2 (74)18 (20.0 mg, 0.041 mmol, 1 equiv) in 
benzene (2.0 mL) at 23 °C was added 1-O-E-acetyl glycoside 565 (56.4 mg, 0.206 mmol, 
5.0 equiv). The bright yellow solution was concentrated and the residue was blanketed 
with argon. Dichloromethane (1.5 mL) and ether (500 PL) were added followed by 
crushed 4-Å molecular sieves (500 mg). The bright yellow suspension was stirred for 30 
min at 23 °C, then was cooled to –78 °C. N-(trimethylsilyl)-
bis(trifluoromethanesulfonyl)imide (20.2 PL, 0.082 mmol, 2.0 equiv) was added 
dropwise by syringe over 10 min. After 20 min, a second portion of N-(trimethylsilyl)-
bis(trifluoromethanesulfonyl)imide (20.2 PL, 0.082 mmol, 2.0 equiv) was added over 10 
min. After 2.5 h, the cold mixture was diluted with 15% methanol–dichloromethane (25 
mL). Saturated aqueous sodium bicarbonate solution (10 mL) was added. The layers were 
separated. The aqueous layer was extracted with dichloromethane (25 mL). The organic 
layers were combined and the combined solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue was purified by 
preparatory HPLC (Agilent Prep-C18 column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  
nm, gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to 
provide after concentration the pure D-glycoside 75 (19.7 mg, 68%, in fractions eluting at 
22.5–25.5 min) as a bright yellow solid.  
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1H NMR:  
(600 MHz, CDCl3) 
14.65 (s, OH). 7.43 (s, 1 H), 5.84 (t, J = 3.6 Hz, 1H), 
5.29 (d, J = 4.2 Hz, 1H), 5.19 (d, J = 4.2 Hz, 1H), 5.01 
(q, J = 6.6 Hz, 1H), 4.75 (t, J = 3.6 Hz, 1H), 4.73 (s, 1H), 
3.88 (s, OH), 3.77 (s, 3H), 3.63 (s, 3H), 3.47 (s, 3H), 3.03 
(app q, J = 5.4 Hz, 2H), 2.84 (d, J = 6.0 Hz, 1H), 2.77 (d, 
J = 6.0 Hz, 1H), 2.72 (app t, J = 6.6 Hz, 2H), 2.58 (s, 
3H), 2.36 (s, 3H), 2.33 (app t, J = 3.0 Hz, 2H), 2.23 (s, 
3H), 2.11-2.06 (m, 2H), 1.08 (d, J = 6.0 Hz, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.7, 204.3, 170.3, 162.9, 151.8, 142.3, 141.7, 135.2, 
130.3, 115.6, 113.2, 113.1, 111.0, 104.5, 101.5, 99.5, 
92.3, 78.2, 72.1, 70.7, 69.2, 68.3, 64.4, 60.9, 56.5, 55.8, 
47.4, 38.8, 28.9, 27.0, 23.6, 22.1, 21.3, 20.3, 14.5. 
 
FTIR, cm–1: 
(neat) 
3482 (w), 2928 (m), 2854 (w), 1740 (s), 1717 (s), 1622 
(s), 1449 (m), 1389 (m), 1238 (s), 1096 (s). 
 
HRMS:  
(ESI) 
Calcd for (C35H40O15+Na) 
Found 
 
723.2259 
723.2135 
TLC: 
(50% ethyl acetatehexane) 
Rf = 0.58 (UV, CAM) 
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[D]23D: +67.1° (c 0.23, CHCl3) 
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Alcohol 75. 
Potassium carbonate (1 mg, 7.24 Pmol, 0.34 equiv) was added to a solution of the 
D-glycoside 75 (15 mg, 0.021 mmol, 1 equiv) in methanol (1 mL) at 0 °C. After 30 min, 
the cooling bath was removed and the reaction mixture was allowed to warm to 23 qC. 
After 10 h, the reaction mixture was partitioned between saturated aqueous sodium 
chloride solution (20 mL) and chloroform (100 mL). The layers were separated. The 
aqueous layer was extracted with chloroform (3 × 30 mL). The organic layers were 
combined and the combined solution was dried over sodium sulfate.  The dried solution 
was filtered and the filtrate was concentrated. The residue was purified by preparatory 
HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,  
gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide 
after concentration the pure alcohol 76 (12.0 mg, 85%, in fractions eluting at 18.0–24.1 
min) as a yellow-orange solid.  
 
1H NMR:  
(600 MHz, CDCl3) 
14.69 (s, OH). 7.46 (s, 1 H), 5.86 (d, J = 2.4 Hz, 1H), 
5.34 (d, J = 4.2 Hz, 1H), 5.24 (d, J = 3.6 Hz, 1H), 5.02 
(q, J = 6.6 Hz, 1H), 4.77 (s, 1H), 4.29 (d, J = 9.6 Hz, 
OH), 4.15 (s, OH), 3.77 (s, 3H), 3.71 (dt, J = 9.6,3 Hz, 
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1H), 3.63 (s, 3H), 3.49 (s, 3H), 3.04 (app q, J = 5.4 Hz, 
2H), 2.98 (d, J = 5.4 Hz, 1H), 2.92 (d, J = 5.4 Hz, 1H), 
2.73 (app t, J = 7.2 Hz, 2H), 2.59 (s, 3H), 2.50 (s, 3H), 
2.43 (t, J = 14.4, 3.6 Hz, 2H), 2.11-2.08 (m, 2H), 1.09 (d, 
J = 6.6 Hz, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
210.5, 204.5, 162.9, 151.6, 142.4, 141.6, 135.2, 130.5, 
115.9, 113.1, 113.0, 111.1, 104.6, 101.4, 99.7, 94.8, 79.6, 
77.2, 71.5, 70.3, 69.4, 68.4, 63.8, 60.9, 56.8, 56.1, 48.2, 
38.8, 27.8, 23.6, 22.1, 20.3, 14.5. FTIR (neat), cm–1: 
3522 (w), 2930 (s), 2857 (m), 1746 (s), 1717 (s), 1622 
(s), 1498 (s), 1456 (s), 1389 (s), 1256 (s), 1095 (s). 
 
FTIR, cm–1: 
(neat) 
3522 (w), 2930 (s), 2857 (m), 1746 (s), 1717 (s), 1622 
(s), 1498 (s), 1456 (s), 1389 (s), 1256 (s), 1095 (s). 
 
HRMS:  
(ESI) 
Calcd for (C33H38O14+Na) 
Found 
 
Calcd for (C33H38O14+NH4) 
Found 
 
681.2164 
681.2110 
 
676.2600 
676.2530 
TLC: Rf = 0.23 (UV, CAM) 
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(50% ethyl acetatehexane) 
 
 
[D]23D: +64.0° (c 0.60, CHCl3) 
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2-Deoxy Synthetic Precursor 78. 
2-Deoxy synthetic precursor 78 was assembled from the epoxy diazo diketone 18, 
cyanophthalide 19, and enone 77 by an analogous sequence to that used to assemble 
synthetic precursor 23 (see Scheme 1.3).  
 
1H NMR:  
(500 MHz, CDCl3) 
15.01 (s, 1H), 7.50 (s, 1H), 7.27 (m, 2H), 6.85 (d, 2H, J = 
7.7 Hz), 5.27 (d, 1H, J = 4.0 Hz), 5.15 (s, 1H), 4.83 (d, 
1H, J = 4.0 Hz), 4.70 (s, 1H), 4.62 (d, 1H, J = 11.0 Hz), 
4.50 (d, 1H, J = 11.4 Hz), 4.37 (s, 1H), 3.83 (s, 3H), 3.79 
(s, 3H), 3.62 (s, 3H), 3.47 (s, 3H), 3.16 (m, 1H), 3.13 (d, 
1H, J = 5.1 Hz), 3.02 (d, 1H, J = 5.1 Hz), 2.61 (s, 3H), 
2.55 (m, 1H), 2.05 (m, 1H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.2, 162.9, 159.2, 143.7, 141.8, 135.2, 130.3, 129.4, 
128.3, 116.5, 114.6, 114.6, 113.8, 109.6, 103.9, 100.1, 
98.5, 73.2, 70.3, 69.6, 69.2, 67.5, 62.7, 57.0, 56.6, 55.3, 
50.4, 32.3, 26.2, 24.7, 20.4. 
FTIR, cm–1: 
(neat) 
3391 (w), 2928 (m), 1678 (m), 1611 (s), 1389 (s), 1069 
(s). 
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HRMS:  
(ESI) 
Calcd for (C33H34O12+H) 
Found 
 
623.2123 
623.2125 
TLC: 
(60% ethyl acetatehexane) 
 
Rf = 0.55 (UV, CAM) 
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Diketone 82. 
2,3-dichloro-5,6-dicyanobenzoquinone (4.8 mg, 21 µmol, 1.1 equiv) was added to 
a solution of 4-methoxybenzyl ether 78 (12 mg, 19 µmol, 1 equiv) in a biphasic mixture 
of dichloromethane (290 µL) and pH 7 aqueous phosphate buffer solution (29 µL) at 23 
°C. The reaction flask was covered with aluminum foil to exclude light. After 1 h, the 
mixture was partitioned between dichloromethane (40 mL) and water (5 mL). The layers 
were separated. The organic layer was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by preparatory HPLC 
(Agilent Prep-C18   column,   10   μm,   30   ×   150  mm,   UV   detection   at   270   nm, gradient 
elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after 
concentration the pure diketone 82 (4.5 mg, 47%). 
 
1H NMR:  
(500 MHz, CDCl3) 
15.14 (s, 1H), 7.74 (s, 1H), 5.28 (d, 1H, J = 4.0 Hz), 4.85 
(d, 1H, J = 4.0 Hz), 4.71 (s, 1H), 4.43 (br, 1H), 3.95 (s, 
3H), 3.62 (s, 3H), 3.48 (s, 3H), 3.17 (d, 1H, J = 5.1 Hz), 
3.11–2.98 (m, 5H), 2.64 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
202.1, 195.1, 162.7, 151.7, 147.6, 143.2, 141.5, 138.8, 
136.4, 121.6, 118.6, 117.4, 104.2, 100.4, 98.9, 73.4, 69.7, 
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 69.5, 63.6, 57.3, 56.9, 50.8, 39.6, 36.9, 20.7. 
 
FTIR, cm–1: 
(neat) 
3433 (br), 2926 (s), 1701 (m), 1616 (s), 1389 (s), 1107 
(s), 1071 (s). 
 
HRMS:  
(ESI) 
Calcd for (C25H24O11+Na) 
Found 
 
523.1211 
523.1217 
TLC: 
(60% ethyl acetatehexane) 
 
Rf = 0.24 (UV, CAM) 
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α-Glycoside 81. 
1-O-β-Acetyl glycoside 65 (37.0 mg, 0.135 mmol, 6.0 equiv) was added to a 
solution of the 2-deoxy synthetic precursor 78 (14.0 mg, 0.022 mmol, 1 equiv) in benzene 
(2.0 mL) at 23 °C. The bright yellow solution was concentrated and the residue was 
blanketed with argon. Dichloromethane (180 µL) and ether (50 µL) were added, followed 
by crushed 4-Å molecular sieves (50 mg). The bright yellow suspension was stirred for 
60 min at 23 °C, then was cooled to –78 °C. N-
(trimethylsilyl)bis(trifluoromethanesulfonyl)imide (1.0 M solution in dichloromethane, 
90 µL, 0.090 mmol, 4.0 equiv) was added dropwise by syringe over 3 h. After 1 h, 
triethylamine (12.5 PL, 0.090 mmol, 4.0 equiv) was added at –78 °C. The resulting 
yellow-orange solution was diluted with 15% methanol–dichloromethane (50 mL) and 
saturated aqueous sodium bicarbonate solution (10 mL). The cooling bath was removed 
and the reaction flask was allowed to warm to 23 °C. The layers were separated. The 
aqueous layer was extracted with dichloromethane (2 × 20 mL). The organic layers were 
combined. The combined solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by preparatory HPLC 
(Agilent Prep-C18   column,   10   μm,   30   ×   150  mm,   UV   detection   at   270   nm,   gradient  
elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after 
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concentration  the  pure  α-glycoside 81 (11 mg, 59%, in fractions eluting at 30–33 min) as 
a yellow-green solid.  
 
1H NMR:  
(500 MHz, CDCl3) 
14.72 (s, 1H), 7.48 (s, 1H), 7.27 (d, 2H, J = 7.8 Hz), 6.86 
(d, 2H, J = 8.7 Hz), 5.83 (t, 1H, J = 2.8 Hz), 5.29 (d, 1H, 
J = 4.1 Hz), 5.19 (d, 1H, J = 4.1 Hz), 5.15 (br, 1H), 5.01 
(q, 1H, J = 6.4 Hz), 4.75 (t, 1H, J = 3.7 Hz), 4.74 (s, 1H), 
4.62 (d, 1H, J = 11.0), 4.51 (d, 1H, J = 11.0), 3.89 (br, 
1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.63 (s, 3H), 3.47 (s, 3H), 
3.17 (ddd, 1H, J = 18.3, 13.7, 5.0 Hz), 2.83 (d, 1H, J = 
6.0 Hz), 2.74 (d, 1H, J = 6.0 Hz), 2.60 (s, 3H), 2.54 (m, 
2H), 2.35 (s, 3H), 2.33 (m, 2H), 2.22 (s, 3H), 2.03 (m, 
1H), 1.08 (d, 3H, J = 6.4 Hz). 
 
FTIR, cm–1: 
(neat) 
2924 (m), 1709 (s), 1614 (m), 1389 (m), 1238 (s). 
HRMS:  
(ESI) 
Calcd for (C43H48O17+Na) 
Found 
 
859.2784 
859.2771 
TLC: 
(60% ethyl acetatehexane) 
 
Rf = 0.31 (UV, CAM) 
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Diketone 86. 
 
Potassium carbonate (2.5 mg, 18 µmol, 2.0 equiv) was added to an ice-cooled 
solution of the acetate ester 81 (7.5 mg, 9.0 µmol, 1 equiv) in methanol (0.7 mL). After 
140 min, the mixture was partitioned between dichloromethane (20 mL) and saturated 
aqueous sodium chloride solution (10 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (2 × 20 mL). The organic layers were combined and 
the combined solution was dried over sodium sulfate. The dried solution was filtered and 
the filtrate was concentrated. The residue was dissolved in a biphasic mixture of 
dichloromethane (333 µL) and water (67 µL) at 23 °C. 2,3-dichloro-5,6-
dicyanobenzoquinone (2.3 mg, 10 µmol, 1 equiv) was added. The reaction flask was 
covered with aluminum foil to exclude light. After 3.5 h, the mixture was partitioned 
between dichloromethane (50 mL) and water (10 mL). The layers were separated. The 
aqueous layer was extracted with dichloromethane (3 × 20 mL). The organic layers were 
combined and the combined solution was dried over sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated. The residue was purified by preparatory 
HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,  
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gradient elution with 30o80% acetonitrile in water, flow rate: 15 mL/min) to provide, 
separately, the benzylic alcohol 85 (1.9 mg, 28%) and the diketone 86 (1.5 mg, 22%). 
 
Diketone 86: 
 
1H NMR:  
(500 MHz, CDCl3) 
14.92 (s, 1H), 7.77 (s, 1H), 5.86 (d, 1H, J = 2.8 Hz), 5.39 
(d, 1H, J = 4.1 Hz), 5.26 (d, 1H, J = 4.1 Hz), 5.02 (q, 1H, 
J = 6.4 Hz), 4.77 (s, 1H), 4.16 (br, 1H), 3.95 (s, 3H), 3.72 
(s, 1H), 3.63 (s, 3H), 3.50 (s, 3H), 3.10 (m, 2H), 3.00 (m, 
3H), 2.91 (d, 1H, J = 5.5 Hz), 2.65 (s, 3H), 2.50 (s, 3H), 
2.45 (dt, 1H, J = 14.7, 3.7 Hz), 2.12 (d, 1H, J = 14.7 Hz), 
1.10 (d, 3H, J = 6.4 Hz). 
 
FTIR, cm–1: 
(neat) 
 
2924 (s), 1699 (m), 1616 (m), 1389 (m), 1089 (s). 
HRMS:  
(ESI) 
Calcd for (C33H36O15+Na) 
Found 
 
695.1946 
695.1951 
TLC: 
(70% ethyl acetatehexane) 
 
Rf = 0.28 (UV, CAM) 
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Diketone 83. 
 
2,3-dichloro-5,6-dicyanobenzoquinone (4.9 mg, 22 µmol, 1.2 equiv) was added to 
a solution of the 4-methoxybenzyl ether 81 (15 mg, 18 µmol, 1 equiv) in a mixture of 
dichloromethane (300 µL) and pH 7 aqueous phosphate buffer solution (60 µL) at 23 °C. 
The reaction flask was covered with aluminum foil to exclude light. After 70 min, the 
product mixture was partitioned between dichloromethane (40 mL) and water (10 mL). 
The layers were separated. The aqueous layer was extracted with dichloromethane (20 
mL). The organic layers were combined. The combined solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by preparatory HPLC (Agilent Prep-C18 column,   10   μm,   30   ×   150  mm,  UV  
detection at 270 nm, gradient elution with 20o90% acetonitrile in water, flow rate: 15 
mL/min) to provide after the concentration the diketone 83 as an orange powder (5 mg, 
39%). 
 
1H NMR:  
(500 MHz, CDCl3) 
14.88 (s, 1H), 7.74 (s, 1H), 5.82 (s, 1H), 5.33 (d, 1H, J = 
4.0 Hz), 5.21 (d, 1H, J = 4.0 Hz), 5.01 (q, 1H, J = 6.6 
Hz), 4.75 (s, 1H), 3.95 (s, 3H), 3.91 (s, 1H), 3.64 (s, 3H), 
3.48 (s, 3H), 3.09 (m, 2H), 3.00 (m, 2H), 2.86 (d, 1H, J = 
5.9 Hz), 2.76 (d, 1H, J = 5.9 Hz), 2.64 (s, 3H), 2.36 (s, 
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3H), 2.35 (m, 2H), 2.23 (s, 3H), 1.09 (d, 3H, J = 6.2 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.6, 201.7, 194.8, 170.3, 162.5, 151.7, 147.2, 143.0, 
136.2, 121.6, 118.2, 116.8, 110.2, 104.6, 101.8, 99.4, 
92.5, 78.1, 72.0, 70.7, 68.9, 68.3, 64.5, 63.4, 56.6, 55.9, 
47.4, 39.4, 36.7, 29.7, 28.9, 27.0, 21.3, 20.3, 14.5. 
 
FTIR, cm–1: 
(neat) 
2930 (m), 1715 (m), 1645 (m), 1510 (m), 1364 (m), 1105 
(s), 835 (s). 
 
HRMS:  
(ESI) 
Calcd for (C35H38O16+NH4) 
Found 
 
734.2558 
734.2593 
TLC: 
(70% ethyl acetatehexane) 
 
Rf = 0.34 (UV, CAM) 
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2-Deoxy Synthetic Precursor 88.74 
2-Deoxy synthetic precursor 88 was assembled from the epoxy diazo diketone 18, 
cyanophthalide 19, and (S)-4-(benzyloxy)cyclohex-2-enone (87) by an analogous 
sequence to that used for the synthesis of synthetic precursor 23 (see Scheme 1.3).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.98 (s, 1H), 7.43 (s, 1H), 7.35–7.27 (m, 5H), 5.24 (d, 
1H, J = 4.0 Hz), 5.17 (br t, 1H, J = 2.8 Hz), 4.88 (d, 1H, 
J = 4.4 Hz), 4.70 (s, 1H), 4.69 (d, 1H, J = 12.3 Hz), 4.56 
(d, 1H, J = 11.9 Hz), 4.54 (br s, 1H), 3.82 (s, 3H), 3.63 
(s, 3H), 3.48 (s, 3H), 3.18 (ddd, 1H, J = 18.3, 13.6, 5.4 
Hz), 3.10 (d, 1H, J = 5.2 Hz), 3.00 (d, 1H, J = 5.2 Hz), 
2.62– 2.53 (m, 2H), 2.57 (s, 3H), 2.09 (tdd, 1H, J = 14.0, 
4.6, 2.0 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.2, 162.9, 151.4, 143.8, 141.8, 138.2, 135.1, 128.3, 
128.1, 127.7, 127.6, 116.4, 114.6, 114.6, 109.5, 103.8, 
100.1, 98.5, 73.2, 70.6, 69.6, 69.2, 67.7, 62.8, 57.0, 56.6, 
50.4, 32.3, 26.3, 20.4. 
                                                 
74 Dr. Andreas Schumacher provided assistance in the large-scale synthesis of 2-deoxy synthetic precursor 
88, which I acknowledge with appreciation. 
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FTIR, cm–1: 
(neat) 
 
2918 (s), 1740 (s), 1620 (s), 1389 (s), 1236 (s), 1084 (s). 
HRMS:  
(ESI) 
Calcd for (C32H32O11+Na) 
Found 
 
615.1837 
615.1842 
TLC: 
(67% ethyl acetatehexane) 
 
Rf = 0.34 (UV, CAM) 
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2-Deoxy-DC-45-A2 (89). 
Palladium hydroxide on carbon (20 wt. %, 18 mg, 0.025 mmol, 1.0 equiv) was 
added to a solution of 2-deoxy synthetic precursor 88 (15 mg, 0.025 mmol, 1 equiv) in 
tetrahydrofuran (1.2 mL) at 23 °C. An atmosphere of hydrogen was maintained by 
sparging with a slow stream of pure hydrogen gas through a 22-gauge stainless steel 
needle. After 2 h, the mixture was diluted with ethyl acetate (20 mL) and filtered through 
a short pad of Celite. The filtrate was concentrated. The residue was purified by 
preparatory HPLC (Agilent Prep-C18  column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  
nm, gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to 
provide after concentration pure 2-deoxy-DC-45-A2 (89) (11.4 mg, 90%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.94 (s, 1H), 7.42 (s, 1H), 5.39 (t, 1H, J = 3.3 Hz), 5.24 
(d, 1H, J = 4 Hz), 4.86 (d, 1H, J = 4 Hz), 4.74 (br s, 1H), 
4.70 (s, 1H), 3.91 (s, 3H), 3.61 (s, 3H), 3.46 (s, 3H), 3.10 
(ddd, 1H, J = 17.6, 12.1, 5.5 Hz), 3.09 (d, 1H, J = 5.1 
Hz), 3.04 (d, 1H, J = 5.1 Hz), 2.75 (br s, 1H), 2.62 (t, 1H, 
J = 4.2 Hz), 2.58 (s, 3H), 2.26 (m, 2H). 
 
13C NMR:  203.9, 162.8, 151.5, 143.6, 142.1, 135.3, 130.2, 116.2, 
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(125 MHz, CDCl3) 
 
114.7, 114.5, 109.0, 103.9, 100.1, 98.6, 73.2, 69.6, 69.2, 
62.7, 62.2, 57.0, 56.6, 50.3, 32.7, 29.1, 20.4. 
 
FTIR, cm–1: 
(neat) 
 
3437 (br w), 2926 (m), 1717 (m), 1620 (s), 1389 (s), 
1065 (s), 978 (s). 
HRMS:  
(ESI) 
Calcd for (C25H26O11+H) 
Found 
 
503.1548 
503.1555 
TLC: 
(5% 
methanoldichloromethane) 
 
Rf = 0.47 (UV, CAM) 
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2-Deoxy-DC-45-A1 (90). 
Boron  trifluoride  etherate  (1.4  μL,  11  μmol,  1.0  equiv)  was  added  to  a  suspension  
of 2-deoxy-DC-45-A2 (89)  (5.7  mg,  11  μmol,  1  equiv),  1-O-acetyltrioxacarcinose A (48) 
(5.6  mg,   23  μmol,   2.0   equiv,   a   ~1:12  mixture   of  D- and E-anomers, respectively), and 
powdered 4-Å  molecular  sieves  (~30  mg)  in  dichloromethane  (380  μL)  at  –40 qC. After 5 
min, saturated aqueous sodium bicarbonate solution (1 mL) was added rapidly. The 
cooing bath was removed and the reaction flask was allowed to warm to 23 °C. The 
mixture was partitioned between dichloromethane (40 mL) and saturated aqueous sodium 
bicarbonate solution (9 mL). The layers were separated. The organic layer was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by preparatory HPLC (Agilent Prep-C18  column,  10  μm,  30  ×  150  
mm, UV detection at 270 nm, gradient elution with 40o90% acetonitrile in water, flow 
rate: 15 mL/min) to provide pure 2-deoxy-DC-45-A1 (90) as a yellow-green powder (3.7 
mg, 47%).  
 
1H NMR:  
(500 MHz, CDCl3) 
15.03 (s, 1H), 7.50 (s, 1H), 5.37 (app s, 1H), 5.26 (d, 2H, 
J = 4 Hz), 4.83 (d, 1H, J = 4 Hz), 4.73 (s, 1H), 4.71 (s, 
1H), 4.49 (q, 1H, J = 6.5 Hz), 4.38 (s, 1H), 4.08 (s, 1H), 
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3.85 (s, 3H), 3.62 (s, 3H), 3.47 (s, 3H), 3.16 (d, 1H, J = 
5.5 Hz), 3.08 (s, 1H), 3.01 (ddd, 1H, J = 18.7, 13.9, 5.1 
Hz), 2.68 (dd, 1H, J = 18.3, 3.7 Hz), 2.61 (s, 3H), 2.46–
2.40 (m, 1H), 2.27–2.19 (m, 1H), 2.13 (s, 3H), 1.93 (dd, 
1H, J = 14.6, 3.7 Hz), 1.59 (d, 1H, J = 14.6 Hz), 1.22 (d, 
3H, J = 6.2 Hz), 1.06 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
203.2, 170.4, 163.3, 151.7, 144.1, 142.3, 135.1, 126.7, 
116.8, 114.9, 114.9, 109.2, 103.9, 100.1, 98.5, 97.0, 74.5, 
73.2, 69.6, 69.3, 68.8, 66.3, 62.8, 62.7, 57.1, 56.6, 50.6, 
36.5, 32.4, 28.3, 25.6, 20.9, 20.4, 16.9. 
 
FTIR, cm–1: 
(neat) 
 
3514 (br w), 2926 (m), 1746 (m), 1620 (m), 1391 (s), 
1236 (s), 1084 (s),  997 (s). 
HRMS:  
(ESI) 
Calcd for (C34H40O15+Na) 
Found 
 
711.2259 
711.2242 
TLC: 
(5% 
methanoldichloromethane) 
 
Rf = 0.43 (UV, CAM) 
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D-Glycoside 92.75 
1-O-E-Acetyl glycoside 6565 (301 mg, 1.10 mmol, 5.0 equiv) was added to a 
solution of 2-deoxy synthetic precursor 88 (130 mg, 0.219 mmol, 1 equiv) in benzene 
(2.0 mL) at 23 °C. The bright yellow solution was concentrated and the residue was 
blanketed with argon. Dichloromethane (3 mL) and ether (600 PL) were added, followed 
by crushed 4-Å molecular sieves (1.2 g). The bright yellow suspension was stirred for 90 
min at 23 °C, then was cooled to –78 °C. Trimethylsilyl trifluoromethanesulfonate (120 
PL, 0.659 mmol, 3.0 equiv) was added dropwise by syringe over 10 min. After 2 h, a 
second portion of trimethylsilyl trifluoromethanesulfonate (40 PL, 0.220 mmol, 1.0 
equiv) was added dropwise by syringe over 10 min. After 3.5 h, triethylamine (122 PL, 
0.878 mmol, 4.0 equiv) was added. The suspension was diluted with dichloromethane (50 
mL) and filtered through a pad of Celite. Saturated aqueous sodium bicarbonate solution 
(10 mL) was added, and the layers were separated. The aqueous layer was extracted with 
dichloromethane (3 × 20 mL). The organic layers were combined and the combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by preparatory HPLC (Agilent Prep-C18 
column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  nm,  gradient  elution  with  40o90% 
                                                 
75 This procedure was conducted by Dr. Andreas Schumacher, whom I acknowledge with appreciation. 
205 
 
acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the pure D-
glycoside 92 (88 mg, 50%, in fractions eluting at 22.5–25.5 min) as a bright yellow solid. 
 
1H NMR:  
(500 MHz, CDCl3) 
14.74 (s, 1H), 7.49 (s, 1H), 7.35–7.26 (m, 5H), 5.84 (t, 
1H, J = 3 Hz), 5.31–5.29 (m, 2H), 5.2 (d, 1H, J = 4.0 
Hz), 5.17 (app s, 1H), 5.02 (q, 1H, J = 6.4 Hz), 4.76 (t, 
1H, J = 2.8 Hz), 4.75 (s, 1H), 4.7 (d, 1H, J = 11.5 Hz), 
4.58 (d, 1H, J = 11.5 Hz), 3.94 (s, 1H), 3.84 (s, 3H), 3.65 
(s, 3H), 3.47 (s, 3H), 3.19 (ddd, 1H, J = 18.1, 13.5, 5.0  
Hz), 2.83 (d, 1H, J = 6.0 Hz), 2.75 (d, 1H, J = 6.0 Hz), 
2.61 (s, 3H), 2.56 (m, 1H), 2.36 (s, 3H), 2.36–2.33 (m, 
2H), 2.23 (s, 3H), 2.06 (m, 1H), 1.09 (d, 3H, J = 6.4 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.6, 204.0, 170.1, 162.9, 151.7, 143.7, 141.8, 138.1, 
135.0, 128.2, 128.1, 127.7, 127.5, 116.2, 114.6, 114.2, 
109.4, 104.4, 101.4, 99.3, 92.2, 78.0, 71.9, 70.5, 69.0, 
68.1, 67.6, 64.3, 62.7, 56.4, 55.8, 47.3, 32.3, 28.7, 26.9, 
26.4, 21.2, 20.2, 14.4. 
 
FTIR, cm–1: 
(neat) 
 
3404 (w), 2932 (m), 1717 (m), 1620 (s), 1389 (s), 1067 
(s). 
 
HRMS:  Calcd for (C42H46O16 + Na) 829.2678 
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(ESI) Found 
 
829.2680 
TLC: 
(50% ethyl acetatehexane) 
 
Rf = 0.58 (UV, CAM) 
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Benzylic alcohol 84.75 
Palladium hydroxide on carbon (20 wt. %, 18 mg, 0.025 mmol, 1.0 equiv) was 
added to a solution of D-glycoside 92 (20 mg, 0.025 mmol, 1 equiv) in tetrahydrofuran 
(1.2 mL) at 23 °C. An atmosphere of hydrogen was maintained by sparging with a slow 
stream of pure hydrogen gas through a 22-gauge stainless steel needle. After 30 min, the 
mixture was diluted with ethyl acetate (20 mL) and filtered through a short pad of Celite. 
The filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent 
Prep-C18  column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  nm,  gradient  elution  with  
40o100% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure benzylic alcohol 84 (16 mg, 89%).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.71 (s, 1H), 7.45 (s, 1H), 5.81 (t, 1H, J = 2.9 Hz), 5.39 
(br s, 1H), 5.29 (d, 1H, J = 4.1 Hz), 5.19 (d, 1H, J = 4.1 
Hz), 5.00 (q, 1H, J = 6.3 Hz), 4.74 (m, 2H), 3.90 (s, 3H), 
3.63 (s, 3H), 3.47 (s, 3H), 3.10 (ddd, 1H, J = 17.3, 11.9, 
5.2  Hz), 2.83 (d, 1H, J = 5.8 Hz), 2.75 (d, 1H, J = 5.8 
Hz), 2.68 (d, 1H, J = 2.1 Hz), 2.63–2.60 (m, 1H), 2.60 (s, 
3H), 2.35 (s, 3H), 2.33–2.27 (m, 3H), 2.24–2.22 (m, 1H), 
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2.22 (s, 3H), 1.07 (d, 3H, J = 6.5 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.7, 203.7, 170.2, 163.0, 151.8, 143.4, 142.1, 135.2, 
130.3, 116.0, 114.5, 114.3, 109.0, 104.5, 101.6, 99.4, 
92.3, 78.2, 72.1, 70.7, 69.1, 68.3, 64.5, 62.7, 62.3, 56.5, 
55.8, 47.4, 32.8, 29.2, 28.9, 27.0, 21.3, 20.3, 14.5. 
 
FTIR, cm–1: 
(neat) 
 
3462 (w), 2926 (m), 1738 (m), 1618 (s), 1389 (s), 1236 
(s), 1099 (s), 982 (s). 
HRMS:  
(ESI) 
Calcd for (C35H40O16+H) 
Found 
 
717.2389 
717.2403 
TLC: 
(67% ethyl acetatehexane) 
 
Rf = 0.18 (UV, CAM) 
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Triol 85.75 
Potassium carbonate (0.5 mg, 4 Pmol, 0.3 equiv) was added to an ice-cooled 
solution of benzylic alcohol 84 (8.0 mg, 11 Pmol, 1 equiv) in methanol (1.0 mL). After 
30 min, the cooling bath was removed and the reaction flask was allowed to warm to 23 
°C. After 2.5 h, the mixture was partitioned between chloroform (40 mL) and saturated 
aqueous sodium chloride solution (10 mL). The layers were separated. The aqueous layer 
was extracted with chloroform (3 × 20 mL). The organic layers were combined and the 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent Prep-
C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution   with  
40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure triol 85 (6.8 mg, 90%, in fractions eluting at 6–11 min) as a yellow solid.  
 
1H NMR:  
(500 MHz, CDCl3) 
14.75 (s, 1H), 7.48 (s, 1H), 5.85 (d, 1H, J = 2.5 Hz), 5.41 
(t, 1H, J = 3.9 Hz), 5.35 (d, 1H, J = 4.1 Hz), 5.24 (d, 1H, 
J = 4.1 Hz), 5.02 (q, 1H, J = 6.4 Hz), 4.77 (s, 1H), 4.16 
(s, 1H), 3.92 (s, 3H), 3.71 (br s, 1H), 3.63 (s, 3H), 3.49 
(s, 3H), 3.13 (ddd, 1H, J = 17.3, 12.1, 5.2 Hz), 2.98 (d, 
1H, J = 5.7 Hz), 2.91 (d, 1H, J = 5.7 Hz), 2.65–2.60 (m, 
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1H), 2.61 (s, 3H), 2.50 (s, 3H), 2.43 (dt, 1H, J = 14.5, 3.5  
Hz), 2.32 (dq, 1H, J = 14.0, 4.7  Hz), 2.23 (m, 1H), 2.12 
(ddd, 1H, J = 14.6, 2.5, 1.4 Hz), 1.09 (d, 3H, J = 6.4 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
210.4, 203.9, 162.9, 151.7, 143.5, 142.0, 135.3, 130.5, 
116.3, 114.2, 110.7, 109.1, 104.6, 101.5, 99.7, 94.8, 79.6, 
71.5, 70.2, 69.3, 68.3, 63.8, 62.7, 62.3, 56.8, 56.1, 48.2, 
32.8, 31.5, 29.2, 27.8, 20.3, 14.5. 
 
FTIR, cm–1: 
(neat) 
 
3514 (m), 2928 (m), 1620 (s), 1389 (s), 1105 (s), 984 (s). 
HRMS:  
(ESI) 
Calcd for (C38H38O15+H) 
Found 
 
675.2283 
675.2279 
TLC: 
(75% ethyl acetatehexane) 
 
Rf = 0.22 (UV, CAM) 
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Diol 93.75 
Potassium carbonate (0.3 mg, 2 Pmol, 0.3 equiv) was added to an ice-cooled 
solution of D-glycoside 92 (5 mg, 6 Pmol, 1 equiv) in methanol (1.0 mL). After 30 min, 
the cooling bath was removed and the reaction flask was allowed to warm to 23 °C. After 
2 h, the mixture was partitioned between chloroform (40 mL) and saturated aqueous 
sodium chloride solution (10 mL). The layers were separated. The aqueous layer was 
extracted with chloroform (3 × 20 mL). The organic layers were combined and the 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent Prep-
C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution   with  
40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure diol 93 (3 mg, 63%, in fractions eluting at 28–30 min) as a yellow solid.  
 
1H NMR:  
(500 MHz, CDCl3) 
14.76 (s, 1H), 7.52 (s, 1H), 7.36–7.28 (m, 5H), 5.86 (br 
d, 1H, J = 2.3 Hz), 5.34 (d, 1H, J = 4.4 Hz), 5.24 (d, 1H, 
J = 4.4 Hz), 5.17 (br s, 1H), 5.02 (q, 1H, J = 6.3 Hz), 
4.76 (s, 1H), 4.7 (d, 1H, J = 11.5 Hz), 4.58 (d, 1H, J = 
11.5 Hz), 4.26 (d, 1H, J = 9.5 Hz), 4.15 (s, 1H), 3.82 (s, 
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3H), 3.71 (d, 1H, J = 9.5 Hz), 3.63 (s, 3H), 3.49 (s, 3H), 
3.2 (ddd, 1H, J = 18.1, 13.6, 5.2 Hz), 2.97 (d, 1H, J = 5.6 
Hz), 2.9 (d, 1H, J = 5.9 Hz), 2.61 (s, 3H), 2.60–2.51 (m, 
2H), 2.49 (s, 3H), 2.43 (dt, 1H, J = 14.5, 3.3  Hz), 2.12 
(d, 1H, J = 14.7 Hz), 2.06 (tdd, 1H, J = 13.5, 4.0, 1.6 
Hz), 1.09 (d, 3H, J = 6.3 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
210.5, 204.3, 163.0, 151.6, 143.8, 141.8, 138.2, 135.2, 
128.4, 128.3, 127.8, 127.7, 116.7, 114.7, 114.1, 109.7, 
104.6, 101.4, 99.7, 94.8, 79.6, 71.5, 70.6, 70.3, 69.3, 
68.3, 67.7, 63.8, 62.8, 56.8, 56.1, 48.2, 32.4, 31.5, 27.8, 
26.5, 20.3, 14.5. 
 
FTIR, cm–1: 
(neat) 
 
3512 (br w), 2926 (m), 1621 (s), 1389 (s), 1084 (s), 984 
(s). 
HRMS:  
(ESI) 
Calcd for (C40H44O15+Na) 
Found 
 
787.2572 
787.2571 
TLC: 
(67% ethyl acetatehexane) 
 
Rf = 0.32 (UV, CAM) 
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3''-O-Acetyl-2-deoxytrioxacarcin A (94). 
A suspension of benzylic alcohol 84 (9.0 mg, 13 Pmol, 1 equiv), 1-
phenylthiotrioxacarcinoside A 55 (11 mg, 38 Pmol, 3.0 equiv, a 3:1 mixture of D and E 
anomers, respectively), 2,6-di-tert-butyl-4-methylpyridine (21 mg, 0.10 mmol, 8.0 
equiv), and powdered 4-Å molecular sieves (~25 mg) in dichloromethane (0.6 mL) was 
stirred for 20 min at 23 °C. The mixture was cooled to 0 °C in an ice bath. Silver 
hexafluorophosphate (19 mg, 75 Pmol, 6.0 equiv) was added in one portion. After 1 h, a 
solution of triethylamine (88 PL, 0.63 mmol, 50 equiv) in dichloromethane (10 mL) was 
added. The suspension was filtered through a pad of Celite, and the filtrate was 
concentrated. The residue was immediately purified by preparatory HPLC (Agilent Prep-
C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution with 
40o100% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration 
pure 3''-O-acetyl-2-deoxytrioxacarcin A (94) as a yellow-green foam (6.2 mg, 55%, in 
fractions eluting at 16–21 min).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.75 (s, 1H), 7.48 (s, 1H), 5.81 (s, 1H), 5.37 (br, 1H), 
5.29 (d, 1H, J = 4.1 Hz), 5.25 (m, 1H), 5.19 (d, 1H, J = 
4.2 Hz), 5.00 (q, 1H, J = 6.4 Hz), 4.73 (m, 3H), 4.49 (q, 
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1H, J = 6.2 Hz), 4.07 (br, 1H), 3.90 (br, 1H), 3.84 (s, 
3H), 3.63 (s, 3H), 3.47 (s, 3H), 3.01 (ddd, 1H, J = 18.5, 
13.8, 5.2 Hz), 2.85 (d, 1H, J = 5.5 Hz), 2.78 (d, 1H, J = 
5.5 Hz), 2.66 (d, 1H, J = 18.2 Hz), 2.59 (s, 3H), 2.59–
2.52 (m, 1H), 2.43 (m, 1H), 2.35 (s, 3H), 2.32 (m, 1H), 
2.22 (s, 3H), 2.20 (m, 1H), 2.12 (s, 3H), 1.93 (dd, 1H, J = 
14.4, 3.8 Hz), 1.60 (d, 1H, J = 14.4 Hz), 1.22 (d, 3H, J = 
6.5 Hz), 1.07 (d, 3H, J = 6.8 Hz), 1.06 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
208.7, 203.1, 170.4, 170.2, 163.3, 151.9, 144.1, 142.3, 
135.0, 126.7, 116.6, 114.9, 114.6, 109.2, 104.5, 101.6, 
99.4, 96.9, 92.4, 78.2, 74.5, 72.0, 70.7, 69.1, 68.8, 68.3, 
66.3, 64.5, 62.8, 62.7, 56.5, 55.9, 47.5, 36.5, 32.4, 28.9, 
28.4, 27.0, 25.6, 21.3, 20.9, 20.3, 16.9, 14.5. 
 
FTIR, cm–1: 
(neat) 
 
3480 (br, w), 2926 (m), 1740 (s), 1620 (m), 1373 (s), 
1236 (s), 999 (s). 
HRMS:  
(ESI) 
Calcd for (C44H54O20+H) 
Found 
903.3281 
903.3284 
TLC: 
(5% methanol 
dichloromethane) 
Rf = 0.47 (UV, CAM) 
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2-deoxytrioxacarcin A (95). 
Potassium carbonate (1.8 mg, 13 Pmol, 2.0 equiv) was added to an ice-cooled 
solution of 3''-O-Acetyl-2-deoxytrioxacarcin A 94 (6.0 mg, 6.7 Pmol, 1 equiv) in 
methanol (1.3 mL). After 1 h, pH 7 aqueous phosphate buffer solution (10 mL) was 
added. The mixture was concentrated by rotary evaporation to remove methanol. The 
concentrated solution was extracted with dichloromethane (3 × 30 mL). The organic 
layers were combined and the combined solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue was purified by 
preparatory HPLC (Agilent Prep-C18  column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  
nm, gradient elution with 20o80% acetonitrile in water, flow rate: 15 mL/min) to 
provide after concentration 2-deoxytrioxacarcin A (95) (2.1 mg, 37%).  
 
1H NMR:  
(600 MHz, CDCl3) 
14.80 (s, 1H), 7.51 (s, 1H), 5.84 (br s, 1H), 5.38 (br s, 
1H), 5.35 (d, 1H, J = 4.2 Hz), 5.26 (m, 1H), 5.24 (d, 1H, 
J = 4.2 Hz), 5.02 (q, 1H, J = 6.4 Hz), 4.78 (s, 1H), 4.74 
(s, 1H), 4.49 (q, 1H, J = 6.2 Hz), 4.25 (d, 1H, J = 9.9 
Hz), 4.16 (s, 1H), 4.07 (s, 1H), 3.85 (s, 3H), 3.71 (d, 1H, 
J = 9.7 Hz), 3.63 (s, 3H), 3.49 (s, 3H), 3.03 (ddd, 1H, J = 
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19.3, 13.6, 5.1 Hz), 2.99 (d, 1H, J = 5.7 Hz), 2.94 (d, 1H, 
J = 5.7 Hz), 2.68 (dd, 1H, J = 18.2, 4.4 Hz), 2.61 (s, 3H), 
2.50 (s, 3H), 2.46–2.41 (m, 1H), 2.25–2.18 (m, 1H), 
2.15–2.11 (m, 1H), 2.13 (s, 3H), 1.94 (dd, 1H, J = 14.5, 
4.0 Hz), 1.60 (d, 1H, J = 14.5 Hz), 1.22 (d, 3H, J = 6.6 
Hz), 1.09 (d, 3H, J = 6.4 Hz), 1.07 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
210.4, 203.3, 170.4, 163.3, 151.8, 144.1, 142.2, 135.1, 
126.8, 116.9, 114.8, 114.5, 109.3, 104.7, 101.5, 99.7, 
97.0, 94.8, 79.6, 74.5, 71.4, 70.2, 69.3, 68.8, 68.3, 66.2, 
63.8, 62.8, 62.7, 56.8, 56.2, 48.2, 36.5, 32.4, 31.5, 28.4, 
27.8, 25.6, 20.9, 20.3, 16.9, 14.5. 
 
FTIR, cm–1: 
(neat) 
 
3509 (br m), 2928 (s), 1719 (s), 1622 (s), 1389 (s), 1234 
(s), 1107 (s), 999 (s). 
HRMS:  
(ESI) 
Calcd for (C42H52O19+Na) 
Found 
 
883.2995 
883.2974 
TLC: 
(5% methanol 
dichloromethane) 
Rf = 0.41 (UV, CAM) 
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Methyl 4-(Benzyloxy)-2-hydroxybenzoate (97).71 
Benzyl bromide (3.54 mL, 29.7 mmol, 1.00 equiv) was added dropwise to an ice-
cooled suspension of methyl 2,4-dihydroxybenzoate (96) (5.00 g, 29.7 mmol, 1 equiv) 
and potassium carbonate (5.75 g, 41.6 mmol, 1.4 equiv) in acetone (30 mL). The 
suspension was heated to reflux. After 18 h, the mixture was concentrated. The residue 
was partitioned between ethyl acetate (100 mL) and water (50 mL). The layers were 
separated. The basic aqueous layer was neutralized (pH ~7) by addition of 1.0 M aqueous 
hydrochloric acid solution, and the neutralized solution was extracted with ethyl acetate 
(100 mL). The organic layers were combined. The combined solution was washed 
sequentially with water (50 mL) then saturated aqueous sodium chloride solution (50 mL) 
and the washed solution was dried over sodium sulfate. The dried solution was filtered 
and the filtrate was concentrated. The residue was recrystallized from methanol to 
provide methyl 4-(benzyloxy)-2-hydroxybenzoate (97) as a white solid (5.31 g, 69%).71 
 
1H NMR:  
(600 MHz, CDCl3) 
10.96 (s, 1H), 7.75 (d, 1H, J = 8.8 Hz), 7.43–7.38 (m, 
4H), 7.36–7.32 (m, 1H), 6.53 (d, 1H, J = 2.3 Hz), 6.51 
(dd, 1H, J = 8.8, 2.4 Hz), 5.08 (s, 2H), 3.91 (s, 3H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
170.3, 164.6, 163.7, 136.0, 131.2, 128.6, 128.2, 127.5, 
108.0, 105.6, 101.6, 70.1, 51.9. 
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FTIR, cm–1: 
(neat) 
 
1667 (s), 1620 (s), 1439 (s), 1346 (s), 1252 (s), 1138 (s). 
HRMS:  
(ESI) 
Calcd for (C15H14O4+H) 
Found 
 
259.0965 
259.0970 
 
  
219 
 
 
(E)-4-(benzyloxy)-N,N-diethyl-2-(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide (98). 
Allyl bromide (3.56 mL, 41.1 mmol, 2.0 equiv) was added to a vigorously stirred 
suspension of methyl 4-(benzyloxy)-2-hydroxybenzoate (97) (5.31 g, 20.6 mmol, 1 
equiv) and potassium carbonate (5.68 g, 41.1 mmol, 2.0 equiv) in N,N-
dimethylformamide (40 mL) at 23 °C. After 18 h, the mixture was partitioned between 
ethyl acetate (600 mL) and water (200 mL). The layers were separated. The organic layer 
was dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated to provide methyl 2-(allyloxy)-4-(benzyloxy)benzoate, which was used in 
the next step without purification. 
Trimethylaluminum (1.8 M solution in toluene, 21.7 mL, 39.0 mmol, 1.9 equiv) 
was added to an ice-cooled solution of diethylamine (8.1 mL, 78 mol, 3.8 equiv) in 
benzene (10 mL). After 10 min, the cooling bath was removed and the reaction flask was 
allowed to warm to 23 qC. A solution of methyl 2-(allyloxy)-4-(benzyloxy)benzoate (1 
equiv, see paragraph above) in toluene (10 mL) was added to the reaction mixture over 5 
min by cannula. The reaction mixture was heated at reflux in an oil bath at 120 qC 
(CAUTION: gas evolution). After 7 h, the heating bath was removed and the reaction 
flask was allowed to cool to 23 qC. The reaction mixture was poured carefully into a 
mixture of ice water (100 mL) and 12 M aqueous hydrochloric acid solution (2 mL). The 
layers were separated. The aqueous layer was extracted with ethyl acetate (3 u 100 mL). 
The organic layers were combined. The combined solution was washed sequentially with 
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water (100 mL) then saturated aqueous sodium chloride solution (50 mL) and the washed 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated to provide 2-(allyloxy)-4-(benzyloxy)-N,N-diethylbenzamide, which 
was used in the next step without purification. 
2-(allyloxy)-4-(benzyloxy)-N,N-diethylbenzamide (see paragraph above) was 
heated neat in an oil bath at 220 qC. After 5 h, the heating bath was removed and the 
reaction flask was allowed to cool to 23 qC. The product, 3-allyl-4-(benzyloxy)-N,N-
diethyl-2-hydroxybenzamide, was used in the next step without purification. 
Potassium tert-butoxide (11.52 g, 103 mmol, 5.0 equiv) was added to a solution 
of 3-allyl-4-(benzyloxy)-N,N-diethyl-2-hydroxybenzamide (1 equiv, see paragraph 
above) in dimethyl sulfoxide (21 mL) at 23 qC. The reaction flask was heated in an oil 
bath at 120 qC. After 70 min, the heating bath was removed and the reaction flask was 
allowed to cool to 23 qC. The reaction mixture was diluted with water (40 mL). The 
diluted solution was acidified to pH ~2 with 6.0 M aqueous hydrochloric acid solution 
(~50 mL). The mixture was extracted with ethyl acetate (2 u 100 mL). The organic layers 
were combined. The combined solution was washed sequentially with water (5 u 100 
mL) then saturated aqueous sodium chloride solution (100 mL) and the washed solution 
was dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated to provide (E)-4-(benzyloxy)-N,N-diethyl-2-hydroxy-3-(prop-1-en-1-
yl)benzamide, which was used in the next step without purification. 
Chloromethyl methyl ether (2.34 mL, 30.7 mmol, 1.5 equiv) was added to a 
solution of (E)-4-(benzyloxy)-N,N-diethyl-2-hydroxy-3-(prop-1-en-1-yl)benzamide (1 
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equiv, see paragraph above) and N,N-diisopropylethylamine (7.17 mL, 41.0 mmol, 2.0 
equiv) in dichloromethane (84 mL) at 0 qC. After 5 min, the cooling bath was removed 
and the reaction flask was allowed to warm to 23 qC. After 22 h, the reaction mixture was 
partitioned between water (200 mL) and dichloromethane (200 mL). The layers were 
separated. The aqueous layer was extracted with dichloromethane (200 mL). The organic 
layers were combined. The combined solution was washed with saturated aqueous 
sodium chloride solution (100 mL) and the washed solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by flash-column chromatography (20% ethyl acetate–hexanes initially, grading 
to 40% ethyl acetate–hexanes) to provide (E)-4-(benzyloxy)-N,N-diethyl-2-
(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide (98) as a yellow oil (5.50 g, 70% over 5 
steps).  
 
1H NMR:  
(500 MHz, CDCl3) 
7.43–7.32 (m, 5H), 7.02 (d, 1H, J = 8.7 Hz), 6.75 (d, 1H, 
J = 8.2 Hz), 6.61 (m, 2H), 5.11 (s, 2H), 5.00 (br, 2H), 
3.68 (br, 1H), 3.51 (s, 3H), 3.41 (br, 1H), 3.30–3.12 (br, 
2H), 1.90 (d, 3H, J = 5.0 Hz), 1.24 (t, 3H, J = 6.9 Hz), 
1.04 (t, 3H, J = 6.9 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
168.7, 157.3, 151.0, 136.4, 131.8, 128.2, 127.6, 126.9, 
125.4, 124.8, 121.1, 120.9, 108.3, 99.4, 70.3, 57.3, 42.8, 
38.8, 19.7, 13.6, 12.6. 
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FTIR, cm–1: 
(neat) 
 
2972 (w), 1626 (s), 1427 (m), 1265 (m), 1265 (m), 1055 
(s), 926 (s), 733 (s). 
HRMS:  
(ESI) 
Calcd for (C23H29NO4+Na) 
Found 
 
406.1998 
406.1989 
TLC: 
(50% ethyl acetatehexanes) 
Rf = 0.41 (UV, CAM) 
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Aldehyde 99. 
tert-Butyllithium (1.7 M solution in pentane, 1.84 mL, 3.13 mmol, 1.2 equiv) was 
added dropwise to a solution of N,N,N,N-tetramethylethylenediamine (472 PL, 3.13 
mmol, 1.2 equiv) and (E)-4-(benzyloxy)-N,N-diethyl-2-(methoxymethoxy)-3-(prop-1-en-
1-yl)benzamide (98) (1.00 g, 2.61 mmol, 1 equiv) in tetrahydrofuran (26 mL) at –90 qC 
in a liquid nitrogen–hexane bath. After 5 min, dimethylformamide (2.42 mL, 31.3 mmol, 
12 equiv) was added. After 10 min, the cooling bath was removed and the reaction flask 
was allowed to warm to 23 qC. After 40 min, the reaction mixture was diluted with water 
(10 mL), and the diluted solution was partially concentrated to remove the volatile 
organic solvents. The aqueous residue was extracted with ethyl acetate (3 × 50 mL). The 
organic layers were combined. The combined solution was washed with water (2 u 50 
mL) then saturated aqueous sodium chloride solution (50 mL) and the washed solution 
was dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated to provide aldehyde 99 as a pale yellow oil (1.07 g, >99%).  
 
1H NMR:  
(500 MHz, CDCl3) 
9.90 (s, 1H), 7.45–7.36 (m, 5H), 7.34 (s, 1H), 6.83 (dq, 
1H, J = 16.0, 6.9 Hz), 6.64 (dd, 1H, J = 16.0, 1.8 Hz), 
5.17 (s, 2H), 5.06 (d, 1H, J = 5.0 Hz), 5.01 (d, 1H, J = 
5.0 Hz), 3.68–3.56 (m, 2H), 3.54 (s, 3H), 3.21–3.11 (m, 
2H), 1.93 (dd, 3H, J = 6.9, 1.8 Hz), 1.30 (t, 3H, J = 7.3 
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Hz), 1.04 (t, 3H, J = 7.3 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
189.5, 165.9, 157.4, 151.3, 136.0, 135.6, 131.2, 128.6, 
128.5, 128.1, 127.6, 127.4, 121.2, 107.0, 100.1, 70.9, 
57.9, 43.3, 39.3, 20.2, 13.8, 12.8. 
 
FTIR, cm–1: 
(neat) 
 
2936 (w), 1694 (m), 1628 (s), 1288 (m), 924 (m). 
HRMS:  
(ESI) 
Calcd for (C24H29NO5+Na) 
Found 
 
434.1938 
434.1942 
TLC: 
(50% ethyl acetatehexanes) 
Rf = 0.47 (UV, CAM) 
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Cyanophthalide 100. 
Cyanotrimethylsilane (524 PL, 3.91 mmol, 1.5 equiv) was added to an ice-cooled 
solution of aldehyde 99 (1.07 g, 2.61 mmol, 1 equiv) in dichloromethane (5.2 mL). After 
5 min, potassium cyanide (1.7 mg, 0.026 mmol, 0.01 equiv) and 18-crown-6 (6.9 mg, 
0.026 mmol, 1 equiv) were added. After 5 min, the cooling bath was removed and the 
reaction flask was allowed to warm to 23 qC. After 5 h, the solution was concentrated 
carefully. The residue was dissolved in glacial acetic acid (5.2 mL) (CAUTION: the 
highly toxic gas hydrogen cyanide may be generated upon treatment of the residue with 
acetic acid: This operation should be conducted in a well-ventilated fume hood). The 
resulting solution was stirred at 23 qC. After 41 h, the solvent was removed by rotary 
evaporation. The residue was partitioned between saturated aqueous sodium bicarbonate 
solution (50 mL) and ethyl acetate (50 mL). The layers were separated. The organic layer 
was washed with water (50 mL) and the washed solution was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (10% ethyl acetate–hexanes initially, grading to 30% 
ethyl acetate–hexanes) to provide cyanophthalide 100 as a white foam (588 mg, 62% 
over two steps). 
 
1H NMR:  
(500 MHz, CDCl3) 
7.44–7.33 (m, 5H), 6.89 (s, 1H), 6.64 (dq, 1H, J = 16.1, 
6.2 Hz), 6.57 (d, 1H, J = 16.1 Hz), 5.90 (s, 1H), 5.34 (q, 
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2H, J = 6.5 Hz), 5.27 (d, 1H, J = 11.7 Hz), 5.20 (d, 1H, J 
= 11.7 Hz), 3.56 (s, 3H), 1.93 (d, 3H, J = 5.9 Hz). 
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Benzyl ether 101. 
Benzyl ether 101 was assembled from the epoxy diazo diketone 18, 
cyanophthalide 100, and cyclohexenone by an analogous sequence to that used for the 
synthesis of synthetic precursor 23 (see Scheme 1.3). 
 
1H NMR:  
(500 MHz, CDCl3) 
14.97 (s, 1H), 7.48 (d, 2H, J = 7.0 Hz), 7.40–7.31 (m, 
3H), 7.00 (s, 1H), 5.55 (d, 1H, J = 4.0 Hz), 5.30 (d, 1H, J 
= 12.1 Hz), 5.23 (d, 1H, J = 12.1 Hz), 4.78 (d, 1H, J = 
4.0 Hz), 4.72 (s, 1H), 4.39 (br s, 1H), 3.66 (s, 3H), 3.60 
(s, 3H), 3.48 (s, 3H), 3.20 (d, 1H, J = 5.5 Hz), 3.09 (d, 
1H, J = 5.5 Hz), 3.01 (t, 2H, J = 6.2 Hz), 2.70 (m, 2H), 
2.07 (m, 2H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.0, 163.0, 159.2, 152.8, 142.0, 136.5, 136.2, 130.7, 
128.6, 128.1, 127.3, 110.1, 109.6, 106.2, 103.8, 100.0, 
98.7, 95.3, 72.8, 70.4, 69.5, 67.2, 60.4, 56.7, 56.2, 50.6, 
38.6, 23.6, 22.1. 
 
FTIR, cm–1: 
(neat) 
3343 (br w), 2945 (w), 1616 (s), 13897 (m), 1080 (s). 
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HRMS:  
(ESI) 
Calcd for (C31H30O11+H) 
Found 
 
579.1861 
579.1856 
TLC: 
(40% ethyl acetatehexanes) 
Rf = 0.13 (UV, CAM) 
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Phenol 102. 
Palladium on activated charcoal (10 wt. %, 1.1 mg, 1.0 Pmol, 0.1 equiv) was 
added to a solution of benzyl ether 101 (6 mg, 10 Pmol, 1 equiv) in ethanol (200 PL) at 
23 °C. The mixture was saturated with hydrogen by bubbling hydrogen gas below the 
liquid surface for 2 min through a 22-gague stainless steel needle, and the mixture was 
subsequently stirred under a hydrogen atmosphere at 23 °C. After 2 h, the mixture was 
diluted with ethyl acetate (20 mL) filtered through a short pad of Celite. The filtrate was 
concentrated to provide phenol 102 (5 mg, >95%) as a yellow-green oil. During attempts 
at purification by rp-HPLC and upon standing in chloroform, phenol 102 underwent 
decomposition, forming a complex mixture of products.  
 
1H NMR:  
(500 MHz, CDCl3) 
16.62 (br s, 1H), 10.67 (s, 1H), 6.91 (s, 1H), 5.56 (d, 1H, 
J = 4.0 Hz), 4.79 (d, 1H, J = 3.7 Hz), 4.69 (s, 1H), 4.29 
(br s, 1H), 3.75 (s, 3H), 3.58 (s, 3H), 3.48 (s, 3H), 3.26 
(d, 1H, J = 5.1 Hz), 3.05 (d, 1H, J = 5.1 Hz), 3.04–2.92 
(m, 2H), 2.73 (t, 2H, J = 6.4 Hz), 2.09 (quin, 2H, J = 6.2 
Hz). 
 
HRMS:  
(ESI) 
Calcd for (C24H24O11+Na) 
Found 
511.1211 
511.1227 
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3-allyl-4-bromo-N,N-diethyl-2-hydroxybenzamide (109). 
Iodomethane (1.66 mL, 26.6 mmol, 1.1 equiv) was added to a mixture of 4-
bromo-2-hydroxybenzoic acid (108) (5.24 g, 24.2 mmol, 1 equiv) and lithium carbonate 
(1.96 g, 26.6 mmol, 1.1 equiv) in dimethylformamide at 23 °C. The reaction flask was 
heated in an oil bath at 60 °C. After 3.5 h, the warm mixture was partitioned between ice 
water (50 mL) and ethyl acetate (80 mL). The layers were separated. The aqueous layer 
was extracted with ethyl acetate (80 mL). The organic layers were combined. The 
combined solution was washed sequentially with water (2 × 50 mL) then saturated 
aqueous sodium chloride solution (50 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated to 
provide the product, methyl 4-bromo-2-hydroxybenzoate, which was used in the next 
step without purification. 
Methyl 4-bromo-2-hydroxybenzoate (1 equiv, see paragraph above) was added to 
an ice-cooled suspension of sodium hydride (60% dispersion in mineral oil, 1.16 g, 29.0 
mmol, 1.2 equiv) and allyl bromide (4.18 mL, 48.3 mmol, 2.0 equiv) in 
dimethylformamide (40 mL). After 10 min, the cooling bath was removed and the 
reaction flask was allowed to warm to 23 °C. After 22 h, the mixture was partitioned 
carefully between ice water (50 mL) and ether (50 mL). The layers were separated. The 
aqueous layer was extracted with ether (2 × 50 mL). The organic layers were combined. 
The combined solution was washed successively with water (3 × 40 mL) then saturated 
aqueous sodium chloride solution (40 mL) and the washed solution was dried over 
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sodium sulfate. The dried solution was filtered and the filtrate was concentrated to 
provide the product, methyl 2-(allyloxy)-4-bromobenzoate, which was used in the next 
step without purification. 
Trimethylaluminum (2.0 M solution in toluene, 23.0 mL, 45.9 mmol, 1.9 equiv) 
was added to an ice-cooled solution of diethylamine (9.59 mL, 92.0 mmol, 3.8 equiv) in 
benzene (15 mL). After 10 min, the cooling bath was removed and the reaction flask was 
allowed to warm to 23 °C. A solution of methyl 2-(allyloxy)-4-bromobenzoate (1 equiv, 
see paragraph above) in toluene (15 mL) was added. The reaction flask was heated in an 
oil bath at 120 °C (CAUTION: gas evolution). After 2.5 h, the oil bath was removed and 
the reaction flask was allowed to cool to 23 °C. The solution was poured carefully into 
0.2 M aqueous hydrochloric acid solution (100 mL). The mixture was extracted with 
ethyl acetate (3 × 100 mL). The organic layers were combined. The combined solution 
was washed sequentially with water (100 mL) then saturated aqueous sodium chloride 
solution (50 mL) and the washed solution was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated to provide the product, 2-
(allyloxy)-4-bromo-N,N-diethylbenzamide, which was used in the next step without 
purification.  
2-(allyloxy)-4-bromo-N,N-diethylbenzamide (see paragraph above) was heated 
neat in an oil bath at 220 °C. After 4 h, the heating bath was removed and the reaction 
flask was allowed to cool to 23 °C. The product was purified by flash-column 
chromatography (5% ethyl acetate–hexanes initially, grading to 15% ethyl acetate–
hexanes) to provide 3-allyl-4-bromo-N,N-diethyl-2-hydroxybenzamide (109) as a yellow 
oil (5.20 g, 69% yield over four steps).  
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1H NMR:  
(600 MHz, CDCl3) 
10.4 (br s, 1H), 7.07 (d, 1H, J = 8.2 Hz), 7.01 (d, 1H, J = 
8.8 Hz), 5.96 (dd, 1H, J = 17.0, 10.6 Hz), 5.10–5.04 (m, 
2H), 3.62 (d, 2H, J = 6.5 Hz), 3.5 (q, 4H, J = 7.2 Hz), 
1.27 (t, 6H, J = 7.0 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
171.2, 157.6, 134.3, 128.8, 128.4, 125.8, 122.3, 116.6, 
115.5, 42.2, 33.8, 13.2. 
FTIR, cm–1: 
(neat) 
 
2974 (m), 2932 (m), 1611 (s), 1587 (s), 1452 (s), 1275 
(s). 
HRMS:  
(ESI) 
Calcd for (C14H18NO2Br+H) 
Found 
 
312.0594 
312.0575 
TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.49 (UV) 
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4-bromo-N,N-diethyl-2-(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide (110). 
Bis(dibenzylideneacetone)palladium(0) (92 mg, 0.16 mmol, 0.01 equiv), tri-tert-
butylphosphine (39 PL, 0.16 mmol, 0.01 equiv), and isobutyryl chloride (17 PL, 0.16 
mmol, 0.01 equiv)77 were added sequentially to a solution of 3-allyl-4-bromo-N,N-
diethyl-2-hydroxybenzamide (109) (5.00 g, 16.0 mmol, 1 equiv) in toluene (40 mL) at 23 
°C. The flask was heated in an oil bath at 80 °C. After 23 h, the solution was 
concentrated. The residue (1 equiv, see above) was dissolved in dichloromethane (80 
mL). N,N-diisopropylethylamine (7.05 mL, 40.4 mmol, 2.5 equiv) and chloromethyl 
methyl ether (2.45 mL, 32.3 mmol, 2.0 equiv) were added at 23 °C. After 20 h, the 
mixture was partitioned between water (100 mL) and dichloromethane (150 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (150 mL). 
The organic layers were combined. The combined solution was washed sequentially with 
water (100 mL) the saturated aqueous sodium chloride solution (100 mL) and the washed 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (10% ethyl 
acetate–hexanes initially, grading to 40% ethyl acetate–hexanes) to provide the product, 
4-bromo-N,N-diethyl-2-(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide (110) as a 
~3.7:1 mixture of E- and Z-isomers, respectively (the alkene stereochemistry is 
inconsequential) (5.25 g, 92% over two steps).  
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1H NMR:  
(500 MHz, CDCl3) 
E-isomer (major): 7.38 (d, 1H, J = 8.2 Hz), 6.94 (d, 1H, 
J = 8.2 Hz), 6.42–6.31 (m, 2H), 5.04–4.90 (m, 2H), 3.65 
(br m, 1H), 3.47 (s, 3H), 3.44 (br m, 1H), 3.18 (br m, 
2H), 1.93 (d, 3H, J = 6.0 Hz), 1.24 (t, 3H, J = 7.1 Hz), 
1.06 (t, 3H, J = 7.1 Hz). 
 
Z-isomer (minor): 7.41 (d, 1H, J = 8.2 Hz), 7.03 (d, 1H, 
J = 8.2 Hz), 6.28 (dd, 1H, J = 11.2, 1.1 Hz), 5.95 (dq, 
1H, J = 11.4, 6.9 Hz), 5.04–4.90 (m, 2H), 3.65 (br m, 
1H), 3.46 (s, 3H), 3.44 (br m, 1H), 3.18 (br m, 2H), 1.58 
(d, 3H, J = 6.9, 1.8 Hz), 1.20 (t, 3H, J = 7.1 Hz), 1.06 (t, 
3H, J = 7.1 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
167.9, 167.8, 151.2, 151.1, 134.0, 133.9, 132.9, 131.7, 
130.2, 129.0, 128.4, 127.1, 126.1, 125.4, 125.2, 125.1, 
124.5, 99.6, 99.5, 98.1, 57.6, 57.4, 43.0, 42.9, 39.0, 39.0, 
19.1, 19.1, 15.1, 14.9, 13.8, 12.8. 
 
FTIR, cm–1: 
(neat) 
 
2976 (w), 1632 (s), 1429 (s), 1159 (s), 949 (s). 
HRMS:  
(ESI) 
Calcd for (C16H22NO3Br+H) 
Found 
356.0856 
356.0863 
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TLC: 
(20% ethyl acetatehexanes) 
Rf = 0.19, 0.13 (UV, CAM) 
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Cyanophthalide 111. 
In a 150-mL heavy-walled glass pressure vessel, a suspension of 4-bromo-N,N-
diethyl-2-(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide (110) (940 mg, 2.64 mmol, 1 
equiv, a ~3.7:1 mixture of E- and Z-isomers, respectively), cyclopropylboronic acid 
pinacol ester (893 PL, 5.28 mmol, 2.0 equiv), and tripotassium phosphate (1.68 g, 7.92 
mmol, 3.0 equiv) in a mixture of tetrahydrofuran (17 mL) and water (17 mL) was 
degassed by sparging for 30 min with a slow stream of argon gas through a 22-gauge 
stainless steel needle. Tetrakis(triphenylphosphine)palladium(0) (152 mg, 0.132 mmol, 
0.05 equiv) was added. The flask was sealed and heated in an oil bath at 120 °C. After 90 
min, the heating bath was removed and the reaction flask was allowed to cool to 23 °C. 
Dichloromethane (250 mL) and saturated aqueous ammonium chloride solution (100 mL) 
were added. The layers were separated. The organic layer was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (10% ethyl acetate–hexanes initially, grading to 30% 
ethyl acetate–hexanes) to provide the product, 4-cyclopropyl-N,N-diethyl-2-
(methoxymethoxy)-3-(prop-1-en-1-yl)benzamide. 
tert-Butyllithium (1.6 M solution in pentane, 3.30 mL, 5.28 mmol, 2.0 equiv) was 
added dropwise to a solution of N,N,N,N-tetramethylethylenediamine (797 PL, 5.28 
mmol, 2.0 equiv) and 4-cyclopropyl-N,N-diethyl-2-(methoxymethoxy)-3-(prop-1-en-1-
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yl)benzamide (1 equiv, see paragraph above) in tetrahydrofuran (26 mL) at –78 qC. After 
10 min, dimethylformamide (2.42 mL, 31.3 mmol, 12 equiv) was added. After 5 min, the 
cooling bath was removed and the reaction flask was allowed to warm to 23 qC. After 30 
min, the reaction mixture was diluted with water (10 mL), and the diluted solution was 
partially concentrated to remove the volatile organic solvents. The aqueous residue was 
extracted with ethyl acetate (3 × 50 mL). The organic layers were combined. The 
combined solution was washed with water (2 u 50 mL) then saturated aqueous sodium 
chloride solution (50 mL) and the washed solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue (1 equiv, see 
above) was dissolved in dichloromethane (5.3 mL). Cyanotrimethylsilane (531 PL, 3.96 
mmol, 1.5 equiv) was added at 23 °C. After 5 min, potassium cyanide (1.7 mg, 0.026 
mmol, 0.01 equiv) and 18-crown-6 (7 mg, 0.03 mmol, 1 equiv) were added. After 5 min, 
the cooling bath was removed and the reaction flask was allowed to warm to 23 qC. After 
3 h, the solution was concentrated carefully. The residue was dissolved in glacial acetic 
acid (5.3 mL) (CAUTION: the highly toxic gas hydrogen cyanide may be generated upon 
treatment of the residue with acetic acid: This operation should be conducted in a well-
ventilated fume hood). The resulting solution was stirred at 23 qC. After 71 h, the solvent 
was removed by rotary evaporation. The residue was partitioned between saturated 
aqueous sodium bicarbonate solution (50 mL) and ethyl acetate (100 mL). The layers 
were separated. The organic layer was washed with saturated aqueous sodium chloride 
solution (50 mL) and the washed solution was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The residue was purified by flash-
column chromatography (10% ethyl acetate–hexanes initially, grading to 25% ethyl 
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acetate–hexanes) to provide cyanophthalide 111 as a colorless oil (490 mg, 62% over 
three steps, a ~2.8:1 mixture of E- and Z-isomers, respectively).  
 
1H NMR:  
(500 MHz, CDCl3) 
E-isomer (major): 6.88 (s, 1H), 6.54 (dd, 1H, J = 16.1, 
1.5 Hz), 6.22 (dq, 1H, J = 16.1, 6.5 Hz), 5.91 (s, 1H), 
5.33–5.28 (m, 2H), 3.55 (s, 3H), 2.20–2.13 (m, 1H), 1.98 
(dd, 3H, J = 6.6, 1.7 Hz), 1.17–1.10 (m, 2H), 0.86–0.75 
(m, 2H). 
 
Z-isomer (minor): 6.80 (s, 1H), 6.40 (d, 1H, J = 6.4 Hz), 
6.08 (dq, 1H, J = 11.2, 6.8 Hz), 5.92 (s, 1H), 5.33–5.28 
(m, 2H), 3.55 (s, 3H), 2.20–2.13 (m, 1H), 1.58 (dd, 3H, J 
= 6.8, 1.5 Hz), 1.17–1.10 (m, 2H), 0.86–0.75 (m, 2H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
165.7, 165.6, 154.5, 154.2, 154.1, 153.2, 142.2, 141.3, 
135.4, 134.4, 134.1, 131.2, 123.1, 123.0, 114.2, 114.1, 
113.5, 112.6, 112.3, 112.1, 100.8, 100.4, 64.7, 64.7, 57.8, 
57.6, 19.3, 15.1, 15.0, 14.2, 10.6, 10.6, 10.1, 10.0. 
 
FTIR, cm–1: 
(neat) 
 
2934 (w), 1778 (s), 1605 (m), 1157 (m), 991 (s), 912 (s). 
HRMS:  Calcd for (C17H17NO4+Na) 322.1050 
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(ESI) Found 
 
322.1053 
TLC: 
(30% ethyl acetatehexanes) 
Rf = 0.53 (UV, CAM) 
 
  
240 
 
 
Cyclopropyl Analog 112. 
Cyclopropyl analog 112 was assembled from the epoxy diazo diketone 18, 
cyanophthalide 111, and cyclohexenone by an analogous sequence to that used for the 
synthesis of synthetic precursor 23 (see Scheme 1.3).  
 
1H NMR:  
(500 MHz, CDCl3) 
14.92 (br s, 1H), 7.25 (s, 1H), 5.64 (d, 1H, J = 4.0 Hz), 
4.84 (d, 1H, J = 4.0 Hz), 4.72 (s, 1H), 4.38 (br s, 1H), 
3.76 (s, 3H), 3.62 (s, 3H), 3.47 (s, 3H), 3.17 (d, 1H, J = 
5.5 Hz), 3.07 (d, 1H, J = 5.1 Hz), 3.03 (td, 2H, J = 6.0, 
2.9 Hz), 2.74–2.70 (m, 2H), 2.27–2.21 (m, 1H), 2.08 
(quin, 2H, J = 6.3 Hz), 1.20–1.11 (m, 2H), 1.06–1.01 (m, 
1H), 0.57–0.53 (m, 1H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.4, 162.7, 151.3, 146.7, 142.5, 135.3, 130.1, 114.2, 
112.9, 111.2, 111.0, 103.9, 100.1, 98.4, 73.3, 69.4, 69.3, 
60.8, 57.0, 56.4, 50.4, 38.7, 23.5, 22.0, 13.5, 9.9, 6.2. 
 
FTIR, cm–1: 
(neat) 
3420 (br w), 2928 (s), 1717 (m), 1618 (s), 1520 (s), 1366 
(s), 1107 (s). 
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HRMS:  
(ESI) 
Calcd for (C27H28O10+Na) 
Found 
 
535.1575 
535.1573 
TLC: 
(60% ethyl acetatehexanes) 
Rf = 0.39 (UV, CAM) 
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D-Glycoside 119. 
1-O-acetyl glycoside 11876 (27.3 mg, 0.106 mmol, 16.0 equiv) was added to a 
solution of synthetic precursor 23 (5.0 mg, 6.6 Pmol, 1 equiv) in benzene (0.5 mL). The 
solution was concentrated and the residue was blanketed with argon. Dichloromethane 
(100 PL) and ether (30 PL) were added, followed by crushed 4-Å molecular sieves (20 
mg). The suspension was stirred for 30 min at 23 °C then was cooled to –78 °C. A freshly 
prepared solution of N-(trimethylsilyl)-bis(trifluoromethanesulfonyl)imide in 
dichloromethane (1.0 M, 70.4 PL, 0.070 mmol, 10.6 equiv) was added dropwise by 
syringe over 1.5 h. After 4 h, triethylamine (0.05 mL) was added. The mixture was 
diluted with 15% methanol–dichloromethane (50 mL) and saturated aqueous sodium 
bicarbonate solution (10 mL). The layers were separated. The aqueous layer was 
extracted with dichloromethane (2 × 20 mL). The organic layers were combined and the 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent Prep-
C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution   with  
40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure D-glycoside 119 (4.5 mg, 64%).  
                                                 
76 1-O-Acetyl glycoside 118 was prepared from daunosamine hydrochloride by a two-step sequence which 
has been described previously: Zhang, G.; Fang, L.; Zhu, L.; Aimiuwu , J. E.; Shen, J.; Cheng, H.; Muller , 
M. T.; Lee, G. E.; Sun, D.; Wang, P. G. J. Med. Chem. 2005, 48, 5269–5278. 
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1H NMR:  
(600 MHz, CDCl3) 
14.61 (br, 1H), 7.48 (s, 1H), 7.28 (d, 2H, J = 8.5 Hz), 
6.87 (d, 2H, J = 8.7 Hz), 5.91 (t, 1H, J = 2.5 Hz), 5.23 (d, 
1H, J = 2.3 Hz), 5.22 (d, 1H, J = 4.1 Hz), 5.19 (m, 2H), 
4.97 (dd, 1H, J = 12.6, 5.3 Hz), 4.74 (s, 1H), 4.70 (d, 1H, 
J = 10.8 Hz), 4.60 (d, 1H, J = 11.0 Hz), 4.40 (q, 1H, J = 
6.6 Hz), 4.09 (ddd, 1H, J = 11.2, 6.4, 3.0 Hz), 3.83 (s, 
3H), 3.80 (s, 3H), 3.63 (s, 3H), 3.46 (s, 3H), 2.85 (d, 1H, 
J = 6.0 Hz), 2.74 (d, 1H, J = 6.0 Hz), 2.72 (m, 1H), 2.59 
(s, 3H), 2.19 (s, 3H), 2.18–2.15 (m, 2H), 1.15 (d, 3H, J = 
6.4 Hz), 0.98 (s, 9H), 0.25 (s, 3H), 0.17 (s, 3H). 
 
FTIR, cm–1: 
(neat) 
 
2926 (s), 2854 (m), 2104 (m), 1746 (m), 1620 (s), 1516 
(m), 1250 (s), 1107 (s). 
HRMS:  
(ESI) 
Calcd for (C47H60O16N3Si+H) 
Found 
 
950.3737 
950.3711 
TLC: 
(50% ethyl acetatehexanes) 
Rf = 0.43 (UV, CAM) 
 
  
244 
 
 
Azido Diol 120. 
2,3-dichloro-5,6-dicyanobenzoquinone (1.1 mg, 4.7 Pmol, 1.0 equiv) was added 
to a solution of D-glycoside 119 (4.5 mg, 4.7 Pmol, 1 equiv) in a mixture of 
dichloromethane (833 PL) and water (167 PL) at 23 °C. The flask was covered with 
aluminum foil to exclude light. Over the course of 6.5 h, the color of the reaction mixture 
changed from myrtle green to yellow. The product solution was partitioned between 
water (10 mL) and dichloromethane (50 mL). The layers were separated. The aqueous 
layer was extracted with dichloromethane (3 × 20 mL). The organic layers were 
combined and the combined solution was dried over sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated. The residue was dissolved in acetonitrile 
(0.5 mL), and triethylamine–trihydrofluoride (23 PL, 0.14 mmol, 30 equiv) was added at 
23 °C. The reaction flask was covered with aluminum foil to exclude light. After 14 h, 
saturated aqueous sodium bicarbonate solution (10 mL) was added. The mixture was 
extracted with dichloromethane (2 × 50 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and 
filtrate was concentrated. The residue was purified by preparatory HPLC (Agilent Prep-
C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm, gradient elution with 
20o80% acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the 
pure azido diol 120 (1.6 mg, 47% over 2 steps). 
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1H NMR:  
(600 MHz, CDCl3) 
13.86 (s, 1H), 7.47 (s, 1H), 5.88 (t, 1H, J = 2.5 Hz), 5.47 
(br, 1H), 5.24 (app d, 2H, J = 4.1 Hz), 5.20 (d, 1H, J = 
4.1 Hz), 4.94 (dd, 1H, J = 12.8, 5.5 Hz), 4.75 (s, 1H), 
4.41 (q, 1H, J = 6.4 Hz), 4.11 (ddd, 1H, J = 11.7, 5.7, 3.0 
Hz), 3.93 (s, 3H), 3.63 (s, 3H), 3.56 (br s, 1H), 3.47 (s, 
3H), 2.89 (d, 1H, J = 6.0 Hz), 2.79 (d, 1H, J = 6.0 Hz), 
2.75 (ddd, 1H, J = 13.3, 5.5, 2.8 Hz), 2.61 (s, 3H), 2.21 
(br, 1H), 2.20–2.17 (m, 2H), 2.19 (s, 3H), 1.16 (d, 3H, J 
= 6.4 Hz). 
 
HRMS:  
(ESI) 
Calcd for (C33H37O15N3+H) 
Found 
 
716.2297 
716.2278 
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D-Glycoside 121. 
1-O-acetyl glycoside 11876 (34.9 mg, 0.136 mmol, 6.0 equiv) was added to a 
solution of dideoxy-DC-45-A2 (74)18 (11.0 mg, 0.023 mmol, 1 equiv) in benzene (2.0 
mL). The solution was concentrated and the residue was blanketed with argon. 
Dichloromethane (850 PL) and ether (280 PL) were added, followed by crushed 4-Å 
molecular sieves (20 mg). The suspension was stirred for 20 min at 23 °C then was 
cooled to –78 °C. N-(trimethylsilyl)-bis(trifluoromethanesulfonyl)imide (22 PL, 0.090 
mmol, 4.0 equiv) was added dropwise by syringe over 10 min. After 2 h, the mixture was 
diluted with 15% methanol–dichloromethane (50 mL). Saturated aqueous sodium 
bicarbonate solution (10 mL) was added. The layers were separated. The aqueous layer 
was extracted with dichloromethane (20 mL). The organic layers were combined and the 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography on 
silica gel deactivated with triethylamine (40% ethyl acetate–hexanes initially, grading to 
50% ethyl acetate–hexanes). The product was further purified by preparatory HPLC 
(Agilent Prep-C18   column,   10   μm,   30   ×   150  mm,   UV   detection   at   270   nm, gradient 
elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide after 
concentration the pure D-glycoside 121 (4.6 mg, 30%).  
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1H NMR:  
(500 MHz, CDCl3) 
14.72 (s, 1H), 7.44 (s, 1H), 5.91 (br t, 1H, J = 2.4 Hz), 
5.24 (d, 1H, J = 2.3 Hz), 5.22 (d, 1H, J = 4.1 Hz), 5.19 
(d, 1H, J = 4.1 Hz), 4.75 (s, 1H), 4.41 (q, 1H, J = 6.4 
Hz), 4.11 (ddd, 1H, J = 11.9, 5.5, 2.8 Hz), 3.78 (s, 3H), 
3.63 (s, 3H), 3.47 (s, 3H), 3.45 (s, 1H), 3.04 (m, 2H), 
2.89 (d, 1H, J = 6.0 Hz), 2.82 (d, 1H, J = 6.0 Hz), 2.73 (s, 
2H), 2.58 (s, 3H), 2.18 (s, 3H), 2.16 (m, 1H), 2.09 (m, 
2H), 1.15 (d, 1H, J = 6.9 Hz). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.4, 170.5, 162.9, 151.6, 142.4, 141.8, 135.2, 130.4, 
115.8, 113.2, 113.1, 111.1, 104.5, 101.6, 99.6, 93.3, 77.2, 
71.9, 70.1, 69.2, 68.3, 66.4, 60.9, 56.9, 56.4, 54.2, 47.7, 
38.8, 23.6, 22.1, 20.8, 20.3, 16.8. 
 
FTIR, cm–1: 
(neat) 
 
2926 (m), 2102 (m), 1748 (m), 1662 (m), 1389 (m), 1233 
(m), 1016 (s). 
HRMS:  
(ESI) 
Calcd for (C33H37O13N3+H) 
Found 
 
684.2399 
684.2424 
TLC: 
(80% ethyl acetatehexanes) 
Rf = 0.77 (UV, CAM) 
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Azido Glycoside 126. 
2,3-dichloro-5,6-dicyanobenzoquinone (11 mg, 47 Pmol, 1.0 equiv) was added to 
a solution of trimethylsilyl hemiketal 122 (39 mg, 47 Pmol, 1.0 equiv) in a mixture of 
dichloromethane (1.7 mL) and water (330 PL) at 23 °C. The flask was covered with 
aluminum foil to exclude light. Over the course of 2 h, the color of the reaction mixture 
changed from myrtle green to yellow. The product solution was partitioned between 
water (10 mL) and dichloromethane (50 mL). The layers were separated. The aqueous 
layer was extracted with dichloromethane (3 × 20 mL). The organic layers were 
combined and the combined solution was dried over sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated. The residue was purified by preparatory 
HPLC (Agilent Prep-C18   column,   10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,  
gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to provide 
after concentration the pure benzylic alcohol 123 (30 mg, 90%). 
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Thioglycoside 12477 (16 mg, 0.051 mmol, 6.0 equiv) was added to a solution of 
benzylic alcohol 123 (6 mg, 0.009 mmol, 1 equiv) in benzene (1.0 mL). The solution was 
concentrated and the residue was blanketed with argon. Dichloromethane (250 PL), 
crushed 4-Å molecular sieves (50 mg), and 2,6-di-tert-butyl-4-methylpyridine (7.0 mg, 
0.034 mmol, 4 equiv) were added sequentially at 23 °C. After 10 min, the suspension was 
cooled to 0 °C. Silver hexafluorophosphate (4.3 mg, 0.017 mmol, 2.0 equiv) was added. 
After 15 min, an additional portion of silver hexafluorophosphate (4.3 mg, 0.017 mmol, 
2.0 equiv) was added. After 12 h, additional portions of silver hexafluorophosphate (4.3 
mg, 0.017 mmol, 2.0 equiv) and 2,6-di-tert-butyl-4-methylpyridine (3.5 mg, 0.017 mmol, 
2 equiv) were added. After 20 min, dichloromethane (5 mL) was added and the mixture 
was filtered through short pad of Celite. The filtrate was partitioned between 
dichloromethane (30 mL) and water (5 mL). The layers were separated. The organic layer 
was dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The residue was purified by preparatory HPLC (Agilent Prep-C18 column, 
10   μm,   30   ×   150   mm,   UV   detection   at   270   nm,   gradient   elution   with   40o100% 
acetonitrile in water, flow rate: 15 mL/min) to provide after concentration the pure D-
glycoside 125 (2.3 mg, 30%). 
Triethylamine–trihydrofluoride (13 PL, 76 Pmol, 30 equiv) was added to an ice-
cooled solution of D-glycoside 125 (2.3 mg, 2.6 Pmol, 1 equiv) in acetonitrile (0.5 mL). 
The flask was covered with aluminum foil to exclude light. After 5 min, the cooling bath 
was removed and the reaction flask was allowed to warm to 23 °C. After 23 h, the 
                                                 
77 Thioglycoside 124 was prepared from daunosamine hydrochloride by a three-step sequence which has 
been described previously: Zhang, G.; Fang, L.; Zhu, L.; Aimiuwu , J. E.; Shen, J.; Cheng, H.; Muller , M. 
T.; Lee, G. E.; Sun, D.; Wang, P. G. J. Med. Chem. 2005, 48, 5269–5278. 
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solution was purified by preparatory HPLC (Agilent Prep-C18  column,  10  μm,  30  ×  150  
mm, UV detection at 270 nm, gradient elution with 20o90% acetonitrile in water, flow 
rate: 15 mL/min) to provide after concentration the pure alcohol 126 (0.55 mg, 30%).  
 
1H NMR:  
(600 MHz, CDCl3) 
14.20 (s, 1H), 7.50 (s, 1H), 5.43 (d, 1H, J = 2.8 Hz), 5.35 
(t, 1H, J = 2.8 Hz), 5.27 (d, 1H, J = 4.1 Hz), 5.19 (s, 1H), 
4.86 (dd, 1H, J = 12.8, 5.5 Hz), 4.84 (d, 1H, J = 4.1 Hz),  
4.71 (s, 1H), 4.39 (s, 1H), 4.17 (q, 1H, J = 6.4 Hz), 3.84 
(s, 3H), 3.79 (ddd, 1H, J = 12.8, 4.6, 2.8 Hz), 3.62 (s, 
3H), 3.59 (s, 1H), 3.47 (s, 3H), 3.16 (d, 1H, J = 5.5 Hz), 
3.03 (d, 1H, J = 5.0 Hz), 2.72 (ddd, 1H, J = 13.3, 5.0, 3.2 
Hz), 2.62 (s, 3H), 2.23–2.17 (m, 1H), 2.19 (s, 3H), 2.08 
(dt, 1H, J = 12.8, 3.6 Hz), 1.78 (dd, 1H, J = 12.8, 4.6 
Hz), 1.25 (d, 3H, J = 6.4 Hz). 
 
HRMS:  
(ESI) 
Calcd for (C33H37O15N3+Na) 
Found 
 
738.2117 
738.2084 
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Methoxymethyl Aglycon 127. 
Chloromethyl methyl ether (26 µL, 0.339 mmol, 5.0 equiv) was added to a 
solution of dideoxy-DC-45-A2 (74) (33 mg, 0.068 mmol, 1 equiv) and N,N-
diisopropylethylamine (118 µL, 0.678 mmol, 10 equiv) in dichloromethane (1.4 mL) at 
23° C. After 25 min, the mixture was partitioned between pH 7 aqueous phosphate buffer 
(10 mL) and dichloromethane (30 mL). The layers were separated. The organic layer was 
dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated to provide methoxymethyl aglycon 127 (36 mg, >99%). 
 
1H NMR:  
(500 MHz, CDCl3) 
14.76 (s, 1H), 7.44 (s, 1H), 5.53 (d, 1H, J = 6.6 Hz), 5.30 
(s, 1H), 5.20 (d, 1H, J = 4.0 Hz), 5.14 (d, 1H, J = 4.6 
Hz), 4.93 (d, 1H, J = 7.2 Hz), 4.77 (s, 1H), 3.77 (s, 3H), 
3.64 (s, 3H), 3.57 (s, 3H), 3.46 (s, 3H), 3.03 (m, 2H), 
2.91 (d, 1H, J = 5.3 Hz), 2.85 (d, 1H, J = 5.9 Hz), 2.72 
(m, 2H), 2.59 (s, 3H), 2.09 (m, 2H). 
 
HRMS:  
(ESI) 
Calcd for (C27H30O11+H) 
Found 
 
531.1861 
531.1872 
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Benzyloxymethyl Aglycon 128. 
Benzyl chloromethyl ether (4.3 µL, 0.031 mmol, 5 equiv) was added to a solution 
of dideoxy-DC-45-A2 (74) (3.0 mg, 6.2 µmol, 1 equiv) and N,N-diisopropylethylamine 
(10.8 µL, 0.062 mmol, 10 equiv) in dichloromethane (0.1 mL) at 23 °C. After 30 min, the 
mixture was partitioned between half-saturated aqueous sodium chloride solution (5 mL) 
and dichloromethane (15 mL). The layers were separated and the organic layer was dried 
over sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography (20% ethyl acetate–hexanes 
initially, grading to 50% ethyl acetate–hexanes) to provide benzyloxymethyl aglycon 128 
(3.7 mg, 99%). 
 
1H NMR:  
(500 MHz, CDCl3) 
14.76 (s, 1H), 7.43 (s, 1H), 7.38–7.26 (m, 5H), 5.64 (d, 
1H, J = 7.0 Hz), 5.21 (d, 1H, J = 4.0 Hz), 5.18 (d, 1H, J 
= 4.0 Hz), 5.11 (d, 1H, J = 7.3 Hz), 4.99 (d, 1H, J = 11.7 
Hz), 4.79 (s, 1H), 4.72 (d, 1H, J = 11.7 Hz), 3.77 (s, 3H), 
3.66 (s, 3H), 3.47 (s, 3H), 3.04 (m, 2H), 2.93 (d, 1H, J = 
5.5 Hz), 2.87 (d, 1H, J = 5.5 Hz), 2.72 (m, 2H), 2.58 (s, 
3H), 2.09 (m, 2H). 
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HRMS:  
(ESI) 
Calcd for (C33H35O11+K) 
Found 
 
645.1733 
645.1725 
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Allyl Aglycon 130.75 
Silver(I) oxide (29 mg, 0.12 mmol, 2.0 equiv) was added to a suspension of 
dideoxy-DC-45-A2 (74), allyl bromide (2 mL), and calcium sulfate (34 mg, 0.25 mmol, 
4.0 equiv) at 23 °C. After 21 h, the mixture was filtered through a short pad of Celite, 
eluting with ethyl acetate. The filtrate was concentrated. The residue was purified by 
preparatory HPLC (Agilent Prep-C18  column,  10  μm,  30  ×  150  mm,  UV  detection  at  270  
nm, gradient elution with 40o90% acetonitrile in water, flow rate: 15 mL/min) to 
provide after concentration the pure allyl aglycon 130 (14.9 mg, 46%). 
 
1H NMR:  
(500 MHz, CDCl3) 
14.79 (s, 1H), 7.43 (s, 1H), 6.10 (m, 1H), 5.39 (d, 1H, J = 
17.5 Hz), 5.23–5.20 (m, 2H), 4.81 (d, 1H, J = 4.4 Hz), 
4.76 (s, 1H), 4.54 (m, 2H), 3.78 (s, 3H), 3.63 (s, 3H), 
3.44 (s, 3H), 3.04 (m, 2H), 2.89 (d, 1H, J = 5.6 Hz), 2.86 
(d, 1H, J = 6.0 Hz), 2.73 (m, 2H), 2.59 (s, 3H), 2.09 (m, 
2H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.4, 163.0, 151.3, 142.4, 141.8, 135.2, 134.6, 130.2, 
117.4, 115.6, 113.5, 111.0, 110.7, 104.4, 102.0, 99.8, 
72.6, 69.3, 68.9, 66.7, 60.9, 57.0, 56.7, 48.2, 38.8, 23.6, 
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22.1, 20.4. 
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5-Hexenyl Aglycon 131. 
4-Å molecular sieves (~20 mg) were added to a solution of dideoxy-DC-45-A2 
(74) (25 mg, 0.051 mmol, 1 equiv) and 1,8-bis(dimethylamino)naphthalene (“Proton–
Sponge”,  165  mg,  0.771  mmol,  15  equiv)  in  dichloromethane  (0.6  mL)  at  23  °C.  After  20  
min, 5-hexenyl trifluoromethanesulfonate (120 µL) was added. After 20 h, the mixture 
was partitioned between saturated aqueous sodium bicarbonate solution (20 mL) and 
dichloromethane (50 mL). The layers were separated and the organic layer was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
residue was immediately purified by flash-column chromatography (10% ethyl acetate–
hexanes initially, grading to 50% ethyl acetate–hexanes). The fractions containing 
product were concentrated. The residue was dissolved in ethyl acetate (30 mL), and the 
resulting solution was washed successively with 0.1 M aqueous hydrochloric acid 
solution (2 × 20 mL), water (20 mL), and saturated aqueous sodium chloride solution (20 
mL). The washed organic solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated to provide the pure 5-hexenyl aglycon 131 (25 
mg, 86%). 
 
1H NMR:  14.78 (s, 1H), 7.42 (s, 1H), 5.84 (m, 1H), 5.21 (d, 1H, J = 
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(500 MHz, CDCl3) 3.8 Hz), 5.03 (d, 1H, J = 17.6 Hz), 4.95 (d, 1H, J = 9.9 
Hz), 4.78 (d, 1H, J = 3.8 Hz), 4.75 (s, 1H), 3.98 (m, 2H), 
3.78 (s, 3H), 3.63 (s, 3H), 3.44 (s, 3H), 3.04 (m, 2H), 
2.86 (m, 2H), 2.73 (m, 2H), 2.58 (s, 3H), 2.10 (m, 4H), 
1.76 (m, 2H), 1.55 (m, 2H). 
 
13C NMR:  
(125 MHz, CDCl3) 
 
204.4, 163.0, 151.5, 142.3, 141.8, 138.9, 135.2, 130.1, 
115.5, 114.4, 113.4, 113.2, 110.9, 104.4, 102.0, 99.8, 
72.1, 69.2, 68.9, 65.3, 60.8, 56.9, 56.7, 48.1, 38.8, 33.5, 
29.4, 25.3, 23.5, 22.1, 20.4. 
 
FTIR, cm–1: 
(neat) 
 
2942 (m), 1620 (s), 1389 (s), 1092 (s). 
HRMS:  
(ESI) 
Calcd for (C31H36O10+H) 
Found 
 
569.2381 
569.2375 
TLC: 
(5% methanol– 
dichloromethane) 
Rf = 0.84 (UV, CAM) 
 
  
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Antiproliferative Activities of Fully Synthetic Trioxacarcins 
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Introduction 
An additional goal of our pursuit of diverse trioxacarcin analogs was to begin to 
define the necessary structural features for potent antiproliferative activity. Accordingly, I 
measured the antiproliferative activities of many of the fully synthetic analogs discussed 
in this dissertation. In this chapter, I provide these measurements of antiproliferative 
activity, reported as the GI50,78 the concentration necessary for 50% growth inhibition. 
The cell proliferation assay was performed using cultured H460 cells, a human lung 
cancer cell line that was reported to be especially sensitive to trioxacarcin A (1)4 (which I 
confirmed, obtaining a GI50 value of 0.85 ± 0.36 nM). I also made the first measurement, 
to our knowledge, of the growth-inhibitory activity of the natural product DC-45-A1 (10) 
(GI50 37 ± 7 nM). After tabulating these measurements, I highlight trends relevant to the 
structure-activity relationship which our program in analog synthesis provided a unique 
ability to observe. 
 
Antiproliferative Activities 
Table 5.1 lists the antiproliferative activities measured for fully synthetic 
trioxacarcins discussed in this dissertation, ordered by their structure number. Table 5.2 
lists the same antiproliferative activities sorted in order of increasing GI50.  
  
                                                 
78 Boyd, M. R.; Pauli, K. D. Drug Develop. Res. 1995, 34, 91–109. 
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Table 5.1. Antiproliferative Activities (GI50) of Fully Synthetic Trioxacarcins, Sorted by 
Structure Number. 
Structure 
GI50  
(H460 cells, nM) 
 
0.85 r 0.36  
 
37 r 7 
 
767 r 74 
 
4.1 r 1.7 
 
19 r 7 
 
105 r 24 
 
18 r 8 
 
294 r 52 
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Table 5.1, Continued 
Structure 
GI50  
(H460 cells, nM) 
 
206 r 70 
 
10.1 r 0.4 
 
200 r 57 
 
17 r 2 
 
679 r 118 
 
315 r 58 
 
56 r 19 
 
4.5 r 2.0 
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Table 5.1, Continued 
Structure 
GI50  
(H460 cells, nM) 
 
>2500 
 
>2500 
 
374 r 87 
 
397 r 82 
 
102 r 3 
 
225 r 26 
 
2.4 r 0.9 
 
2.6 r 0.4 
 
< 1.1 
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Table 5.2. Antiproliferative Activities (GI50) of Fully Synthetic Trioxacarcins, Sorted in 
Increasing Order of GI50. 
Structure 
GI50  
(H460 cells, nM) 
 
0.85 r 0.36  
 
< 1.1 
 
2.4 r 0.9 
 
2.6 r 0.4 
 
4.1 r 1.7 
 
4.5 r 2.0 
 
10.1 r 0.4 
 
17 r 2 
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Table 5.2, Continued 
Structure 
GI50  
(H460 cells, nM) 
 
18 r 8 
 
19 r 7 
 
37 r 7 
 
56 r 19 
 
102 r 3 
 
105 r 24 
 
200 r 57 
 
206 r 70 
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Table 5.2, Continued 
Structure 
GI50  
(H460 cells, nM) 
 
225 r 26 
 
294 r 52 
 
315 r 58 
 
374 r 87 
 
397 r 82 
 
679 r 118 
 
767 r 74 
 
>2500 
 
>2500 
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Discussion 
Our synthetic efforts provided us with access not only to trioxacarcin A (1) but 
also to its 4-deglyco analog DC-45-A1 (10) and its previously unknown 13-deglyco 
analog, monoglycoside 71. Both DC-45-A1 (10) and 71 were substantially less active in 
our antiproliferative assay than trioxacarcin A (Figure 5.1). Still, DC-45-A1 (10), which 
contains only the trioxacarcinose A sugar, was ~20 times more potent than 
monoglycoside 71, which contains only the trioxacarcinose B sugar. Both of these were 
also far more potent than the trioxacarcin aglycon, DC-45-A2 (11).18 The presence of the 
trioxacarcinose A and B sugar residues clearly imparts high potency relative to the 
presence of the corresponding free hydroxyl and hemiketal groups, at least in this assay. 
 
Figure 5.1. Comparison of GI50 Values for the Natural Products Trioxacarcin A (1), DC-
45-A1 (10), and DC-45-A2 (11),18 Alongside Analog 71. 
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Another finding that can be extracted from our measurements is the striking effect 
on antiproliferative activity of changes in the substitution of the cyclohexenone ring 
within the dihydroanthracenone chromophore. Figure 5.2 compares the GI50 values of 
four compounds differing only in their C2 and C4 substituents. Relative to 
monoglycoside 71, 2-deoxy monoglycoside 85 lacks a C2 hydroxyl group and was more 
active in our assay; the 2,4-dideoxy analog 76 and the diketone 86 were even more 
potent. This mirrors the earlier observation that dideoxy-DC-45-A2 (74) is a much more 
potent antiproliferative agent than DC-45-A2 (11).18 
 
 
Figure 5.2. Antiproliferative Activities of Analogs 71, 85, 76, and 86, which Differ in 
Cyclohexenone Ring Substitution. 
The analog 2-deoxy-DC-45-A1 (90) was, interestingly, roughly 2 times more 
active than the natural product DC-45-A1 (10) itself. 2-Deoxytrioxacarcin A (95), while 
still an exceptionally potent antiproliferative agent, was less active than trioxacarcin A 
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(1), an exception to the broad trend of increasing activity through the removal of C2 or 
C4 hydroxyl groups. 
 
 
Figure 5.3. Comparison of the Antiproliferative Activities of DC-45-A1 (10) and 
Trioxacarcin A (1) with the Corresponding 2-Deoxy Analogs. 
None of the small group of analogs prepared by modification of the 
cyanophthalide component (19)—namely, benzyl ether 101, unstable phenol 102, and 
cyclopropyl analog 112—exhibited increased potency relative to dideoxy-DC-45-A2 
(74),18 which possesses the C6 methyl substituent normally present within the 
trioxacarcins (and is otherwise identical to 101, 102, and 112). Benzyl ether 101 and 
phenol 102 showed no antiproliferative effects within the range of concentrations 
examined (Figure 5.4). 
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Figure 5.4. Antiproliferative Activities of Analogs Prepared By Variation of the 
Cyanophthalide Component (19), Alongside Dideoxy-DC-45-A2 (74).18 
The azido sugar-containing analogs 120, 121, and 126 retained some 
antiproliferative activity (Figure 5.5). Interestingly, compound 120 was a modestly more 
active antiproliferative agent than the analogous structure bearing the natural 
trioxacarcinose B residue (71). This was not a general result of incorporation of this azido 
sugar, as analogs 121 and 126 are less active than their counterparts bearing the naturally 
occurring trioxacarcinoses. 
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Figure 5.5. Antiproliferative Activities of Azido Sugar-Containing Analogs 120, 121, 
and 126. 
The most surprising results came in the form of the GI50 values of C13 alkylated 
analogs 127, 129, and 130 (Figure 5.6). Each of these analogs was nearly two orders of 
magnitude more active than the corresponding free hemiketal, dideoxy-DC-45-A2 (74). 
These compounds represent our most potent trioxacarcin analogs to date and showed 
activities comparable to trioxacarcin A (1) despite their far simpler chemical structure. 
The reason for the remarkable activity of these compounds in particular is not 
immediately clear, though factors such as improved cellular membrane penetration, 
facilitated duplex DNA intercalation, improved kinetics of guanosine alkylation, and 
even improved chemical stability could all play a role, and further study will be required 
to determine the relative significance of these and other factors.  
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Figure 5.6. Antiproliferative Activities of C13-Alkylated Trioxacarcins, Compared to 
Dideoxy-DC-45-A2 (74).18 
 
Conclusion 
Measurement of the antiproliferative activities of the novel trioxacarcins prepared 
using our synthetic route has begun to define the effects of structural variations around 
the polycyclic scaffold and within the glycosyl residues. The majority of the analogs we 
prepared were at least submicromolar inhibitors of the growth of a cultured human lung 
cancer cell line. We also identified several analogs which are considerably simpler than 
trioxacarcin A (1) yet retain highly potent antiproliferative activity. 
In this dissertation, I have presented my work related to the development of a 
component-based synthetic route to trioxacarcins. I developed two efficient routes to the 
sugar trioxacarcinose A by diastereoselective allylmetal additions to ketones, and I used a 
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scalable dihydroxylation–recrystallization protocol to provide the common starting 
material for these two routes. An activated derivative of trioxacarcinose A was then used 
in a highly convergent synthesis of trioxacarcin A (1) from five components of similar 
synthetic complexity: epoxy diazo diketone 18, cyanophthalide 19, cyclohexenone 20, 
trioxacarcinose A donor 55, and trioxacarcinose B donor 65. Subsequent efforts in 
trioxacarcin analog synthesis underscored the modularity of this route and produced a 
large and varied collection of novel trioxacarcins. These studies have significantly 
expanded the pool of trioxacarcin structures available for study. Finally, through 
measurements of antiproliferative activity we have begun to study the effects of particular 
structural modifications on the growth-inhibitory properties of trioxacarcins in cancer 
cells. 
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Experimental Section 
Cell Culture.  
All cell-culture work was conducted in a class II biological safety cabinet. H460 
cells (P2–P4, American Type Culture Collection) were maintained in RPMI-1640 
medium supplemented with 10% fetal bovine serum (FBS). 
Cell Proliferation Assay 
H460 cells were grown to approximately 80% confluence, and then were 
trpysinized, collected, and pelleted by centrifugation (10 min at 183 × g, 4 °C). The 
supernatant was discarded and the cell pellet was resuspended in 10 mL of fresh medium. 
A sample was diluted 10-fold in fresh medium, and the concentration of cells was 
determined using a hemacytometer. The cell suspension was diluted to a concentration of 
3000 cells/100 PL. The wells of a pre-sterilized 96-well plate were charged with 100 PL 
per well of the diluted cellular suspension. The plate was incubated for 24 h at 37 °C (5% 
CO2).  
Stock solutions of each compound in DMSO were diluted serially with RPMI-
1640 medium (supplemented with FBS), and 100-PL aliquots of the resulting solutions 
were added to the wells containing adhered cells to achieve final concentrations of 0.11 
nM to 250 nM (trioxacarcin A) or 1.1 nM to 2500 nM (all other compounds). After 
incubating at 37 ºC for 72 h (5% CO2), 20 PL of resazurin solution (Promega CellTiter-
Blue® Cell Viability Assay) was added to each well. After incubating at 37 °C for 2.0 h 
(5% CO2), the fluorescence (544 nm excitation/590 nm emission) was recorded using a 
microplate reader (SpectraMax PLUS384) as a measure of viable cells.  
Percent growth inhibition was calculated for each well, based upon the following 
formula:  
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Percent growth inhibition = 100 × (S – B0) / (Bt – B0) 
 
where S is the sample fluorescence, Bt is the average fluorescence of an untreated 
population of cells at the completion of the assay, and B0 is the average fluorescence of 
an untreated population of cells at the beginning of the assay.  
Each compound was assayed at eight separate concentrations per experiment. The 
percent inhibition at each concentration was plotted against log(concentration), and a 
curve fit was generated using the XLfit4 plugin (IDBS Software) running in Excel 
(Microsoft). GI50 values were computed to reflect the concentrations at which the 
resulting curves pass through 50% inhibition. GI50 values for each compound are reported 
as the average of at least six experiments, with standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 
 
Catalog of Spectra 
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Comparison of Natural and Synthetic DC-45-A1 (10) 
 
Comparison of 1H NMR Spectral Data of Natural and Synthetic DC-45-A1 (10) 
Natural3 Synthetic 
(CDCl3) 500 MHz (CDCl3) 
   
1.07 (s, 3H) 1.07 (s, 3H) 
1.24 (d,  J = 6.4 Hz, 2H) 1.24 (d, J = 6.2 Hz, 3H) 
1.50–2.50 1.61 (d, J = 14.3 Hz, 1H) 
– 1.96 (dd, J = 14.3, 4.0 Hz, 1H) 
2.14 (s, 3H) 2.14 (s, 3H) 
– 2.22 (dt, , J = 13.2, 2.6 Hz, 1H) 
2.60 (s, 3H) 2.62 (s, 3H) 
– 2.83–2.77 (m, 1H) 
3.02 (d,  J = 5.4 Hz, 1H) 3.04 (d, J = 5.5 Hz, 1H) 
3.13 (d,  J = 5.4 Hz, 1H) 3.16 (d,  J = 5.1 Hz, 1H) 
3.46 (s, 3H) 3.47 (s, 3H) 
– 3.58 (br, 1H) 
3.63 (s, 3H) 3.62 (s, 3H) 
3.84 (s, 3H) 3.84 (s, 3H) 
4.50–5.50 4.43 (br, 1H) 
– 4.54 (q,  J = 6.2 Hz, 1H) 
– 4.71 (s, 1H) 
– 4.78–4.73 (m, 2H) 
– 4.84 (d,  J = 3.7 Hz, 1H) 
– 5.26 (d,  J = 4.0 Hz, 1H) 
– 5.40–5.37 (m, 2H) 
7.43 (s, 1H) 7.49 (s, 1H) 
14.3 (s, 1H) 14.2 (s, 1H) 
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Comparison of 13C NMR Spectral Data of Natural and 
Synthetic DC-45-A1 (10) 
 
Natural3 Synthetic 
(CDCl3) 125 MHz (CDCl3) 
   
16.9 16.9 
20.5 20.5 
20.9 20.9 
25.7 25.7 
36.7 36.6 
36.7 36.7 
50.2 50.5 
56.6 56.6 
57 57.1 
62.7 62.7 
63 62.9 
68 67.7 
68 67.9 
68.9 68.8 
69.2 69.3 
69.4 69.5 
73.3 73.2 
74.4 74.4 
98.3 98.1 
99 98.6 
100.1 100.1 
104.1 103.9 
107.1 107.3 
114.8 114.8 
115.4 115.3 
116.7 116.8 
126.5 126.5 
135.4 135.5 
143 143 
144.9 144.8 
151.6 151.7 
163 163.1 
170.4 170.3 
203.1 202.8 
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Comparison of Natural and Synthetic DC-45-A1 (10) (1H NMR, CDCl3, 500 MHz).  
Natural sample obtained from Pfizer, Inc. 
14 13 12 11 10 9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Natural
Synthetic
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Comparison of Natural and Synthetic DC-45-A1 (10) 
(RP- HPLC, 10–90% acetonitrile–water containing 0.1% trifluoroacetic acid) 
 
 
Natural DC-45-A1 (10) 
Synthetic DC-45-A1 (10) 
Co-injection of natural and synthetic DC-45-A1 (10) 
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Comparison of Natural3 and Synthetic DC-45-A1 (10) (FT-IR) 
 
 
     
Natural DC-45-A1 (10) 
Synthetic DC-45-A1 (10) 
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Comparison of Natural and Synthetic Trioxacarcin A (1) 
 
Comparison of 1H NMR Spectral Data of Natural and Synthetic Trioxacarcin A 
Natural2 Natural6 Synthetic 
100 MHz (CDCl3) 100 MHz (CDCl3) 500 MHz (CDCl3) 
1.07 (s, 3H) 1.07 (s) 1.07 (s, 3H) 
1.10 (d, J = 6.8 Hz, 3H) 1.10 (d) 1.10 (d, J = 6.2 Hz, 3H) 
1.24 (d, J = 6.5 Hz, 3H) 1.24 (d) 1.24 (d, J = 6.6 Hz, 3H) 
1.40–2.30 – 1.62 (d, J = 14.7 Hz, 1H) 
– – 1.97 (dd, J = 14.7, 4.0 Hz, 1H) 
– – 2.11 (m, 1H) 
2.14 (s, 3H) 2.14 (s) 2.14 (s, 3H) 
– – 2.21 (dt, J = 13.2, 2.2 Hz, 1H) 
– – 2.45 (dt, J = 14.3, 3.3 Hz, 1H) 
2.49 (s, 3H) 2.50 (s) 2.50 (s, 3H) 
2.63 (s, 3H) 2.62 (s) 2.62 (s, 3H) 
2.30–2.81 – 2.81 (m, 1H) 
2.91 (d, J = 5.6 Hz, 1H) 2.90 (d) 2.91 (d, J = 5.5 Hz, 1H) 
3.00 (d, J = 5.6 Hz, 1H) 3.00 (d) 2.99 (d, J = 5.9 Hz, 1H) 
3.49 (s, 3H) 3.49 (s) 3.49 (s, 3H) 
– – 3.56 (s, 1H) 
3.63 (s, 3H) 3.63 (s) 3.63 (s, 3H) 
3.60–4.00 – 3.72 (br d, J = 8.8 Hz, 1H) 
3.85 (s, 3H) 3.85 (s) 3.84 (s, 3H) 
4.18 (s, OH) 4.16 (s) 4.16 (s, OH) 
– – 4.24 (d, J = 9.2 Hz, 1H) 
4.55 (q, J = 6.8 Hz, 1H) 4.55 (q) 4.54 (q, J = 6.6 Hz, 1H) 
4.70–4.90 4.77 (s) 4.75 (app s) 
– – 4.77 (s, 1H) 
– – 4.78 (m, 1H) 
5.03 (q, J = 6.5 Hz, 1H) 5.02 (q) 5.02 (q, J = 6.6 Hz, 1H) 
5.25 (d, J = 4.0 Hz, 1H) 5.24 (d) 5.24 (d, J = 4.0 Hz, 1H) 
5.39 (d, J = 4.0 Hz, 1H) 5.38 (d) 5.37 (d, J = 4.0 Hz, 1H) 
– – 5.39 (m, 1H) 
5.87 (m, 1H) 5.87 (d) 5.85 (d, J = 2.6 Hz, 1H) 
7.52 (s, 1H) 7.51 (s) 7.51 (s, 1H) 
14.10 (s, 1H) 14.1 (s) 14.05 (s, 1H) 
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Comparison of 13C NMR Spectral Data of Natural and Synthetic 
Trioxacarcin A (1) 
Natural2 Natural6 Synthetic 
25 MHz (CDCl3) 25 MHz (CDCl3) 125 MHz (CDCl3) 
14.5 14.7 14.5 
16.8 17.0 16.8 
20.3 20.2 20.3 
20.8 20.9 20.9 
25.7 25.7 25.7 
27.7 28.0 27.8 
31.5 32.2 31.5 
36.7 (2 × CH2) 36.5 36.6 
48.1 – 48.1 
56.2 55.9 56.2 
56.7 57.3 56.8 
62.7 – 62.7 
62.9 62.8 62.9 
63.8 64.0 63.8 
67.6 66.3 67.4 
67.9 67.9 67.9 
68.3 68.8 68.3 
68.8 69.3 68.8 
69.1 69.6 69.1 
70.2 – 70.2 
71.5 71.1 71.4 
74.4 74.6 74.4 
79.5 79.0 79.5 
94.8 85.1 94.8 
98.0 93.7 97.9 
99.7 97.2 99.7 
101.5 99.7 101.5 
104.6 105.3 104.6 
107.5 108.3 107.4 
114.8 (2 × Cq) 114.2 114.8 
116.9 117.0 116.9 
126.6 126.7 126.6 
135.4 135.3 135.4 
142.8 142.3 142.8 
144.7 145.2 144.8 
151.7 152.5 151.7 
163.1 162.1 163.1 
170.2 170.3 170.3 
203.0 203.8 202.9 
210.3 210.9 210.3 
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Comparison of Natural and Synthetic Trioxacarcin A (1) (1H NMR, CDCl3, 500 MHz). 
Natural sample obtained from Pfizer, Inc. 
 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0
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Comparison of Natural and Synthetic Trioxacarcin A (1) (Circular Dichroism). 
Natural sample obtained from Pfizer, Inc. 
Ellipticity (Δε) values are normalized such that the maximum for each sample (at 270 
nm) equals 1. 
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Comparison of Natural and Synthetic Trioxacarcin A (1) 
(reversed-phase HPLC, 10–90% acetonitrile–water containing 0.1% trifluoroacetic acid) 
  
 
 
Natural trioxacarcin A (##) 
Synthetic trioxacarcin A (##) 
Co-injection of natural and synthetic trioxacarcin A (##) 
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Comparison of Natural2 and Synthetic Trioxacarcin A (1) (FT-IR) 
 
Natural Trioxacarcin A (1) 
 
Synthetic Trioxacarcin A (1) 
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